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As a modern science, psychopharmacology is still in its
infancy despite the fact that the race has been exposing itself to
drugs since antiquity# In the past decade we have seen the new field
of psychopharmacology develop at an unprecedented rate, from very
small beginnings. The pharmacologists are pressed by urgent
practical needs to discover new and better drugs for use in psychiatry.
They are also pressed to seek new theoretical foundations for an
understanding of the higher functions of the central nervous system.
In these tasks they are not self sufficient. Psychopharmacology can
hardly go forward faster than the rate of progress in the related
fields of psychology, neurophysiology, neurology, neuroanatomy and
biochemistry.
SECTION I
THE 'PSYCHO' IN PSYCHOimEi-laCoLuOY
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CONTEMPORARY PSYCHOLOGY
There are two sides to contemporary, experimental
psychology. One takes behaviour to indicate intraorganismic
occurrences, and may be symbolized S-Q-R. The other takes
behaviour as a direct consequence of response- environmental
d r
contingencies. It may be symbolized 8 -R-S .
According to the first tradition, a quality or purpose
is assigned to behaviour to bring 'what the organism is behaving
for1 into the effective present, or the organism is said to
behave in a given way because it 'intends to achieve", or
'expects to have', a given effect. The teleological problem
is, of course, not solved until we have answered certain questions*
What gives the action its purpose or what leads an organism to
expect its behaviour to have an effect? The answers to such
questions are eventually to be found in past instances in which
similar behaviour has been effective. This is the position
taken by the S^-R~Sr tradition.
The S^-R-S1" psychologist, in their search for the
environmental determinants of behaviour, often employ
operant conditioning techniques. To some, the use of these
techniques constitutes the experimental analysis of behaviour
but it is no more than aij experimental analysis. Its
advantage lies in the control the experimenter has over the
consequences of a response. The behaviours evoked by mazes,
puzzle boxes, memory drums etc. are shaped without specific
programming of contingencies. The rat in a maze is exposed
to a set of conditions for which it possesses no adequate
behaviour. Responses occur - the rat explores the maze
and eventually some responses are reinforced in a way that
leads to a terminal performance. The data is usually plotted
in the form of a learning curve from which we may predict,
within limits, how another organism will behave in similar
circumstances. The curve,however, tells us little about the
process of conditioning and extinction that can be revealed
in an operant analysis. It is merely a crude overall effect
of adventitious contingencies, and it often tells us more about
the apparatus or procedure than about the organism.
The psychologist's primary contribution to psycho-
pharmacology lies in the development of a behavioural analysis
in the laboratory. The ultimate test of reliability or
reproducibility for any such technique is not to be found in
the method but in the degree of control achieved, at test
which operant conditioning usually passes easily.
The operant analysis, which recognizes the individuality
of organisms is particularly valuable when contact is made with
other disciplines. Furthermore, the S^-R-Sr psychologist,
by avoiding hypothetical constructs as 'explanations' of behaviour,
leaves the internal mechanism controlling behaviour in the hands of
biochemists and physiologists. By correlating environmental input
with behavioural output the S^~R-Sr psychologist leaves the way open
for a translation of these events into physiological or biochemical
processes.
INTERDISCIPLINARY RESEARCH
The universal common interest of the biological sciences is
behaviour, the single characteristic which best defines and differentiates
the living animal# When the biochemist, pharmacologist, physiologist
or anthropologist employs behaviour as a dependent variable then he is
contributing to interdisciplinary research# These disciplines all
represent different levels of analysis of the behavioural output but
theoretically even cultural variables should be able to be defined in
biochemical terms#
From the viewpoint of the Sd-R-Sr psychologist, the effects
of a drug are examined in terms of the relevant environmental variables
responsible for the behaviour and by the differential effect of the drug
on the various behavioural processes. The cause of the behaviour,
for the psychologist, is in environmental variables that produce it
and a drug can alter behaviour only by weakening, strengthening or
modifying one or more of the environmental variables maintaining or
otherwise determining the occurrence of that behaviour.
From the viewpoint of the pharmacologist, the effects of a drug
are examined in terms of the relevant physiological processes responsible
for the behaviour and by the differential effect of the drug on these
processes. Both analyses are perfectly compatible since the environmental
influences have physiological concomitants and the different viewpoints
only represent different levels of analysis - both, however, fall within
the realm of psychopharmacology.
OPERANT TECHNIQUES
Operant condition involves manipulating and recording
the behaviour of an organism within a controlled experimental
environment. The organism is free to behave in any way, but by
arranging for certain events to be dependent upon a particular
behavioural pattern it has been shown that the probability of this
behaviour can be increased. The behaviour pattern selected for
manipulation is normally a response that can be detected by auto¬
matic equipment. This apparatus sets a criterion for the response
so that its occurrence is defined by the equipment and is not a
subjective estimation by the experimenter. The apparatus also
arranges for certain events to occur as a consequence of these
responses. A common consequence of a response is the presentation of
a reinforcement. Reinforcement is defined empirically. When
reinforcements follow a response they increase the likelihood
that the organism will behave in the same way agaih. Thus food can
be a reinforcement if an organism has been deprived. Normally,
the response is a lever press although many other responses have
been employed. The independent variables which govern this arbitrary
piece of behaviour are examined in detail and it is assumed that,
although there are undoubtedly differences in complexity,
no new principles (with the exception of respondent conditioning*) are
involved in the control of other forms of behaviour.
Normally, reinforcements do not follow every lever press
but their occurrence is contingent upon some pre-determined conditions.
These conditions are referred to as the reinforcement schedule.
For example, reinforcement may only be delivered after a fixed
number of responses (fixed-ratio schedule) or after a fixed period
of time has elapsed (fixed-interval schedule). It is possible to
program negative as well as positive reinforcement schedules. By
definition, an event is a negative reinforcement if its termination
reinforces behaviour (and therefore leads to an increase in the
probability that the organism will behave the same way again).
Negative reinforcement may be delivered according to a punishment,
escape or an avoidance schedule. If a neutral stimulus (e.g. light)
is repeatedly paired with a negative reinforcement it can be shown
that termination of the former will reinforce behaviour. The previously
neutral stimulus is then a conditioned negative reinforcer. The
schedule employed in the present investigation is a discriminated continuous
avoidance schedule. The consequence of a response on this schedule can
be escape from a conditioned negative reinforcer.
+
These two cases exhaust the possibilities: an organism is conditioned
when a reinforcer (i) accompanies another stimulus or (il) follows
upon the organisms own behaviour.
- 7 -
THE STEADY STATE METHODOLOGY
One consequence of the increased control over behaviour,
as a result of operant techniques, has been the development of a new
methodology in psychology - the steady-state methodology.
Steady state behaviour is behaviour whose characteristics
do not change over long periods of time. When an animal is exposed
to a reinforcement schedule there is a characteristic acquisition
period during which the behaviour is rapidly changing. After
prolonged training, however, it becomes apparent that this transitional
state is no longer being recorded; the animal's behaviour is in
equilibrium with the independent variables of the schedule. The
dependent variable is then said to be under stimulus control and it
becomes possible to predict, with great accuracy, the behaviour
which will occur during any experimental session. It is this
highly predictable nature of steady states that makes them particularly
useful for examining the effects of any further independent variables
which are introduced into the experimental situation. The effects of
additional independent variables can be seen clearly against the
stable behavioural baseline.
In the past the effects of drugs on behaviour have
normally been assessed by comparing the performance of groups of
subjects without the drug with that of other groups after drug
administration* A statistical analysis of the differences in
performance between the groups is then carried out* This
estimates the probability that such a difference could have resulted
from chance factors (such as individual differences between
subjects) other than the drug itself. With steady state
methodology, group analysis is not necessary since each animal
acts as its own control. If a stable level of performance
exists prior to drug administration then any changes in behaviour
following drug administration may be attributed to the drug if,
on a subsequent day5 the former steady state can once more be
achieved. This recovery of the initial state eliminates the
possibility that the behavioural changes were simply a sequence
effect. The immediate virtue of the steady state as a sub¬
stitute for the control group is the elimination of inter subject
variability. This enormously increases the sensitivity of the
behavioural measurements. Variables that might have been
dismissed as having little or no effect, when group comparisons
are made, may prove to be extremely powerful when evaluated against
a stable individual baseline. The steady state approach eliminates
the use of statistics in behavioural analysis*. Sidman ( 149)
in fact has attacked statistical analysis on the grounds that if
a phenomena cannot be demonstrated within the behaviour of a single
organism then it does not have any psychological meaning. He
points out that behaviour is, in the final analysis, characteristic
of the single organism, not of groups. In this context, it should
be noted that statistics, as they exist today, were evolved to deal
with discrete events. They are not applicable to any time
sequence (e.g. E.E.Q. recordings or lever pressing) where any change
does not constitute a discrete event, and may be highly dependent
upon an immediately preceding event.
With reference to the steady state methodology, three
important topics must be discussed! sample size, reliability and
generality of results. The first is often considered to fall
within the realm of statistical theory - this is not true. The
sample size required in any psychological experiment should be
empirically determined. It is dependent upon the degree of control
in the experimental situation and the behavioural stability which is
necessary to demonstrate the effects of the manipulated variable.
As a criterion of reliability or generality, inter
subject replication is a more powerful tool than inter group
replication. Inter group replication provides an indicator of
reliability in so far as it demonstrates that changes in control
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tendency for a group can be repeated. With reapect to generality,
however, inter group replication does not answer the question of
how many individuals the data actually represents. With inter subject
replication, on the other hand, each additional experiment increases the
representativeness of the findings. Indeed, replication of an
experiment with two subjects establishes greater generality for
the oata among the individuals of a population than does replication
with two groups of subjects whose individual data have been combined.
Operant techniques and the Steady-State methodology
are entirely independent and many experimenters have used the
technique without the methodology or the methodology without the
technique. The author is of the opinion that, when used together,
they form a powerful tool in experimental psychology and a very
useful approach to psychopharmacology.
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REVIEW OF TIE LITERATURE
As a consequence of the large variety of behavioural techniques
and drugs employed in psychopharmacological investigations any survey
of the literature must be highly selective. This review will be
limited to a discussion of experimental results that are more or less
relevant to the present investigation and involve the use of amphetamine,
chlorpromazine or psychotomimetic drugs.
The toxicity of amphetamine is markedly enhanced by experimental
procedures involving stress. Factors such as grouping of animals,
temperature, size of cage, noise and shock have all been effective
in reproducing this phenomena (33, 34, 87, 178). Chlorpromazine has
been shown to antagonize this enhanced toxicity (24, 79, 109, 121, 126,
167) whereas pentobarbital, meprobamate and benzactyzine have all
been reported to be devoid of any protective action (24, 109). The
ability of CPZ and related drugs to reduce the restionsiveness of the
animal to stress-producing stimuli, probably by their influence as
afferent collaterals entering the reticular formation (18) may explain
these results, rather than a direct action CPZ on the lethal actions
of amphetamine.
Thiopropazate, perphenazine, prochlorperazine and promethazine
have all been reported to be effective in protecting again the lethal
actions of mescaline. In this study (127) CPZ, promazine and reserpine
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were relatively ineffective, but no information is available as to
whether the animals were grouped or isolated following the mescaline
injections.
There have been numerous studies of the effects of CPZ and
amphetamine on Spontaneous Motor Activity (14, 79, 92, 116, 167, 169).
CPZ appears to reduce S.M.A. whereas amphetamine has the opposite
effect. This increase in S.M.A, caused by amphetamine is antagonized
by CPZ given either before (104) or after (67) the former, but the
reduction in S.M.A, following CPZ appears to be resistant to any
reversal by amphetamine (67).
Amphetamine and CPZ cause a dose-dependent reduction of food
and water intake (3, 150) although the CPZ effect may well be non¬
specific since this drug has been reported to have a general suppressing
action on all behaviours maintained by both positive and negative
reinforcement (58, 123, 181). A selective inhibition of either
positively or negatively reinforced behaviour, by CPZ, has been suggested
(123, 181) but any such comparisons are open to alternative explanations.
A direct comparison of the effects of a drug on positive and negative
reinforcement schedules would require an equilibration of the magnitude
of the positive and negative reward (related to deprivation and shock
threshold) as well as frequency of reinforcement - such an exoeriment
has not yet been designedl
In spite of the anorexic properties of amphetamine it will
increase the rate of responding even when the reinforcement is food
or water (20, 52, 136, 146). larger doses, however, cause a marked
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reduction in behavioural output and a peculiar behavioural pattern
often called (134) 'amphetamine stereotyped behaviour' (A.S.8.).
The effects of amphetamine on behaviour maintained by multiple
schedules of reinforcement have been investigated by Weissman (18<l),
Cook and Kelleher (43)» Kelleher and Morse (102) and Clark and
Steele (40)• The general result of these studies suggest that the
amphetamine 'excitation' is highly dependent on the pre-drug rate of
responding. Low rates of responding (e.g. during periods) are
increased whereas high rates (e.g. during FR periods) are decreased
by the same dose, Clark and Steele describe the effects of high
doses of amphetamine (2 rag/kg - 4 mg/kg) as producing 'a moderate
rate of responding characterized by burst of two or three responses
separated by larger inter-response times during which animals
were hyperactive, although not responding to the lever,' This
disruption appears to occur at doses which have been reported, by
other authors, to produce A,S«B. (134)•
Amphetamine also substantially increases the output of behaviour
maintained by positive reinforcement if electrical stimulation of the
brain, rather than food or water, is used as the reward (38, 160,
161, 163)• Increases in the rate of free operant avoidance behaviour
under amphetamine have been obtained by Sidman (143), lerhave (177),
Teitelbaum and Derks (171) and Heise and Boff (84) • ?his is a general
effect since increase in avoidance rates using noise (33) or cold (179)
as the aversive stimuli have also been reported. Kelleher and Morse (102)
have demonstrated tint higher doses cause a decrease in rate similar
to the effects on behaviour maintained by positive reinforcement.
Once again, this was observed at doses which are normally associated
with A.S.B. (134).
Verhave (177) made the interesting observation that no increase
in response rate can be detected against very low rates of responding.
This has been confirmed by other experimenters (51).
In order to account for the many aetions of amphetamine Dews
(52) has put forward the general statement that ".mall doses of
amphetamine decrease the frequency of long inter-response times while
large doses also decrease the frequency of short inter-response times.
This does not account for the findings of Verhave (177) where no
increase in rate was detected# Stein (162) has suggested that
moderate or optimum doses <f amphetamine can be said to have a
facilitating effect on behaviour if account is taken for the following,
(i) amphetamine depresses food and water intake; (ii) some minimum
tendency to respond is required; (iii) the facilitating effect will
be less conspicuous when the tendency to respond is great. Further¬
more, he suggests that the facilitation caused by amphetamine is a
result of a reduction in reward thresholds, and presents some convincing
evidence by demonstrating that currents, which will not maintain
behaviour on saline days, are effective after amphetamine, in an
I.C.S.S. experiment. By an independent line of reasoning, Weiss
and Laties (ISO) have concluded that moderate doses of amphetamine
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•might be said to generate responding at probabilities of reinforcement
that ordinarily are not great enough to maintain responding.' This
statement incorporates the idea of a reduced reward threshold,
a minimum probability of reinforcement being necessary, and presumably
the decrease in behaviour having a high probability is a direct
result of the increase in behaviour having a low probability of
occurrence.
The effects of CPZ on avoidance behaviour have been described
by Courvoisier et al (47), Cook and Weidley (42), Neilsen et al (121)
and many others. They all found that CPZ causes an abolition of
the conditioned response (CR) while the unconditioned response (UCR)
remains intact. The dosage, which is dependent upon the test used
and route of administration, varied from an effective dose (ED^q)
10.5 rag/kg by mouth for pole climbing avoidance (42) to 4 mg/kg (i.p.)
for shuttle box ED^q (121) using rats as experimental subjects.
Strictly speaking, the term unconditioned response is inaopropriate
in this context (pole climbing is not a UCR to shock) and the CPZ
effect is better described as blocking an avoidance response but not
an escape response. More sophisticated analyses of CPZ interaction
with avoidance schedules has been made by Morpurgo (119), Maffii (114),
Bovet and Gatti (16, 68, 69) and Clark and Steele (39) but these will
be discussed at some length later.
A blockade of the GAR is not confined to the action of
•tranquillizers' and has been demonstrated in the case of psychoto¬
mimetic drugs, CNS stimulants, monoamine oxidase inhibitors, serotonin
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and cholinergic drags (42, 71, 170). The effects of psychotomimetic
drags on avoidance behavioar have been described by numerous authors
(36, 42, 46, 71, 30, 97, 134, 154, 155, 156, 157, 163). The dosage
of hallucinogenic drugs which blocks the avoidance response also
normally affects the escape response. Both mescaline (17) and LSD
(62) have been reported to produce a period of no-responding on
positive reinforcement schedules involving ratio requirements and a
gradual decline in response rate on interval schedules.
The ability of a drug to block a conditional avoidance resoonse
may be related to its affect on the aversive qualities of the conditioned
stimulus. This reasoning has encouraged many experimental
investigations (19, 21, 22, 36, 89, 90, 91) of drug effects on the
•conditioned emotional response* (CER).
The CER was first described by Estes and Skinner (55).
After several pairings of a previously neutral stimulus (e.g. light)
with an aversive stimulus (e.g. shock) the neutral stimulus acquires
the ability to suppress behaviour maintained by positive reinforcement,
The behavioural suppression is accompanied by all the physiological
signs of 'anxiety' (132), Many drugs have been examined for their
ability to enhance or abolish this conditioned suppression. Brady
(19, 21, 22) has reported that amphetamine enhances and reserpine
abolishes conditioned suppressions. He employed a partial suppression
effect as a baseline whereas, to the authors knowledge, all other
experimenters have used complete or almost complete suppression.
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The amphetamine effect reported by Brady remains therefore, unconfirmed
but many subsequent experiments have demonstrated that the complete
suppression is virtually unaffected by the drug. Brady's result with
amphetamine is consistent with Steiris observations that the drug
decreases reinforcement thresholds - in this case it is negative
reinforcement.
Reserpine and CPZ have been tested many times (13, 39, 103,
111, 135) and it would appear that, contrary to the report by Brady,
these drugs do not affect the CER, The observation that CPZ does not
abolish complete suppression suggests that factors other than its action
on afferent collaterals to the reticular formation (18) or decrease
in 'anxiety' are responsible for its CAR blockade.
ISD has been reported to reduce suppression in a dose-related
manner when a 50-60 cps tone was used but failed to produce any such
reduction when the OS was a 523 cps tone (36). This experiment
highlights the importance of investigating the effect of these drugs
on auditory or visual discrimination since a disruption of avoidance or
a reduction in conditioned suppression could easily be due to a
failure in discrimination.
It would be impossible to make any general statoients about
drug3 and discrimination since the results are highly dependent upon
the nature of the discrimination (colour, size, shape, pattern, temperal,
visual, auditory etc,) and the experimental design employed. For
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example, in one experimental situation a drug may cause an animal
to take shock which in turn disrupts a learned discrimination, whereas
the same drug, in a non-shock situation, may have no effect on this
same discrimination. Furthermore, any claim to support a positive
ssLation of drug-response effects to the visual condition under which
they occur, must eliminate the possibility of direct or indirect drug
effects on the response measured. The results of the discrimination
experiment to be described will, therefore, only be discussed within
the context of the experimental design which is employed, and no
attempt will be made to relate these to the findings of other
experimenters.
- 19 -
A BEHAVIOURAL DEFINITION OF A HALLUCINOGENIC DRUG:
Barrios (9) defined a hallucination as 'a highly vivid image
which is incongruous with the present sensory environment.' A
better definition which covers auditory as well as visual hallucinations,
is 'an experience having the character of sense perception but without
relevant or adequate sensory stimulation' (54-)•
Whatever the word hallucination may or may not mean, one thing
must be true if it is to be of any relevance to a behavioural scientist -
it must evidence itself in observable behaviour. To hold that
hallucinations have an independent, noncorporeal existence, either in
themselves or as a cause of behaviour, puts the matter into metaphysics.
To hold that hallucinations exist corporeally but have no effect on
behaviour, both contradicts the asserted importance of hallucinations
as a factor contributing to psychotic behaviour and makes them irrelevant
to the science. To hold that a hallucination is a hypothetical construct
is to agree, apart from the debatable merits of such a construction,
that behaviour is the initial datum of reference.
Normally, the evidence for hallucinating at the human level
is in the form of verbal behaviour. A subject who has taken I£D may
report his visual experiences as evidence of his hallucinations. If
the experimenter takes this data as refertially introspective, then he
becomes the captive of his subjects verbal reinforcement history and
must accept his pubject's perceptual lexicon. On the other hand, he
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may accept the verbal behaviour as a response and determine the extent
to which this response is compatible with the stimulus situation and
personality, or reinforcement history of the subject.
'/hen treating verbal responses in this manner, he is accepting
that languages is not privileged data exempted from the controls
necessary when examining any other behaviour, as did the language
analyses of Kantor (100,101) and Skinner (151).
The defining characteristic of an hallucinogenic drug is the
extent to which the subjects responses, verbal or otherwise, are
inconsistent with the physical environment. The drug may be
characterized by the subject reporting that he sees a non-existent
cup of tea or equally well by drinking itl It is unfortunate
that, at the human level, so much emphasis has been placed on the
verbal report as defining characteristic of hallucinations and no
adequate incompatibility tests have been devised to recognize the
drugs in a non-verbal situation. At the animal level no verbal
response i3 available, so we must rely on a non-verbal characterisation
of the drug.
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STUDIES OF HALLUCINOGENIC DRUGS USING ANIMAL TESTS
Early attempts by Noteboom (121) and De Jong (98) to recognize
hallucinogenic drugs using animal tests, relied on the production of
•experimental catatonia'. A number of^2> phenyl©thylamine derivatives
were investigated but unfortunatdy very large drug doses were
necessary in order to obtain this effect and one cannot exclude the
possibility that peripheral effects may account for many of their results.
Some of their findings have, however, been confirmed by other authors
using more sensitive techniques. In particular, their report
that replacement of the 4-aethoxy group by hydroxy, in mescaline,
abolishes activity has been investigated by Smythies and Levy (153)
using the Winter and Flataker test. They were able to confirm the
De Jong finding and further demonstrate that activity was decreased by
removing the 5-Methoxy group and increased by substituting a benzyloxy
group in the ^position.
The effects of fh phenyls thylamine derivatives on Shuttle-box
avoidance behaviour (CAR) in the rat has been studied by Smythies
and Sykes (154-, 155 > 156, 157). It was shown that mescaline at 25.0
mg/kg produced a biphasic effect on reaction time manifested by a GAR
inhibition followed by excitation. Mescaline at 12.5 mg/kg caused
only a decrease in reaction time. 3,4-»5 trimethoxyphenylethylamine
was completely inactive and N,B-dimethyl mescaline produced effects
unrelated to the mescaline profile.
Knoll et al (105) have attempted to distinguish between
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amphetamine-like activity and psychoidmimetic activity in a series of
methamphetamine derivatives. To do this, it was necessary to emoloy
a combination of techniques including behavioural effects in cats and
avoidance, mobility and anti-tetrabenasine or anti-reserpine properties
of the drugs in rats. They concluded that side-chain substitutions
in metharaphetamine derivatives had little or no effect on the properties
of the drug, but ring substitution, particularly in the para-position,
could greatly increase the psychotomimetic properties, as measured by
their tests. Ortho-substitution, on the other hand, resulted in a
strong stimulant drug with anti-reserpine or anti-tetrabenazine
properties similar to methamphetamine. It would be valuable if these
interesting observations could be confirmed and behavioural techniques
developed which ;rould enable amphetamine-like compounds to be distinguished
from psychotomimetics using a single experimental procedure. It would
also be desireable to increase the sensitivity of the behavioural
measures since Knoll reports that 200.0 mg/kg Mescaline was the ED95
for blockade of hot-plate avoidance - at this dosage peripheral effects
must be taken into consideration (154)»
Other attempts to use animal tests as indices of hallucinogenic
activity in man have included hypothermia in rabbits, anti-analgetic
action in mice and hyper-activity in rats (95, 96, 113). More
recently, Corne et al have employed drug-induced head-twitches in mice
as a possible index (44). It would appear that most of these techniques




The present investigation is concerned with ascertaining the
features of the hallucinogenic molecule, which are necessary for its
unique effect. This may be the first step in explaining its mode
of action. It is clear that the fundamental pre-requisite for any
such programme is the ability to reliably detect and quantify
hallucinogenic activity using animal test3. In the present state
of evolution of the biological sciences such a test can only be
determined empirically. If it is possible to show that a particular
behavioural change is unique for known hallucinogenic drugs then, with
the normal scientific reservations which govern any animal experiment¬
ation, this may be used to investigate the mode of action of these
drugs and examine unknown compounds for possible hallucinogenic
activity. The usefulness of any such test must ultimately depend
on its success when measured by the results obtained from human
experimentation.
SECTION II
THE ♦PHARMACOLOGY1 IN PSYCH0PMRM4C0LQGY
THE CATECHOLAMINES
Our knowledge of the way the various tranquillizers, anti¬
depressants and hallucinogens act is incomplete, but an effort will
be made to present what is known or presumed about the pharmacology
of these substances.
The brain is certainly involved in carbohydrate, protein
and lipid metabolism but, important as these activities are, it
appears that specific amines, and their enzymes dominate the picture
of psychoactive pharmacology. It is these biogenic amines that act
as synaptic transmitters, and it is at or near the synapse that the
psychopharmaceuticals exert their differential effect on the higher
nervous functions.
The presumed neurohumoral transmitters are predominantly
amines although this is not invariably true. They may be sub-divided
into a number of classes: the catecholamines like noradrenaline,
indole amines like seretonin and a number of others including
^aminobuteric acid, ^ltaraic acid and histamine. In addition,
acetylcholine is a well proven C.N.S. transmitter which does not have
an amine structure.
There is now much indirect evidence which suggests that the
catecholamines, in particular noradrenaline, act as transmitters in
the C.N.S. They have been shown to exist within neurones in thw C.H.S*
and in close proximity to enzymes which are involved in their synthesis
and metabolism. Furthermore, it is now clear that NA is concentrated
in the terminal regions of the neurones where its concentration may
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be several hundred times greater than elsewhere in the same nerve
cell (94-) • Although the amine appears to be stored only in the
'small, granulated vesicles' (129) there is considerable pharmacological
and biochemical evidence that these stores do not constitute a
single homogenous pool. This might be explained by different types
of binding of M within the vesicles, unequal distribution of vesicles
leading to different availability to drugs or the existence of an
axoplasmic 'pool' (48, 93, 107, 117, 131, 172).
A schematic model of the adrenergic synapse which is most
compatible with the existing evidence, is shown on Fig. 1. The
functional pool, from which the amine is readily released, exhibits
a rapid rate of NA turnover and is in equilibrium with an essentially
nonfunctional storage pool in which the amine is tightly bound.
The level of NA in the functional pool is maintained by transfer from
the storage pool which serves as a reservoir and also by reuptake
of NA from the synaptic cleft.
The enzyme systems responsible for the synthesis and metabolism
of NA are now well understood (Fig. l). The first 3tep is the
conversion of the dietary amino acid L-tyrosine to L-dopa. This
reaction takes place in the presence of tyrosine 3-hydroxylase (TH)
+
The enzyme will not convert metahydroxytyrosine to Dopa but will
convert phenylethylamine to parahydroxytyrosine. It appears then








FIGjXLi Schematic Diagram of Adrenergic Synapse.
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and is the rate limiting step in the synthesis of NA. A number of
amino acids have bean shown to be potent inhibitors of TH activity
by competing with the substrate. The most potent inhibitors are
3-halogenated derivatives of methyltyrosine. It has been noted by
Udenfriend (173) that catechol compounds, including NA, can also
inhibit the enzyme by competing with the pteridine cofactor
(dihydrobiopterin) which has been shown to activate adrenergic tyrosine
hydroxylase. This latter inhibitory process may constitute a feedback
mechanism for the regulation of NA synthesis.
The second stage in the synthesis of NA is the decarboxylation
of L-dopa to form 3,4- dihydroxyphenylethylamine (Dopamine) in a
reaction catalysed by the enzyme aromatic-L-amino acid decarboxylase.
This enzyme is also responsible for the decarboxylation of 5-
hydroxytryptophan, I-histidine,/c methyl dopa and other amino acids.
This synthetic step can be inhibited by L-^ methyl dopa and
D^ me thyl-m-tyrosine but not by the IMsomer s (158). It is important
to note, when employing these agents in pharmacological manipulations,
that they are not soeeifie inhibitors of this reaction but affect
a wide range of enzyme systems (158).
Dopamine is converted to NA by a further hydroxylation.
The ensyme involved is dopamine^ -hydroxylase and the reaction
requires the presence of oxygen and ascorbic acid. Dopamine-^ -hydroxylase
is probably a copper enzyme, the function of ascorbate being to reduce
the cupric ions to cuprous, which are reoxidized during the
- 27 -
hydroxylation. The enzyme is non-specific and accepts a variety
of amines including phenylethylamine, tyramine, (+) amphetamine,
(+) p-GH-amphetamine and mescaline (74-) •
Competative inhibition by amino acetophenone analogues
of A and MA (adrenalone and arterenone) has been deomonstrated
in vivo (78). As one would exnect from the nature of the enzyme,
chelating agent3 such as E.D.T.A. and Msulfiram (reduced to
diethyldithiocarbamate) are also powerful inhibitors. It is
important to note that, with the possible exception of Disulfirara,
the inhibitors of neither decarboxylase nor dopamine-/^-hydroxylase
reduce endogenous levels of catecholamines appreciably as a
consequence of inhibition of synthesis (159). Several agents,
such a3^methyl-m-tyrosine, reduce tissue MA content but this has
been shown to be due to the displacement of the catechol by a 'false
transmitter' (27, 70, 174).
The^-hydroxylation of dopamine probably takes place within
the storage pool where the newly formed HA may form a complex with
ATP (94)• The active form of NA is released from the sympathetic
nerves on stimulation and an efficient process for the removal of
the transmitter must be available. Two enzyme systems, mono amine
oxidase (MAO) and catechol-O-raethyl transferase (CQiiT) are obvious
candidates for this role.
MAO which catalyses the oxidative dearaination of catecholamines
remains poorly characterized, largely because of the difficulty in
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in obtaining soluble preparations of this enzyme from raitrochondrial
particles. It does not aopear to be concerned with the removal of the
transmitter (since sympathetic nerve stimulation is not enhanced by
MO inhibition) but is probably responsible for the regulation of the
intraneuronal concentration of M (94-) • Inhibitors of MO fall Into
tvo classes. In general the non-hydrasine type are more specific than
the hydrazine inhibitors which interfere with a variety of enzymes
systems other than MAO. A high degree of MAO inhibition is necessary
for an increase in endogenous monoamines and this effect is dependent
on the species, the tissue, the amine, the mode of administration as
well as the chemistry of the inhibitor. It seems, that the concept
of a monoamine oxidase is still badly defined and the current
classifications of amine oxidases are obsolete. Blaschko (11) has
shown that the histaminaae of pig kidney is a •diamine oxidase' and the
histaminase in pig plasma is a 'monoamine oxidase'. Plasma amine
oxidases have been shown to exist in a number of mammalian species (12)
and have been implicated in the metabolism of exogenous amines (11) -
in particular mescaline.
COMT catalyses the transfer of methyl groups from S-adenosyl
methionine to the 3-hydroxy position of catecholamines. Hepatic
COMT appears to play an important role in the metabolism of circulating
MA (29) however, in vitro experiments (94) suggest that it only plays
a minor role in the inactivation of NA released by nerve stimulation.
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The discovery of dopacetamide, an inhibitor of COMT with a low
toxicity, should soon lead to a better understanding of the exact
function of the enzyme in vivo (28)*
It i3 now becoming generally accepted that the removal
of NA from active receptor sites is carried out by a non-raetabolic
process. The findings that tissue innervated by sympathetic
nerves lose their abilit" to take up MA when denervated and that
cocaine, which inhibits the active uptake of MA (184) causes a
marked potentiation of the effects of nerve stimulation, suggest that
the system is an important process in the inactivation of the amine.
HA, released from the sympathetic nerve presumably reacts
with an active receptor site on the nostsynaptic membrane. There Is
still much debate concerning the nature of adrenergic receptor 3ites.
Recently, on the occasion of the Second Symposium on Catecholamines,
lioran (113) has reviewed the situation and is of the opinion that
•Ahlquistb original classification of aloha and beta receptors
has been strengthened by events in the past 17 years, esoeclally by
the discovery of QC1 and subsequent beta adrenergic blocking drugs."
He concludes that "at present, the broad classification of two main
adrenergic receptor sites is the simplest and most convenient" and
that "most physiological effects of sympathomimetic drugs can be
placed in one of these two broad categories." There has been some
speculation about the nature of theo^and /^sites on the basis of the
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chemical properties of the catecholamines. However, in the absence
of more direct experimentation, the simple adrenergic receptor
proposed by Moran would appear to be the most acceptable i/orking
model.
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Muscholl (120) has suggested that it is useful to divide
sympathomimetic amines into three classes on the basis of their
effects followin denervation or cocaine* Using the nictitating
membrane of the cat, Fleckenstein and Burn (59) distinguished between
(a) amines which have no effect following denervation, (b) those that
are only slightly affected and (c) those whose actions are enhanced
by this procedure* The amines in group (a) which contain either
one or only one phenolic hydroxy1 group and lack of /^-hydroxy group
were assumed to act indirectly since their action was dependent upon
the presence of the transmitter at the nerve ending. Group (b) amines,
which have no more than one phenolic hydroxy grouo but all have a
^ -hydroxy group, appear to act both directly and indirectly* The
grouo (c) amines, catecholamines, probably act directly on the ost-
synaptic receptor site. Burn and Rand (35) observed that, after
reserpine pretreatment, the pressor action of the group (a) amines was
abolished*
Amphetamine, in this classification, is an indirectly acting
sympathomimetic amine (group (a)) and presumably acts by releasing NA*
I'his is supported by a number of experiments by Seheckel and Boff (U-0)
who have correlated behavioural excitation on a continuous avoidance
schedule with the selective retase of MA, The duration of the
stimulant effects of dCmmT was shown to coincide with the release of
MA, Also behavioural stimulation produced by TBZ, RQ4*-1234 or reserpine,
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in aniEials pretreated with HAGI, followed the .sane time course as the
depression produced by these drugs when given alone* The behavioural
depression had previously been shown to be related to the decrease
in brain amines* In the iproniazid pretreated animals, biochemical
studies revealed that there was a marked reduction in IIA concentrations
but only a sLight or no fall in the 5 HT levels* Iproniasid could not
reverse TBZ depression in rats pre treated with^ MMT indicating that,
when MA concentrations wore reduced, the subsequent administration of
Iproniaaid and TBZ could not release HA in sufficient quantities to
produce stimulation. The selective release of HA by email doses of
TBZ caused behavioural stimulation if imioramine is given to prevent
the reuptake of the released HA, There was a close temporal relation
between NA release and behavioural stimulation, which could be blocked
by first depleting th' amine with^ MKT,
However, Van Rossum et al (139) have demonstrated that
reserpine pretreatment did not appreciably affect the excitating
response to amphetamine in mice but the action of cocaine was completely
abolished. They concluded; 'These results strongly indicate that
coijicaine has an indirect arterenergic mechanism of action presumably
by releasing catecholamines from their stores. On the other hand,
Its seems to be proven that amphetamine has a direct a.rtenergic mechanism
of action,' These authors also reoort that large substituents on the
nitrogsn atom of amphetamine abolished the direct stimulant action of the
drug since the effect could be blocked by pretreatment with reserpine,
The results are 3omewhat confounded by their use of reserpine as an
amine-depleting agent 3ince this drug does not block the biosynthesis
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of NA nor inhibit uptake nto the nerve terminal (26). These two
processes may continue to supply the functional pool with Ilk,
enabling normal or even ehhanced sympathetic output (4-5).
Quintern and Ha lliwell (133) have carried out a complex
series of pharmacological manipulations in order to examine the mod#
of action of the amph tamine excitating response in rats. They
found that amphetamine excitation was enhanced by pretreatment with
reserpine (13 hours before) and this ehhanced excitation could be
abolished by ^Zd'eDopa (but not RQ4-4602, a powerful decarboxylase
inhibitor) given two hours orior to the amphetamine injection.
Furthermore, the blockade of reserpine induced enhancement of
amphetamine excitation could be reversed by DL DOP given approximately
one hour after amphetamine. In the absence of either, reserpine
pre treatment or reserpine and^MeBopa pretreatment, the DL dona had
no effect on amphetamine excitation. If the^ MeDopa was given just
before the reseroine or a MAO I just after it, then the reserpine induced
enhancement of amphetamine excitation could not be observed. Their
results suggest that although reserpine itself cannot block amphetamine
excitation the combined amine depleting actions of reserpine and<^ MeDopa
can. Tetrabenazine (TBZ) by itself can abolish the amphetamine
excitation, and DOPA given after the amphetamine can only cause an
excitation if t( MeDopa has been given previously. They report that the
amphetamine action can be accentuated by imipraralne and prolonged by
MAOIs.
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Although these results support the general hypothesis that
amphetamine excitation is dependent upon available HA, it is possible
thatX MeDopa, which can be converted into a 'false transmitter1,
only interferes with a direct action of amphetamine.
Weisoman et al (182) have used the amphetamine induced
excitation on a non-discriminated avoidance schedules and investigated
the effects of inhibition of HA synthesis on this response. They
demonstrated that^CMeT pre treatment abolishes the amphetamine excitation
and this blockade can be overcome by prior administration of MAOI
or imiprasine. Both MAQIs and iaipramine probably restore NA
levels to the critical level necessary for amphetamine action. This
evidence strongly supports an indirect action for amphetamine.
The issue becomes more complicated with the finding that D.H.I,
pretreatment or reserpine (13j, 164) plus D.M.I, pretreatraent potentiate
amphetamine action (165) but again, there has been no block of HA
synthesis and this may be sufficient to maintain the amphetamine
excitation and prolong the action by preventing reuptake. Sulser (164)
has shown that D.M.I, pretreatment resulted in a striking and subtained
elevation in the body levels of d-amphetamine. This suggests that
D.H.I, inhibits the metabolism of amphetamine in vivo leading to a
greater direct action of the drug. However, Dingell et al (53) have
confirmed this increase in brain amphetamine level following D.M.I.
but have further demonstrated that, even in the presence of this
enhanced concentration, the stimulatory actions of the drug could be
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prevented by tyrosine hydroxylase inhibition# It would appear than
that ^methyl tyrosine, in contrast to reserpine or^ methyl-meta-tyrosine
in doses which deplete brain HA. (166, 132), is capable of blocking
amphetamine excitation# This suggests that the mechanisms of stimulation
of amphetamine is dependent upon the availability of newly aynthesised
noradrenaline*
Axelrod (6) has examined the metabolism of amphetamine
in dogs* Within 4-3 hours of an intraperitoneal injection of the
d—isomer, 30$ was excreted in the urine unchanged, 11$ as free p-OH
amphetamine and 9$ as conjugated p-OH amphetamine. Plasma levels
were low and rate of removal from plasma was only 8$/hr* suggesting
extensive localisation in the tissue* Although this was true for both
dogs and rats he found that guinea pigs and rabbits excreted only small
amounts of amphetamine or the p-OH metabolite. In virto studies (7)
suggest that deamlrrtion may be an important mechanism in the guinea
pig and rabbit.
Goldstein et al (77) noted that the metabolism of amphetamine
isomers was similar, but that only (+) amphetamine was a substrate for
dopamine-^ -hydroxylase in vitro. Using tritrlated amphetamine,
Goldstein and Anagoste (75) found that in the rat the (♦) isomer
accumulated, in all organs, to a greater extent thai the (-) form.
Only amphetamine was found in the brain, amphetamine and p-OH amphetamine
in the liver and amphetamine, p-OH amphetamine and p-OH norephedrine
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(3-hydroxy,/£-GH amphetamine) in the heart* Pretreatment with a
powrful dopamine hydroxy la se inhibitor (diaulfiram) prevented the
formation of pOH norephedrine (76)* Whereas amphetamine is an
in vitro substrate for dopamines-hydroxy la ae it would not appear
to be so in vivo since no norephedrine was detected in any organ.
Goldstein et al (75) have suggested that amphetamine must first be
para-hydroxyla ted (mainly in the liver) before hydroxy la tion is
possible. It has been demonstrated by Kopin et al (106) that
^ -hydroxylation probably occurs in sympathetic nerve endings
and more specifically (130) in the granulated vesicles.
The pharmacology of the phenothiazlnes and hallucinogens
is not known, but a number of theories are held concerning possible
mechanisms of action. Much experimentation will be necessary
before any of them could finally be accepted. One assumption Is
that phenothiazines prevent the transition from resting to higher
levels of activity within the neurone by impeding electron transport.
Some investigators consider that phenothiazine activity is centred
at the cell membrane, selectively enhancing permeability. These
drugs are electron donors and they may prime the Na-K pump shifting
cellular activities toward normal, thereby quietening the manic and
activating the catatonic.
Since the phenothiazines have a carbon-nitrogen group on the
side chain just like 11kt competitive inhibition at the synapse is
another possibility. Sulaer (165) has suggested that C?Zs main
action is a blockade of adrenergic post synaptic sites whereas imipramine
like drags block the reuptake of N& through the pre-synaptic membrane
and have only weak adrenergic blocking properties at post synaptic
sites# Furthermore, the metabolic conversion of tertiary amines to
the corresponding secondary amines increases M potentiation (blockade
of amine transparent mechanism) and decreases sympatholytic
properties (blockade of post synaptic sites).
Very little indeed is known about the pharmacology of the
psychotomimetic drugs# LSD is a strong seretonin antagonist;
however this is not its mechanism of producing hallucinations since
Brom-LSD is a better seretonin antagonist, it crosses the blood-
brain barrier, and yet has not psychotomimetic properties. Although
a simple explanation of LSD action by the antagonism of brain
aeretonin is no longer tenable some close relationship between LSD and
indole amine receptor sites, may still exist. More subtle interactions
involving the binding, release and competition with seretonin may
still play an important role.
There is other evidence linking LSD to receptors for seretonin
in train. For example, when brain monoamines were depleted following
pre treatment with ressmine, the effect of LSD was markedly enhanced
and prolonged in both rat and man (5$ 60). MAOIs which raise amine
levels in brain have been reported to diminish the effects of LSD
in man (137)•
It has been noted that the half life of the drug as human plasraa
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correlated with the peak effect (l) and maximum increase in seretonin
liveIs were associated with the termination of the acute behavioural
effects (61)• As yet# this latter finding remains unexplained#
The chemical structure of mescaline suggests that it may
belong to the same pharmacologic group as U& and related sympatho¬
mimetic amines. In vitro studies (49) have shown that mescaline
can be demethyla ted to 3 #4 diraet hoxy-5-taydroxyphettfchylamine and
ne
3,5dimethoxy-4-hydroxypheJthyla®ine. The major metabolite, however,
is 3#4,5 triraethoxyphenylacetic acid and this deaaination could be
inhibited by iproniasid, aeaicarbazide and by nicotinamide and TPN.
Lesser inhibition was observed with n-octanol. Slotta and Muller (152)
were unable to detect the presence of 3*4,5 triraethosyphenylacetlc
acid in human urine although later experimenters have found that
IB% of the administered mescaline does occur as the acid derivative
(64) - the remaining recovered maternal being unchanged mescaline
(23%), Charalaxapoua et al (35) have confirmed the presence of mescaline
and the acid metabolite in humans# They also report finding small
amounts of N-scetyl-y^- (3,4 dimethoiy-S-hydroxyphenyl) ethylaraine
and K-acetylmescaline.
The acid metabolite (35, 152) and 3,4 dimethoxyphenethylamine
(64) have both been reported to be inactive in human studies.
Furthermore, the 2,3#4 triaethoxy derivative had little or no effect
in normal subjects bit reacted more strongly on the schizophrenic
than mescaline (152)# Peretz et al (125) found that#^ methyl
mescaline (3*4,5 trimethoxyamphetamine) was about twice as active
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as mescaline in humans. This has been confirmed by Shulgin (144)
who also reported that 2,4,5 triraethoxyamphetaraine was seventeen
times more active than mescaline and the 2,3,4 ,w®s inactive in
human subjects, (144).
Friedhoff and Van Winkle (65, 66) claimed that tritriated
dopamine given to schizophrenics was converted to 3,4-dimethoxy
phenylacetic acid which was detected in the urine. There is,
however, no confirraating evidence that it is actually WPS which is
present in schizophrenic urine but it is possible than some
schizophrenics are excreting a substance not found in normal
subjects. This appears as a pink spot on the chroma togram but has
not been positively identified as methoaylated derivative of
- phenylethylamine. Barbeau et al (8),using Friedhoff and Van
Winkle's chromatographic method, have shown that a pink spot occurs
in the urine of 80 per cent of patients suffering from arkinson' s
disease. Many studios, however, have failed to detect the pink
spot compound at all and the position has recently been reviewed by
Boulton et al (15)♦ Their studies, using a mass spectrograph,
indicate that 'pink spot* is, in fact para-tyramine and is more
prominent in Parkinson's disease than schizophrenia. This, in
Itself, is an interesting finding but since these authors used a
different extraction procedure from that employed by Friedhoff and






Avoidance procedures have figured prominently in studies of
psychopharmacological agents and have been of particular value in
characterizing some of the pharmacological properties of the earlier
tranquillizers and clearly differentiate them from C.N.S.
depressants ( 4-2) *
Heise and Boff ( 84. ) have compared avoidance procedures with
food-reinforced sehedules and conclude that the former are more
appropriate in drug interaction studies because there is greater
inter- and intra-session stability and they allow an examination
of behavioural depression unconfounded by 'anti-appetite* effects.
In general, the avoidance procedures can be separated into
two classes: discrete avoidance and continuous avoidance. The
discrete avoidance procedure involves presentation of a stimulus
(C.S.) for a fixed period of time before the delivery of a shook
(U.S.). A response during the C.S. terminates the C.S. and avoids
shock. If the conditioned avoidance response (C.A.R.) does not
oocur, the U.S. is presented and an escape response will terminate
the U.S. In a typical continuous avoidance procedure shocks of
brief duration are delivered at regular shock-shock intervals
unless the animal responds; each response postpones the shock
for a specified response-shock interval. The delivery of a
shock is the only exteroceptive stimulus change in this procedure
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whereas a C.3. is always involved in the discrete avoidance procedure,
The schedule employed in the present investigations was
a combination of both discrete and continuous avoidance procedures -
a discriminated continuous avoidance task, A stimulus light was
introduced into the continuous avoidance procedure to signal the
occurrence of shock. The effect of this preaveisive stimulus is
to create an area within the schedule (light on) where there is a
high probability of a response and a second are (light off) where
few responses occur. Thus the schedule is sensitive to both
stimulant and depressant drugs.
On the discriminated avoidance schedule employed in the
present investigation an animal receives a shock every 10 seconds
(Sg-Sj interval) unless it makes a lever press, A response on
the lever at any time postpones shock for 30 second (R-S2 interval).
During the last ten seconds of this response-shock interval a
discriminative stimulus light is turned on inside the experimental
chamber and remains on until the next lever press occurs. When
an animal has been exposed to this schedule for a long period of
time, the majority of its responses occur in the presence of the
preaversive stimulus - thus efficiently avoiding shock.
This schedule is similar to that used by two Italian
experimenters, Bovet and Gatti (16, 68, 69). They carried out
a fairly comprehensive study of a large variety of drugs over wide
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dose ranges and developed behavioural profiles which enabled them
to distinguish between drugs from different pharmacological
categories. The response output of the animal was classified
according to where it occurred in the schedule cycle. The
parameters used were an R-Sg interval of 30 seconds, and R-S^
interval of 18 seconds and an S2~S2 interval of 30 seconds.
Two electronic counters recorded the number of times the rat
pressed the lever during the 12 seconds after the light appeared
and the number of responses made during the 12 second period after
delivery of shock. Three response categories were then distinguished,
the number of 'conditioned responses*, tne number of 'unconditioned
responses* and the number of *non-motivated responses.* It is not
clear to the author why any response occurring within 12 seconds
of shock should be classified as an 'unconditioned response* since
the first response after shock terminates the stimulus light
and there is no justification for describing a response up to
12 seconds following this as an *unconditioned response' thus
implying that it is functionally related to the shock. An alternative
method of dealing with the data, without prejudging the issue, is to
make a distinction between interresponse times less than three
seconds (burst responses) and those greater than three seconds but
less than twenty seconds (premature responses) and then examine the

















FIG, 2: Classification of intern-response times on
discriminated continuous avoidance schedule
Since every response on a continuous avoidance schedule
postpones shock the term premature response (P) has been sub¬
stituted for 'non motivated' response, In experimental psychology
the term 'unconditioned response' is normally reserved for a response
which is elicited by a stimulus without previous conditioning,
^hus the knee> jerk in the patellar-tendom reflex is an 'unconditioned
response' since it is elicited by a tap on the knee without previous
learning. Rats do not normally press levers when they are shoekedl
The response category which Bovet and Gatti have called 'unconditioned
responses' has been renamed late responses (L) and includes only the
first response which is emitted following shock. Furthermore, since
responses at any time in the schedule cycle are products of the
reinforcement contingencies, and thus can be called conditioned, the
response category 'conditioned response' has been renamed efficient
response (E), The new response classification is shown in Fig, 2
Bovet and Gatti express the cumulative reaction time as a percentage
of the total experimental duration ($RT).
With these minor changes in definition and nomenclature,
the Bovet-Gatti classification has been employed in the present
investigations. Fig, 3 shows typical behavioural profiles
induced by chlorpromazine, reserpine and amytriptiline (or amphetamine)
taken from Bovet and Gatti ( 68 ), They have also tested
Imipramine, perphenazine, triflumethazine, chlorprothizene,










Premature Responses —Efficient Responses Late Responses Reaction Time
FIG* 3t Behavioural profiles for Chlorpromazine (A),
Reserpine (B) and Amytriptiline (C) after
Bovet and Gatti (68).
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During these drug investigations they found that the behavioural
parameters, described above, varied in a manner which was characteristic
of the drug in question.
It is clear that these studies form a very useful basis for
any psychopharmacological investigation which employs a discriminated
continuous avoidance schedule as a behavioural baseline.
4-5
DATA PROCESSING
The data from all the behavioural and drug experiments to be
described was collected in the form of cumulative records and the
time between consecutive responses# These inter-response times
(I.R.T. s) were recorded in sequence by a printing counter and
subsequently analysed by digital computer. It will be convenient to
discuss the entire functions of the computer program (Appendix A)
at this point since this standard program was employed throughout.
First Order Functions
The Programs Corrected all I.R.T.s for errors due to the printing
time of the counter.
Summated all corrected I.R.T.s until their sum was
equal to one hundred minutes, to the nearest I.R.T., and neglected
all others. Thus the experimental duration was kept constant.
Ill All corrected I.E.T.s falling within the first
one hundred minutes of the experiment were classified into four
categories (see Fig. 3)
(a) Burst Responses:- All responses occurring within three seconds
from previous response (I.R.T. 3 seconds)
(b)/
(b) Premature Responses:- All other responses occurring before the
onset of the stimulus light
(3 seconds <4 ^ 20 seconds)
(c) Efficient Responses:- All responses emitted during the conditioned
stimulus but before shock
(20 seconds I»R«T, ^ 30 seconds)
(d) Late Responses:- All responses emitted during the stimulus
light but after shock
(30 seconds ^ I.R.T.),
IV The frequency and probability of these four response
categories was calculated,
e.g. Probability of Efficient Response = Frequency of Efficient Response
Total number of I.R.T.s
V The frequency df the efficient responses during each
second of the ten second stimulus period was calculated and these
frequencies expressed as probabilities
e.g. Probability of 25 seconds ^ I.R.T. ^ 24 seconds »
Frequency 85 seconds > I»R.T, ^ 24 seconds
Total I.R.T.s
VI The Inter Response Time per opportunity statistic
(IRT/OP) was computed for each second of the 10 second stimulus period.
This estimates the probability of a response in a certain time interval
on the condition that the animal reaches the initial boundary of the
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interval and hence has an opportunity for a response in the interval.
It is clear that the number of opportunities for a given band of
I.R.T.S equals the number of I.R.T.s in the sample than are longer than
the lower limit of this band (Anger, 1963).
e.g. IRT/OP for 25 seconds I.R.T. ^ 24 seconds =
Frequency 25 seconds > I.R.T. ^ 24 seconds
Frequency I.R.T. ^ 24 seconds
VII The percentage reaction time was calculated in the same
manner as Bovet and Gatti
% RT - ((I.R.T. ^.20 seconds)-(20 seconds))xl00
Experimental Duration in seconds
All first-order data can be found in appendix B.
Second Order Functions*
This section of the program deals with the four response
categories classified by the First Order Analysis* Burst Responses (B),
Premature Responses (P), Efficient Responses (E) and Late Responses (L).
The program in appendix A calculates sequential dependencies up to 3rd
order condition probabilities but this information will not be referred
to in the present investigations since it was soon found that the sample
size which one can obtain from drug experiments using rats is not
sufficiently large to make meaningful deductions from this data.
Consider the sequence of I.R.T.ss-
25.4, 25.6, 30.1, 00.2, 00.1, 19.0, 27.6, 30.3
These would be classified:-
E ELB BPEL
The program then calculated the frequency of a B response
being followed by a B. The frequency of B being followed by a P etc.
For the data above f(B.B) = 1. That is, the frequency of all over¬
lapping binary combinations was calculated and expressed in a frequency
matrix in Appendix C.
These frequencies were then transformed into probabilities
by dividing each frequency by the total frequency of all binary
combinations. This data is also expressed as a matrix in Appendix C
For example, p(B.B) = l/7 = .H3.
A conditional probability matrix was also calculated
(Appendix C). For example the conditioned probability of the binary
combinations (B.B) is equal to the frequency of (B.B) divided by the
frequency of (B). For the data above
e.g. cp(B.B) ~ ~ 0.5
That is, the conditional probability of any binary combination is the
frequency of that combination divided by the frequency of the
first member of the combination. This data is more meaningful
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than the probability data sinee it takes into account the occurrence
of the first event and relates the second event to this occurrence.
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EXPERIMENT 1: AN ANALYSIS OF THE CONTROLLING VARIABLES
An adequate description of the behaviour generated by-
continuous avoidance schedules must include an identification of reinforce¬
ment for the avoidance response. Anger (4) and Wertheim (182)
investigated the nature of the controlling variables in non-discriminated
avoidance behaviour, and suggest that the decrease in aversiveness
of temporal stimuli at long post-response times (P.R.T.s) is the primary
source of reinforcement. ^idman (147) has reported that prolonged
training on a discriminated continuous avoidance schedule facilitates
the formation of an independent time discrimination, thus implicating
CATS (conditioned aversive temporal stimuli) as one source of reinforce¬
ment on the discriminated schedule. The relative importance of the
•temporal discrimination1 and the warning stimulus as controlling variables
has been studied by Ulrich et al (175)* They reported that with a
constant response-shock interval, response rate increased as the interval
between the response and the onset of the warning stimulus was shortened,
and hence concluded that the termination of the pre-shock signal was
the primary source of reinforcement on the discriminated schedule.
Since the schedule manipulations, carried out by Ulrich et al,
did not include any conditions where there was an opportunity for
the termination of long P.R.T.s ( and hence reinforcement ) prior
to the onset of the pre-aversive stimulus, and the results only
indicate that avoidance behaviour can be maintained in the absence of
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CATS and do not reflect directly on the relative importance of each
source of reinforcement on the original schedule.
It has been shown that the avoidance response may be maintained
(i) by the substitution of short P.R.T.s in place of longer P.R.T.S without
any exteroceptive warning stimulus, and (ii) by the termination of a
pre-aversive stimulus in the absence of CATS, The present report
describes the significance of both sources of reinforcement on the
continuous discriminated avoidance schedule.
Method
Subjectst
Six male Lister hooded rats, approximately 100 days old at
the start of the experiment, served a3 subjects.
Apparatus!
The apparatus was a standard one-lever rat chamber (GS-E3125C)
fitted with a shock grid, house light and stimulus lights. All
programming and recording equipment was contained in a separate room.
Procedure!
Ss were exposed to daily 2f hour sessions of discriminated
avoidance. A brief shock of 0.6 ma. and 0.5 seconds duration occurred
every 10 seconds (Ssg - S2) unless the lever was pressed. A response
on the lever at any time postponed the next shock for 30 seconds (R-S2).
After 20 seconds of the response-shock interval had elapsed the stimulus
lights (Si) were turned on inside the experimental chamber and remained
on until the next lever-press was emitted. These experimental
SECONDS |ONSET OF S°
FIG. Lki Inter-response time distribution on 75th avoidance
session for Rl.
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contingencies were introduced on the first day of training and were
in operation for 75 consecutive experimental sessions prior to the
schedule manipulation. All results presented or discussed are taken
from the last 2 hours of the experimental session. Inter-response
times were recorded in sequence by a printing counter and subsequent
analysis was carried out by digital computer.
jaatU&a a9d jBlaaaaalaa
Early avoidance is characterized by a high probability of a
response being emitted prior to the onset of the pre-aversive stimulus.
With prolonged training there is a progressive decline in this behaviour,
accompanied by an increase in the probability of a response occurring
in the presence of S-^ (Sidman, 147j Ulrich et al, 175)* A third
phase in the development of avoidance behaviour is shown in Fig. 4,
which is taken from the 75th avoidance session of animals R1 and R2+
(Appendix B Nos# 1-2). There is no further increase in the probability
of responses being emitted during SL but the inter-response time
distribution becomes skewed towards the latter half of the Naming'
stimulus. Both the I.R.T. distribution and the IRT/OP statistic
(Anger, 1963) reflect the development of a differential response to
•temporal' cues within the;pre-averslve stimulus.
+The I.R.T. distributions of these two animals represent the maximum
variation between animals found at this stage in training.
FIG ZJB: Intern-response time distribution on 75th avoidance
session for R2.
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It appears then, that early in acquisition, the light is a
conditioned aversive stimulus by virtue of repeated light-shock pairings.
Responses which are Emitted prior to the onset of the pre-shock signal,
avoid this conditioned aversive stimulus, and are thus reinforced.
Consequently, the number of light-shock pairings is reduced and the aversive
properties of the stimulus light diminish. Kamin et al (99) using a
conditioned suppression technique, have been able to monitor this decrease
in the aversive properties of warning stimulus which develops during the
course of avoidance training. In the second phase of avoidance behaviour,
the signal, as a conditioned aversive stimulus, is too weak to support
avoidance but sufficiently strong to support escape. The reinforcement
which maintains the avoidance behaviour described in Fig. 4 is probably
not the termination of the 'warning' signal per se, but rather escape
from a compound stimulus situation, involving both the pre-aversive stimulus
aad conditioned aversive temporal stimuli. That is, the variables which
control a non-discriminated avoidance schedule are operating within the
light period and are under control of the pre-shock signalj The CATS
associated with long post-S^ onset times (PS^T) would be very aversive
by virtue of their close proximity to shock. The 'temporal1 stimuli
at short PSjT would be less aversive and the CATS at short P.R.T. would
be least aversive. The greater the PSjT preceding the response (up to
shock) the greater the reinforcement of responses following long PSjTs.
It is clear that this 'temporal discrimination' is entirely dependent
upon the presence of and is distinct from that proposed by Sidman (147).
FIG. 5i Cumulative records showing the effects of different
R-Sn intervals on the avoidance response rate of R1
and R2, The records are taken from the first day on
which the schedule parameters were varied. Deflections
on the cumulative records signify shock and those on
the event marker signify responses prior to the onset
of the.stimulus light.
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On session 76 of the avoidance training, the R-S^ interval
was altered for 10 minute periods and the parameters were changed in a
different sequence for each of the two animals, R]_ and &lg» 5
is a series of cumulative records taken from session 76. Deflections
on the event-marker record indicate responses which occurred prior to
the onset of Sp When was decreased from 20 seconds to 10 seconds
and R-Sjfc was kept constant, the response rate of both subjects increased.
This agrees with the findings of Ulrich et al (175)• However, #hen the
R-S-^ Interval was increased to 30 seconds and - 3g interval kept at
10 seconds, there was no change in the response rate. The majority of
responses were emitted between 20 and 30 seconds. Since these occurred
before the onset of the pre-shock signal, it would appear that they are
reinforced by the substitution of short P.R.T.s for long P.R.T.s, thus
implicating conditioned aversive temporal stimuli as one source of
reinforcements on the original schedule. The R~3j_ manipulations described
in Fig. 5 were carried out on the following three daily sessions. By
session 79, the increase in rate associated with the decrease in R-Sp
still persisted but responding prior to Sp when R-S^ was increased,
had extinguished. This suggests that escape from is the most
important source of reinforcement on the discriminated schedule.
It is relevant that the response distribution within the pre-shock signal,
when R^-S]_ was decreased, still tended to be skewed.
It would appear, then, from these investigations, that the
primary source of reinforcement on the discriminated continuous avoidance
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schedule, is escape from the conditioned aversive temporal stimuli
which are at present at long &-jT.
Summary
Having examined the reinforcement contingencies which are
in operation on the continuous discriminated avoidance schedule it will
now be useful to review the suitability of this schedule for pgycho-
p ha rmacologica1 investigations.
I Avoidance schedules generate greater inter- and intra-
session stability than positive reinforcement schedules (34.) and are
thus more compatible with a Steady-State Methodology (149).
II Avoidance schedules allow an examination of drug induced
behavioural depression unconfounded by 'anti anpetite' effects (34)•
III The programming and data analysis can be entirely
automatic thus reducing experimental error.
IV Continuous avoidance schedules are more sensitive to
drug action than discrete avoidance schedules (34)•
V The extensive studies of Bovet and Gatti form a useful
basis for any drug manipulations using this schedule (16, 63, 69).
VI The schedule generates periods of high and low response
probability and is thus suitable for examining stimulant a© well as
depressant drugs.
VII The schedule involves both a visual and temporal discrimin¬
ation so that drug effects may be examined on behaviour controlled by both
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external and internal stimuli (110)•
VIII The schedule is capable of detecting any 'biphasic
effect' on reaction time such as that reported to occur then hallucinogenic
drugs were administered to animals on discrete avoidance schedules
(154, 155, 156, 157).
SECTION IV
THE EFFECTS ON DRUGS ON THE SCHEPITTE
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BEHAVIOURAL STABILITY
No stability criteria were employed but it is clear from
Appendix B Nos. 1-6, that all animals had reached a high level of
performance ( > 30$ efficient) after 75 avoidance sessions. An
earlier study had shown that an even higher level of performance
was possible ( >95$ efficient) using higher shock intensities (l»5 ma.)
and a shorter S]_ - Sg interval (5 seconds). Increasing the - S?
interval to ten seconds and decreasing the shock intensity to 0.5 ma.
aided the development of the temporal distribution within the stimulus
light and made the schedule more sensitive to drug action.
The level of performance remained stable throughout the
experiments. Data in Appendix B ^os. 1-12 compares the performance
of all the animals at least six months later, with the performance on
the 75th avoidance session.
Saline injections were administered to all animals on the day
before and the day after every drug administration during experiments
2, 3,4, 5, 6 and 7. No effect of saline injections could be detected
except for a slight disturbance on the day following high doses of amphetamine,
(This also occurred in the absence of the injection). In the
remaining experiments, with the exception of pretreatment studies, where
fluid volume might haye been important, all saline injections were
neglected. This negligence appears to be justified by the absence of
+
This experiment drew attention to the importance of the response
distribution within the - 32 interval which was then increased
from five to ten seconds for all subsequent experiments.
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any saline effect and the importance of maintaining the health of
the animals by minimizing the number of intraperitoneal injections.
FIG* 6» The effects of increasing dosage of Chlorpromazine
on three parameters of the avoidance schedule.
T.R. = Total responses
p(E) = Probability of efficient response
p(L) = Probability of late response.
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EXPERIMENT 2: THE EFFECTS OF OHIORFROM&ZINE ON THE AVOIDAN T SCHEDULE
Method
Subjects and Apparatus!
Two of the trained Lister hooded rats (R^ and R^) served as
subjects. The aoparatus was similar to that described in the previous
experiment#
Procedures
Throughout the experiment each subject was tested at the same
time every day for 2f~ hours. The experimental session can be subdivided
into a 15 minute 'warm up' period, a 30 minute pre-injection or control
period and a two hour test period. Each S served as his own control
and was injected with 0.5 ccs (i.p.) of a physiological saline solution
on the pre- and oost-drug days, Drugs were given after the pre-injection
period and the subject was immediately placed in the Skinner box for
the two hour test period.
Each S received three doses of CPZ (0.5 mg/kg, 1,0 mg/kg and
2,0 mg/kg) in a total fLud volume of 0,5 ccs (i.p#) Each animal i-ms
subjected to a different drug sequence with two weeks elapsing between
each drug administration.
The data was collected in the form of sequential I.R.T.s
and analysed by the standard computer program (Appendix A),
Results and Discussion






FIG» 7: Inter-response time distribution showing the




FIG. 8: Cumulative record showing the occurrence of burst
responding following 3hock after treatment with
Chlorpromazine.
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the saline control days nor the pre-injection period prior to drug
administration. Fig. 6 shows the effects of increasing dosage of
CPZ on the behaviour of both animals (Appendix B Nos. 13-18).
Concurrent with the decrease in total response rate (TR) and the probability
of an efficient response (p(E)) there is an increase in the probability
of a late response (p(L))* Fig. 7 is a typical I.R.T. distribution
following CPZ (Appendix B No. 14.). It is clear that there is an
increase in the probability of a response being emitted before the onset
of the stimulus light (premature and burst responses). Bovet and Gatti
(68), however, have reported a decrease in premature responses (they
call this category 'non-motivated' responses) under CPZ. There appears
to be a simple explanation for this discrepancy. Under CPZ the animals
tend to 'ignore' the warning stimulus and thus receive shock. From
the sequential print out of I.R.T.s it was clear that a shock was often
followed by a number of very short latency responses (Fig. 8). Since
Bovet and Gatti classified all responses occurring within twelve seconds
of shock as 'unconditioned responses' then they would detect no increase
in 'non motivated' response. Burst responses, as defined earlier, would
be classified in the 'unconditioned response' category# When I.R.T.s
^ 3 seconds are ignored on Fig. 7 then the probability pre-light responses
are not affected by the drug. Furthermore, it is very probable that the
animals used by Bovet and Gatti were not trained to the same level of
performance and made a high percentage of 'non motivated' responses on
control days. Measurements from their published data (68) suggest that
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that this was indeed the case. The acquisition data reported in
Experiment 1 andthe observations of Maffi (114) suggest that these «non
motivated' responses can be considered as secondary avoidance responses.
That is, they avoid the stimulus light which is a strong conditioned
negative reinforcer during acquisition (Kamin (99))• Maffi (114)
has demonstrated that CPZ blocks both the primary and secondary avoidance
response. It would appear then that where there is a high probability
of 'non motivated' responses the effect of CPZ would be to cause a
substantial reduction in this response category as reported by Bovet
and Gatti (Fig. 2). On the other hand, where there is only a low
probability of a premature response being emitted, as in the present
experiment, one would expect little or no change in this category.
Figs. 9, 10, 11 show the complete second-order probability
distributions for all three doses of CPZ, All probabilities which
occupy less than 5% of the total distribution are neglected on the
figures (Appendix C Nos. 1-3). The equivalent data for the second
animal is in Appendix C Nos. A - 6. As the dose of CPZ increases from
0.5 mg/kg to 2.0 mg/kg there is a progressive increase in p(L.L) and of
course p(E.E) decreases. The characteristic burst following shocks
p(L.B) shown in Fig. 8 is present at all dose levels. An increase in
p(L,B) could easily be due to increased frequency of shock. i.e. Increase
in p(L) causes increase in p(B) and therefore increase in p(L,B). An
examination of the conditional probabilities, however, reveals that this
is not the whole story.. The relationship between late and burst
FIG. 9? Histogram showing the second order probability-
distribution following 0.5 rag/kg Chlorpromazine.
All probabilities less than 0.05 are neglected
from the figure. (Subject R5).
FIG. 10: Histogram showing the second order probability-
distribution following 1.0 mg/kg Chlorpromazine.
All probabilities less than 0.05 are neglected
from the figure. (Subject R5).
FIG* lit Histogram showing the second order probability
distribution following 2.0 mg/kg Ghlorpromazine.
All probabilities less than 0.05 are neglected
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FIG. 12: Conditional probability of a burst response (A)
or a late response (B) following a late response
under three doses of Chlorpromazine.
(Subject R6).
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responses, where the frequency of late responses is taken into
consideration, (conditional probabilities) is shown in Fig. 12.
At all dose levels there is a higher conditional probability of a
burst response following a late response (cp(L.B)) than on control
days. The values (0.1 to 0.3) are much lower than that reported by
Clark and Steele (0.98) using a non-discriminated avoidance schedule
(39). This is probably related to the fact that there is immediate
feedback (light goes off) on the discriminated schedule indicating
that a response has been effective.
The present experiment does not throw any light on the
reason for the increase in cp(L.B) under CPZ. At least two hypotheses
are possible (a) CPZ per se decreases shock threshold (b) CPZ leads to
the animal receiving more shock and therefore shock threshold is
decreases (sensitization). It should be possible to distinguish
between these two alternatives by delivery of a fixed number of 'free
shocks' (not related to schedule) to the same animal during extinction
with or without CPZ.
Fig. 12 shows a clear dose dependent increase in cp (L.L).
This indicates that, as the dose of CPZ increases, there is an increase
in the frequency of runs of late responses (see Fig. 8).
gppclflpj,pnfr
When account is taken of the slightly different response
classification employed in the present investigation then the effects of
CPZ on the discriminated avoidance sbhedule are similar to those reported
by Bovet and Gatti.
FIG* 13i The effects of increasing dosage of Amphetamine
on four parameters of the avoidance schedule.
T.R. = Total responses
$RT = Percentage reaction time
p(p) = Probability of premature response
p(L) = Probability of late response.
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EXPERIMENT 3: TIE EFFECTS OF AMPHETAMINE ON THE AVOIDANCE SCHEDULE
Method
Subjects and Apparatus:
Two of the trained Lister Hooded rats (RI and R4) served
as subjects. The apparatus was similar to that described before.
Procedure:
The session length and injection procedure were similar
to that described in the previous experiment. Each S served as his
own control and received 0.5 ccs (i.p.) of physiological saline on
the pre-and post-drug days. Four doses of amphetamine 0.5 mg/kg,
1.0 mg/kg, 2.0 mg/kg and 4.0 mg/kg were studied. Rl was given
all doses in the following order - 2,0 mg/kg, 0.5 mg/kg, 1.0 mg/kg
and 4.0 mg/kg. B4 received 4.0 mg/kg on two separate occasions.
The drugs were dissolved in 0.5 cc saline and two weeks elapsed
between each administration.
The data ■was collected in the form of sequential I,R.T.s
and analysed by the standard computer program.
Results and Discussion
Fig. 13 shows the effects of increasing dosage on the
performance of Rl (Appendix B Nos. 19-22). As the dose of amphetamine
increased from 0.5 mg/kg to 2.0 mg/kg there was a corresponding increase
in the total number of responses, the probability of a premature response,
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and the percentage reaction time. The increase in the probability
of premature responding agrees well with the general hypothesis of
Weiss and Laties (130) that amphetamine 'generates responding at
probabilities that ordinarily are not great enough to maintain
responding.' This was also reflected in the form of the response
distribution within the pre-aversive stimulus (Fig. 14)* There was
a marked skew in the distribution towards the onset of the stimulus
light. On control day3, few responses occurred early in the stimulus
period since the conditioned aversive temporal stimuli at these short
post S]_ times were not sufficient to maintain responding (see
Experiment 1). Under amohetamine, however, it would appear that the
reinforcement threshold has been reduced (162) and the stimulus light
is a strong negative reinforcor. It is relevant that Brady (19) has
shown that amphetamine enhances conditioned suppression. This supnorts
the general hypothesis that amphetamine increases the aversive
properties of a stimulus by reducing the reinforcement threshold.
The increase in response rate under amphetamine should,
therefore, not be considered as a 'motor stimulation' per se but as
a direct result of increased 'motivation', or more explicitly decreased
reinforcement threshold. It is possible that premature responses
occurred as a result of a loss in stimulus control. That is, the
animal could no longer 'discriminate' between the light-on period and
the light-off period. This will be considered in a subsequent experiment.
The behavioural effects of 4»0 mg/kg amphetamine for R1 and
O-2-i
2 nig / Kg AMPHETAMINE
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FIG. 1A: Inter-response time distribution showing the effects
of 2.0 mg/kg Amphetamine. (Subject Rl).
- 65 -
and R4 are shown in Fig. 13. It is clear that the effects of this
high dose of amphetamine were not in line with the general trend. Although
there is a further increase in the probability of late responses} the
total response rate and probability of a premature response both decreased.
Observation of the animals suggest thit was not due to any motor deficit.
The animals were hyperactive although not responding on the lever.
Increased salivation was also apparent. The behaviour was similar
to that observed by Clarke and Steele (4-0) using high doses of amphetamine
on a positive reinforcement schedule. The animals often received many
shocks before emitting a lever press (long IiR.T.s) as well as the
typical short I.R.T,s which occurred with lower doses of the drug.
If the animal did not respond early in the stimulus period
then, normally, it would not respond at all until a shock, or series
of shocks, had been delivered. Therefore, I.R.T. distributions
(Appendix B Nos. 22 - 24) for the high dose of amphetamine still exhibit
a marked dkew towards the onset of the stimulus light.
Fig. 15 presents the second order probabilities for R1
at the low doses of amphetamine (Appendix C Nos. 7 - 9). There is
a clear trend in the data. The stimulation of amphetamine is reflected
in the increasing p(P.P) with the increasing dosage. It is important to
note that the increased p(P) and p(P.P) occur in their absence of any
significant increase in p(L). This exiudes the possibility that the
increase in premature responding under amphetamine can be considered as
avoidance responses of the stimulus light which has become a stronger
0-5'
v 0-4-
FIG. 15: Histograms Showing the second order probability
distributions following three doses of Amphetamine.
All probabilities less than 0.05 are neglected
from the figure. (Subject Rl).
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conditioned negative reinforcer by virtue of increased light-shock
pairings.
Cpnclflpioqg
The effects of low doses of amphetamine on the discriminated
continuous avoidance schedule are similar to those described by Sovet
and Gatti and can easily be distinguished from the effects of CPZ.
High doses of amphetamine cause an unusual behaviour pattern which
resembles the low dosage effect only in the marked skew in the response




FIG. 16; Intern-response time distribution showing the effect
of 12.5 mg/kg Mescaline.
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EXPERIMENT Li THE EFFECTS OF HALLUCINOGENS ON THE AVOIjANC ' SCHEDULE
Method
Subjects and Apparatus:
Five of the trained Lister hooded rats (Rl, R2, R3, R-4 and R5)
served as subjects. The standard programming and recording equioment
were employed.
Procedure:
The experimental design and drug administration procedure
have already been described in the previous experiments. Animals
Rl, R2 and R3 each received 12.5 mg/kg, 17.5 mg/kg and 25.0 rag/kg
mescaline, in a random order. Subject P4 wa3 given 0.25 mg/kg, 0.5 mg/kg
and 1.0 mg/kg LSD and R5 received 25.0 nig/kg mescaline, 1.0 mg/kg LSD
and 10.0 mg/kg N,N Dimethyltryptamine. These three drugs cover a wide
range of structural differences within the psychotomimetic classification.
As before, all drugs were given intraoeritoneally in 0.5 ccs
saline and two weeks were allowed to elapse between each drug administration.
The data was analysed by the standard program.
Results and Discussion
Fig. 16 shows a typical I.R.T. distribution following
12,5 mg/kg mescaline. The only observable effect of this dose was a
disturbance of the I.R.T. distribution within the stimulus period
(cf« Fig. 4). The p(?) and p(L) remained unchanged. The net result
therefore, was a decrease in the % RT, Using a shuttle-box avoidance
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procedure, Smythies and Sykes (154-) have reported a similar decrease in
reaction time following 12.5 mg/kg mescaline. Measurements from their
published data (156) reveal that, in some cases, they obtained (D-S)
scores for four animals, with greater than 16 seconds reduction in
reaction time, Thus, since the average (D-S) score was approximately
J+ seconds, it follows that on saline control days, their animals must
have allowed at least four seconds, of the five second C3, to elapse before
crossing to the other side of the shuttle-box. It would aopear then,
that the experimental procedure they employed, (80-85$ avoidance criterion
and prolonged 'warm up' period) facilitated the development of a 'temporal
discrimination', similar to the present experiment, and it is the disruption
of this process that causes the decrease in reaction time observed at
low doses of mescaline.
It is not surorising that a disturbance of the response
distribution within the C.S, is the first detectable behavioural change
since Laties and Weiss (lid) have shown that behaviour controlled by
internal stimuli (temporal discrimination) is less resistant to drug
effects than behaviour controlled by external stimuli (visual discrimination).
There was no marked skew in the response distribution towards
the onset of the Cf3. as was the case for amphetamine. This wfi3 true
for all doses of the drug (Appendix B Nos. 25 - 33). The 'stimulant'
action of mescaline is therefore much less than that for amphetamine
and not sufficient to cause an increase in p(p) at 12,5 mg/kg. This
is also true for a Irw dose (0.25 mg/kg) of LSD.
Dosage of Mescaline in mg/kg
R1 R2 R3
FIG. 17» The effects of Increasing dosage of Mescaline
on four parameters of the avoidance schedule.
p(P) = Probability of premature response
p(E) = Probability of efficient response
p(L) = Probability of late response
$RT = Percentage reaction time.
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Using low doses of LSD, Taeschler et al (163) found a similar
decrease in latency of jumping a rod in an avoidance situation - in this
case performance was improved. Jerard (97) had also reported an
improved performance with small doses of LSD, in a non-discriminated
avoidance situation. Both these authors used a decrease in the probability
of shock as an index of improved performance and the efficiency of the
behaviour was not considered. Thus, even amphetamine at low doses,
which causes a decrease in shock received, would be considered to improve
performance even though the high rate was inefficient in terms of the
number of responses necessary for successful avoidance.
Although no significant improvement was detected against the
high pre-drug performance levels in the present pxperiment, the results
suggest that a reduction in shock probability could be observed against
a less efficient behavioural baseline. It was noted in Experiment 1
that the temporal distribution within the C3 period was equivalent to
a non-discriminated avoidance schedule. Since 12,5 mg/kg mescaline
caused a shift in this response distribution towards shorter I.R.T.s
then it would abiost certainly have the same effect on a non-discriminated
schedule causing less efficient behaviour", but a reduction in the number
of shocks received. Although Jerard does not report the exact shock
frequency on control days it aopears to be in the order of 130 shocks in
a two hour session. Even the slight forward skew in the response
distribution observed after 12.5 mg/kg mescaline should be sufficient
to reduce this shock frequency.
FIG. 18: Behavioural profiles for 25.0 mg/kg Mescaline (A),
0.5 mg/kg L.S.D. (B) and 10.0 mg/kg N,N-Dimethyl-
tryptamine.
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The effects of increasing dosage on four of the behavioural
parameters can be seen in Fig. 17. Mescaline caused a dose dependent
increase in p(P), p(L) and % RT. The impaired performance at high
doses of hallucinogens has been reported by many authors (97, 154) and
does not aopear to be due to any motor defect at these doses. Both
Smythies and Sykes (154) and -Jerard (97) have stressed these 'central-
stimulating* and 'central-depressing' actions of hallucinogenic drugs
depending on dose level.
The high dose mescaline effect is presented in the form of
a Bovet and Gatti behavioural profile in Fig. 18 (Appendix B No. 37).
The effects of 0.5 mg/kg LSD (Appendix B No. 38) and 10 mg/kg N,N DMT
(Appendix B No. 39) are also shown.
It would appear that high doses of hallucinogenic drugs cause
an increase in p(P), p(L) and % RT, whereas low doses only decrease
% RT on this behavioural test. This is quite different from the
amphetamine increase in p(P) which was not associated with an increase
in p(L), At high doses of amphetamine, when an increase in p(L) did
occur, there was always a marked skew in the I.R.T. distribution towards
the onset of the stimulus light. The response distribution within the
stimulus period following a high dose of hallucinogen, was similar
to that observed following low doses of these drugs.
The second order distributions for all animals receiving
three doses of mescaline are shown in Figs. 19, 20, 21. Although
there was some individual difference, the general trend was similar for
FIG. 19I Histograms showing the second order probability-
distributions following three doses of Mescaline,
All probabilities less than 0.05 are neglected
from the figure. (Subject Rl).
FIG. 20: Histograms showing the second order probability
distributions following three doses of Mescaline.
All probabilities less than 0.05 are neglected
from the figure. (Subject R2).
FIG. 21: Histograms showing the second order probability-
distributions following three doses of Mescaline,
All probabilities less than 0.05 are neglected
from the figure. (Subject R3).
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for all animals. The p(P.P) was very low and never occurred in the
absence of a comparable increase in p(L.L). Premature responses
under mescaline do not therefore occur in runs to the same extent as
that observed with amphetamine. Unlike CPZ, the p(L,B) was very low
at all dose levels.
Conclusions
The typical behaviour profile for a high dose of a psychoto¬
mimetic drug is (a) an increase in p(L)j (b) an increase in p(P)j
(c) an increase in % RTj (d) a decrease in p(E); (e) a disruption of
the I.R.T, distribution Within the stimulus light. This last effect
occurs, at low doses of hallucinogens, without any increase in p(L)
and is reflected in a decrease in % RT.
The 'stimulant' action of amphetamine, which is characterized
by (1) increase in response rate, (II) marked skew in response distribution
within CS and (ill) incye4ajge in p(P) at doses which do not increase p(L),
can be clearly distinguished from the effects of hallucinogenic drugs.
The behavioural changes following GPZ are quite different.
At no dose investigated was their any significant increase in premature
responding and the I.R.T. distribution during the stimulus light was
not affected.
None of the drugs studied by Bovet and Gatti feave behavioural





From the viewpoint of a functional analysis of behaviour
a drug alters behaviour by modifying the control of the independent
variables of the schedule which controls that behaviour. It was
clear from experiment 1 that the major controlling variable on the
discriminated avoidance schedule was the stimulus light. We can
distinguish between two aspects of the stimulus; the stimulus control
or visual discrimination nnd the avoraive prooerties of the stimulus.
These arc not independent properties of the stimulus since the light
car. have no avergive -rooerties unless it 'can be discriminated* by
the animal. Two experiments, however, were carried out to investigate
the effects of C?Z, amphetamine and mescaline on these two aspects
of the visnal stimulus irhich controlled the standard avoidance
schedule.
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EXPERIMENT 5: THE EFFECTS OF DRUGS ON VISUAL DISCRIMINATION
Method
Subjects and Apparatus!
Two male Lister hooded rats (R7 and R8) served as subjects.
The experimental chamber was a modified two-lever Behaviour Aoparatus
Skinner Box fitted with a house light, two cue lights, a buzzer and
shock grids. The shock grids of the standard Behaviour Apparatus
box were turned through 90°, so that they ran parallel to the sides
of the chamber. This was necessary since it was soon found that
the animals could avoid shock by standing on one bar of the grid,
rather than pressing the lever. In the new position, bar-press
avoidance developed in preference to any other avoidance behaviour.
The intensity of the house light, cue lights and shock source were
altered until they appi*oxima ted that of the Grason-Stadler chamber.
A volt house buzzer was used as an auditory stimulus.
Procedure!
Both animals were exposed to the standard discriminated
continuous avoidance schedule, with a R-Sp interval of 30 seconds
and a 3p-S2 interval of 10 seconds, for daily, two hour avoidance
sessions, The warning stimulus (S^) in the present experiment,
however, was a buzzer, instead of the two cue lights, and a response
on either lever was effective in postooning shock, These experimental
conditions were in operation for thirty days. At the end of this
saline
FIG. 22: Kymograph record showing the effects of Saline on a
two lever discriminated continuous avoidance schedule.
(Subject R7).
Sf = Warning buzzer
R-^ = Responses on first lever
Sd = Discriminative stimulus light
Rg = Responses on second lever
S^r » Shock.
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time both animals had attained a high level of avoidance behaviour.
On day thirty-one of avoidance training, the cue lights
(S ) were turned on inside the exoerimental chamber. In the
presence of only a response on one lever (R^) was effective in
avoiding shock. When the animals were efficiently avoiding on this
lever the cue lights were turned off and only a response on the
other lever (Rg) postponed shock. This switching procedure was
in operation over the following twenty days with fS on' and
d
'S off periods becoming progessively shorter. At the end of this
period rat R7 was under the control of but the behaviour of
R8 became completely disorganized and eventually this animal had to
be discarded from the experiment.
The behaviour of R7 was monitored by a five channel pen
recorder and a series of counters which recorded the number of
shocks, number of responses on R1 and number of responses on R2,
d d
The presentation of S was under manual control and S vras never
J
turned on or off in the presence of the buzzer. The final SQ
interval was approximately theee minutes and a typical record of
the steady-state performance of R7 under these conditions is shown
in Fig. 22. The pen marked was deflected to the right in the
-t
presence of the cue lights and to the left in their absence. 3 g
marked the occurrence of shock and Sf was deflected in the presence






FIG. 23t Kymograph record showing the effects of 1.0 mg/kg
Amphetamine on a two lever discriminated continuous
avoidance schedule. (Subject R7).
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and R2. There was a very high level of performance on saline control
days# Few responses were emitted in the absence of the warning
stimulus (see regular S^r) and very few shocks were delivered.
The animal received 1.0 mg/kg amphetamine, 17.5 mg/kg mescaline,
2.0 mg/kg CPZ, 25.0 mg/kg mescaline, 1.0 mg/kg CPZ and 4»0 mg/kg
amphetamine in that order, Two weeks elapsed between each drug
administration and physiological saline control injections were
given on the pre- and post-drug days. Drugs and saline injections
(0.5 ccs fluid) were given after a one hour 'warm up' period and the
animal replaced in test chamber for a one hour test period. The
complete drug and average saline data are in Appendix D Nos. 1-7.
Results and Discussion
Fig. 23 shows the effects of 1.0 mg/kg amphetamine (Appendix D
No. 2). This dose of the drug caused a high rate of responding
on both levers but the responses were still well under the control
of S^. There was a high percentage of premature responses reflected
in the figure by a decrease in the frequency of S][r. When the
buzzer was allowed to come on, a response was emitted almost
immediately.
The typical effects of CPZ are shown in Fig, 24., Total
response rate was decreased following both doses of this drug and
the frequency of shock increased. At 1.0 mg/kg there was no escape











.34' Kymograph record showing the effects of 2.0 mg/kg
Chlorpromazine on a two lever discriminated continuous
avoidance schedule. (Subject R7).
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shocks before an escape response was emitted. Bar holding was
prevalent at both doses of the drug (prolonged deflection of R1 or
R2). There was a loss in 'discrimination' especially after
r\
2,0 mg/kg of CPZ but the errors almost always occurred at the 5
switch over. Thus, in Appendix D, a distinction is made between
errors immediately following the change in the cue lights (Oj^) and
other discrimination errors (%)•
The effects of 25*0 mg/kg mescaline are shown in Fig, 25.
As with CPZ, there was an increase in shocks at both doses although
escape failure was more prominent following the higher dose of the
drug. The record is characterized by both bar holding and discrete
pressing with an increase in both premature and late responding.
The loss in visual discrimination was marked at the 25*0 mg/kg
level and this was not confined to periods when shock was being
delivered (see upper section of Fig, 25). A very similar record
was obtained for 4*0 mg/kg amphetamine (Appendix D No. 7).
The drug effects on the basic avoidance schedule in the
present experiment are very similar to those obtained with the
standard schedule described in the previous experiments. One
notable exception is the increase in response rate following
mescaline and the high dose of amphetamine. This is probably
related to the buzzer being a more effective warning stimulus
than the lights.
25mg/kg mescaline
FIG. 25: Kymograph record showing the effects of 25*0 mg/kg
Mescaline on a two lever discriminated continuous
avoidance schedule# (Subject R7)•
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A discussion of the results of the present experiment
will be witheld until the next experiment has been described.
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EXPERIMENT 6: THE EFFECTS OF DRUGS ON CONDITIONED INFLATION
The conditioned suppression effect was first described by
Estes and Skinner (55)« They carried out a series of experiments
in which they demonstrated that repeated presentations of a tone,
terminated by an electric shock, had the effect of suppressing
bar-pressing behaviour which was maintained by food reinforcement.
Sidman (14-9) has demonstrated that the same procedure was an
avoidance schedule. Both conditioned suppression and conditioned
inflation are accompanied by the behavioural and physiological"1" signs
of stress.
If a drug decreases the aversive properties of stimulus
then one would expect a loss of the conditioned suppression or
inflation which normally accompanies the presence of this stimulus.
Thus, a condition suppression or inflation experiment allows an
investigation of the effects of drugs on the aversive properties of
the stimulus lights which control the standard avoidance schedule.
The conditioned inflation technique is more relevant to the present
The author has assisted in an experiment demonstrating conditioned
suppression and conditioned inflation in human subjects. Records
of skin resistance reported a marked decrease in the presence of the
conditioned stimulus and all subjects reported feeling very anxious
in the presence of the warning stimulus (132).
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investigation since it permits an examination of the negative
reinforcement properties of a stimulus in an avoidance situation.
Method
Subjects and Apparatus*
Two male Lister hooded rats (R9 and RIO) served as subjects.
The experimental chamber was a one-lever Behaviour Apparatus Skinner
Box with the modifications described in the previous experiment.
Procedure:
Both animals were exposed to a norv-discriminated avoidance
schedule with a R-Sj_ interval of 30 seconds and a S2 - Sg interval
of 10 seconds. When these experimental contingencies had been
in operation for twenty-seven consecutive daily, two hour
sessions, both animals had reached a high level of performance.
During the next ten experimental sessions a conditioned inflation
procedure was brought into operation. Following a one hour 'warm
up' period, the stimulus lights were turned on for the last three
minutes of every ten minute period, in the remaining hour of the
experimental session. Each of the six stimulus periods was immediately
followed by a brief unavoidable electric shock (0.5 m.a., 0.5 sec.).
At the end of sixty stimulus-shock pairings both animals showed
a consistent increase in response rate in the presence of the warning
stimulus.
Each animal received 1.0 mg/kg amphetamine, 17.5 mg/kg mescaline,
2.0 mg/kg CPZ, 12.5 mg/kg mescaline, 1.0 mg/kg CPZ, 25.0 mg/kg mescaline
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and 4,0 mo/kg amphetamine in that order. Two weeks elapsed between
each drug administration and physiological at line control injections
were given on the pre- and post-drug days. Drugs and saline
injections (0.5 ccs fluid) were given after the one hour *warm up*
period and the animal replaced in the test chamber for a one hour
test period. Two counters recorded the number of lever presses
eiidttea during the three minutes just before stimulus light and
the three minutes stimulus period. An inflation ratio was then
c&eulated. t
Degree of Inflation - fl£ jMBfflaaa 3 jataa&Sa c«ti«
no. during 3 minutes prior to C.S.
BaaaJUift *a& /Dtamsatan
Both animals had a fairly consistent increase in response
rate on the saline control days. The average inflation ratio and
range for each animal is shown in Appendix D No, 8 and 9*
Following both 1.0 rag/kg amphetamine and 12.5 rag/kg mescaline there
was a small but consistent increase in the inflation ratio. At
higher doses of these drugs (4*0 rag/kg amphetamine, 17.5 rag/kg mescaline
and 25.0 ag/kg mescaline) the inflation ratio was markedly reduced.
A decrease in the inflation ratio was also observed following both
1.0 mg/kg and 2.0 mgAg CPZ. This result is particularly Interesting
since C?Z has been shown to have no effect on conditioned suppression
(13, 89, 103, 131, 135).
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Morpurgo (119) has investigated the action of CPZ on an
active and passive avoidance situation. He found that CPZ, in a
dose which had no effect on visual discrimination, caused a marked
increase in active avoidance failures but had no effect on passive
avoidance failures. He suggested that the drug suppresses the
avoidance response by delaying locomotor initiation. This conclusion
would also explain the apparent discrepancy between the effects of
CPZ on conditioned inflation and suppression. The former would be
reduced since it requires an active response by the animal, whereas
no response is required in the case of conditioned suppression.
The hypothesis would explain why discrimination errors, in the
previous experiment, only occurred at changeover times. The
increased bar holding, under CPZ, may also be related to this
delay in locomotor initiation.
The effects of 1.0 mg/kg amphetamine on conditioned inflation
support the observations of Brady (19) on conditioned suppression.
Amphetamine increases the aversive properties of a conditioned negative
reinforcer. This would also aopear to be true for 12.5 mg/kg
mescaline which also enhanced conditioned inflation. At higher
doses of mescaline and amphetamine there was a decrease in
conditioned inflation but the results of the previous experiment
suggest that this wa3 probably due to a failure in visual discrimination.
Since similar stimulus lights have been employed in the
discrimination and condition inflation experiments as those used
« 82 -
in the standard continuous avoidance schedule the following deductions
can be made.
(I) The increase in shocks under CPZ are probably not related
to any loss of visual discrimination but may be due to a delay in
locomotor initiation. This conclusion has also been arrived at by
Posluns, (128).
(II) The increase in premature responses and the marked
skew in the I.R.T. distribution within the stimulus light, under
low doses of amphetamine, is probably related to an increase in
the aversive properties of the stimulus light.
(ill) The slight skew in the I.R.T. distribution following
12.5 Eg/kg mescaline may reflect a similar process.
(IV) Increased premature and late responding at high doses
of amphetamine or mescaline are due to a failure in visual discrimination.
It is clear that there is a close similarity between the
actions of amphetamine and mescaline on all the behavioural parameters
studied in the preceding experiments. Both drugs caused a disruption
of the temporal distribution x/ithin the stimulus light at low
doses, and a loss of visual discrimination at higher doses. It
should also be noted that both drugs are closely related structurally
and many authors (162, L41) have reported the strong stimulant action
of small doses of ^3 -phenylethylamine in animals pretreated with
iproniazid. Some authorities believe that amphetamine in high doses ,
is a true hallucinogen. Cornell (4-1), who has made a detailed study
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of amphetamine * toxicity1 concluded} 'Amphetamine can be considered
a true hallucinogen, sine© it will produce a psychoses with
hallucinations after a single large dose.1 He also noted that
•the most important finding in the present study was the absence of
disorientation as a sign of intoxication. Thus, one of the main
psychiatric criteria in the diagnosis of a toxic stato was lacking.*
He went on to make the constructive suggestion that 'proper investigation
of this problem may reconcile the well-known fact that schisophrenic
symptoms are intensified by amphetamine, with the fact that paranoid
symptoms on as yet unknown basis develop after ingestion of this
drug in persons who are not schizophrenic and appear not to develop
schizophrenia.'
As far as the present investigations are concerned, however,
any drug having a strong stimulant action will be considered to be
an amphetamine-like compound and will be distinguished from those
with a 'sure halluc-nogenie profile'. This seems to be a reasonable
position since, although amoh' tamine may or may not be hallucinogenic
in high doses, there is no doubt that the moin effect of the drug
is stimulation.
SECTION VI
STRUCTURE-ACTIVITY RELATIONSHIP STUDIES ON THE MESCALINE MOLECULE
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INTRODUCTION
The effect induced by a drug is the resultant of an inter¬
action between the molecules of that drug and the molecules of which
the organism is composed. The higher the specificity required in the
structure of the drug molecule, the more probable it becomes that
the effect is based on an interaction of these molecules with certain
specific molecules in the biological object. These specific
molecules are often called the receptor for the drug.
There has been much speculation about the nature of receptor
sites but there is no doubt that if the forces at work are of
physiochemical origin, as is generally supposed, and the physio-
chemical properties of a compound are the direct result of its
chemical structure, then there must be a relationship between structure
and biological activity. Structure, in this context, is not
confined to the physical structure, as in the lock-key model for
drug-receptor interaction, but includes the charge distribution and
the location of the active groups on a molecule.
The present investigation is an attempt to determine the
structural requirements of the mescaline molecule. This information
should throw some light on the nature of the receptor site on which
the drug is acting.
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EXPERIMENT 7: THE INFLUENCE OF THE METHOXY GROUP CQNFIGUMTION
Method
Subjects and Apparatus:
Nineteen male Lister hooded rats were used in this study.
Three of the subjects (Rl, R2 and R3) had previously been trained
on the discriminated continuous avoidance schedule.
Two modified Levine shuttle-boxes and a Standard Grason-
Stadler Skinner box were used. These experimental chambers
were enclosed in ventilated and sound-proofed chests and all experi¬
mental contingencies were controlled by a system of relays and timers
in an adjacent room. Two behavioural schedules were used in this
experiment} discrete trial avoidance in the shuttle box and the
standard continuous avoidance schedule in the Skinner box.
Procedure:
The Shuttle box procedure was similar to that used by
Smythies et al (154-)» The animal was required to cross from one
side of the shuttle box to the other in response to a conditioned
stimulus. The C.S. (a buzzer) sounded for five seconds, at the end
of which time the unconditioned stimulus (electric shock of I.Oma)
was presented if the animal had failed to terminate the C.S. by a
cross. A two hour experimental session consisted of seven runs of










FIG. 26: Cumulative records showing the effects of position
and number of raethoxy group substitution on the















Sixteen animals were trained to an 85$ avoidance criterion
on this schedule. On treatment days, intra peritoneal injections
of either drug or saline were given after 4-0 trials: i.e. two runs
of 20 trials. The seven sets of twenty trials then continued as
on training days. Drug results are expressed as (D-S) scores
(the difference between the drug score and the mean of the pre- and post-
drug saline scores). All nineteen possible ring methoxylated
combinations on the ^b-phenethylamine molecule were tested.
Initially the response to 25.0 mg/kg mescaline was determined
for each animal. Then the series of ring-methoxylated-pheny-
lethylamine was tested at two dose levels, 12.5 mg/kg and 25.0 mg/kg.
Penta methoxy-^? - phenylethylamine, which was found to be very
active, was also tested at 3.1 mg/kg and 6.2 mg/kg. Four animals
received each dose level of a ginen drug according to a random
design, and two weeks were allowed to elapse between every drug
treatment.
The three trained avoidance animals were given 25.0 mg/kg
mescaline and then each was subjected to a different drug sequence
with fourteen days between each drug administration. The experiment
was designed so that each drug result was replicated on two different
animals. Finally, each subject received a further 25.0 mg/kg
mescaline. As before, drug and saline Injections (0.5 ecs fluid)
were given after the pre-injection period and saline control records









— Premature Responses Efficient Responses Late Responses Reaction Time
FIG. 29* Behavioural profiles for the three active compounds.
A - 3,4>5 Trimethoxy phenylethylamine.
B - 2»3»4->5 Tetramethosy phenylethylamine.




In all cases no disruption of behaviour was detected during
the saline control days nor the pre-injection period prior to drug
administration. The cumulative records on Figs. 26, 27 and 28
show the behavioural effects of the drugs on the continuous avoidance
animals. A comparison of the effects of 25.0 mg/kg mescaline
given before and after the drug sequence reveals that any tolerance
which had developed over the experimental days was negligible. In
all cases, no dose greater than 25.0 mg/kg was tested since it has
been suggested that higher doses may have netiro-muscular effects
(154-) • The results of the mono and di methoxy substituting are
not shown since they were all inactive.+
The three active compounds; 3,4*5 trimethoxy, 2,3,4*5
tetramethoxy and 2,3,4*5*6 pentamethoxy phenylethylamine all inhibit
bar pressing. Animal R2, received all the active drugs and
allows a direct comparison of their relative potencies. The
behavioural profiles for this animal (Fig. 29) revealed that the active
compounds had behavioural effects similar to mescaline, Pentamethoxy
was by far the most potent; 6.25 mg/kg of this drug had a more
pronounced effect than 25.0 mg/kg mescaline. The 2,3,4*5 tetramethoxy
compound was also more active than mescaline.
+
This includes 3,4 dimethoxyphenylethylamine, the so-called 'pink spot'
compound, which has previously been shown to be inactive in both
human subjects (64) and animals (5).
FIG. 301 Comparison of effects of Mescaline and 2,3>4-»5
Tetramethoxy phenylethylamine. Abscissa:
Blocks of runs of 20 trials each. The interval
between runs represents 13 min. in each case
(run 8 min., 5 min. time out). Ordinate: Mean
change in reaction time in seconds (D-S). Each
point represents 80 readings (20 trials x 4- animals)
averaged. A - 12.5 mg/kg. B - 25.0 mg/kg.
I - in each case is the averaged drug response and
II - in each case is the averaged response to
25.0 mg/kg Mescaline for the same 4. animals.
FIG. 31? Comparison of effects of Mescaline and 2,3,4>5>6
Pentamethoxy phenylethylamine. A - 3.1 mg/kg.
B - 6.25 mg/kg. I - in each case is the averaged
drug response and II — in each case is the alcreraged
response to 25.0 mg/kg Mescaline for the same
4 animals.
FIG, 32: Comparison of effects of Mescaline and 2,3,5>6
Tetramethoxy pheny lethylamine. A - 12,5 rag/kg
B - 25 mg/kg, I - in each case is the averaged
drug response and II - in each case is the averaged
response to 25,0 mg/kg Mescaline for the same
U animals.
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Very similar results were obtained using the Shuttle box
procedure (Figs. 30, 31, 32). Each figure shows two doses of the
active drugs compared with the 25.0 mg/kg mescaline response for the
four animals involved. A biphasic curve for 2,3,4->5 tetramethoxy
phenylethylamine was obtained with 12.5 mg/kg and a pure inhibitory
effect was found at 25.0 mg/kg. (Fig. 30). Only 3.125 mg/kg of penta-
methoxy was required to give the biphasic response (Fig, 31)* Fig. 32
shows a typical inactive drug, 2,3,5*6 tetramethoxy phenylethylamine.
At no dose studied was a biphasic response observed for any compounds
other than the 2,3,4*5 tetramethoxy, the penta methoxy and mescaline
itself.
PAPPUSslpn
It would aopear from these results that the 3,4*5 configuration
is necessaryifor 'psychotomimetic activity' in ^-phenylethylamines.
The effect of i.dding extra methoxy groups is to increase the activity,
provided that the 3,4*5 configuration is maintained. One extra methoxy
group oroduces a moderate increase in activity; two a marked increase.
How can these findings be explained? The first obvious
suggestion is that the hallucinogenic properties of these compounds
may be related to their resistance to attack by amine oxidase. That
is, those which are quickly metabolized are not hallucinogens and the
compounds which are not broken down by amine oxidase, are hallucinogens.
Data has been published by Clark et al (3S) on the relation¬
ship between methoxy group configuration and the susceptibility to
- 89
oxidation of these compounds by 'tyramine oxidase' and 'mescaline
oxidase'. These studies were carried out in vitro using a rabbit-
liver preparation with and without semicarbazide. The results
indicated that all the compounds in this series with both 2 and 6
positions substituted and all compounds with more than three methoxy
groups were not shbstrates for either 'tyramine' or 'mescaline'
oxidases. Furthermore, in the presence of semicarbazide, mescaline
was no longer a substrate for this enzyme system. If amine oxidase
susceptibility was the major factor governing the hallucinogenic
activity of this series of compounds, then 2,6 dimethoxy phenylethylamine
should be hallucinogenic; this is not the case. However, amine
oxidase activity may explain why the praatamethoxy compound and the
2,3,4-,5 tetramethoxy compound are more potent hallucinogens than
mescaline. That is, if we assume that the 3,-4,5 configuration is
necessary for the psychotomimetic activity, but havdng these, the
potency of the drug depends on its resistance to amine oxidase then
mescaline would be relatively inactive. The 2,3,4*5 tetramethoxy
compound should be more active since it contains the four methoxy groups
necessary for protection and the 2,3,4,5,6 should be most active since
it contains, not only the four protective methoxy groups, but also has
the additional protection of the 2 and 6 positions being filled.
An alternative, and perhaps more parsimonious explanation
of the results can be found by an examination of the lipid solubilities
of these compounds. Both the tetfcamethoxy and the pentamethoxy
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compounds are more lipid soluble"1" than mescaline (Appendix E).
If the lipid solubility was the whole story then we would expect
the 2,3,4->6 compound to be a potent hallucinogen. But once again,
if we accept that the 3,4,5 configuration is necessary for the
compound to be hallucinogenic then the increase in potency with
additional methoxy groups correlates well with the increase in lipid
solubility.
The relative lipid solubilities were estimated from lipid solvent































FIG. '3.3; Three inactive derivatives of Mescaline
EXPERIMENT 8: THE EFFECTS OF SICE-CHAIN MANIPULATIONS
Method
Subjects and Apparatus?
Three of the trained avoidance animals (Rl, R2 and R3)
served as subjects. The apparatus was the standard Grason-Stadler
test chamber and programming equipment.
Procedure:
Three side-chain derivatives of the mescaline molecule
were tested (Fig. 33). Each animal received 25.0 mg/kg of all
the drugs in 0.5 ccs saline, at two week intervals.
Results and Discussion;
N-methyl and both acid and alcohol derivatives of mescaline
were inactive when given in a dose of 25.0 mg/kg (Appendix B Nos. 44-52),
Friedhoff and Goldstein (63) have claimed that the aldehyde or alcohol
derivatire could be the active metabolite of mescaline and found the
latter to be active in the rabbit when injected intravenously.
It is possible that the route of administration or the species difference
may account for the different findings of the present investigation.
and pantamethoxy pjphenylethylamine are active and yet they are immune
to attack by amine oxidase. It would appear then, that aldehyde
or alcohol formation is not necessary for psychotomimetic activity.
Also, the rate of onset of the mescaline effect, suggests that a
metabolite is not involved.
However, this seems unlikely mescaline (125)
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It is interesting that even a small substitution on the
nitrogen atom abolishes the psychotomimetic action of mescaline.
This same substitution in the NA molecule, changes a probable
neurotransmitter into what is now believed to be primarily on a
hormone with no transmitter function (112). If this is so, then the
primary amine configuration is required for successful interaction
with the preceptor site. Perhaps, it is this requirement which
governs the structure of the mescaline molecule. It should be possible
to support this speculation by examining the effects of ^ sympatholytics
on the mescaline response,
A side chain manipulation, of particular interest, is the
substitution of an 6^ methyl group. Since this change in the molecule
makes the compound immune to amine oxidase then it allows an examination
of the ring-mnthoxy group configuration, required for psychotomimetic
potency, unconfounded by amine oxidase activity.
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EXPERIMENT 9: THE INFLUENCE OF THE MBTHQXY GROUP CONFIGURATION
ON THE 0^METHYL MESCALINE MOLECULE
methyl mescaline is 3,4 >5 trimethoxy amphetamine. This
compound has already been shown (125, 14-5) to be twice as active as
mescaline in human studies. Shulgin (144) has examined three
trimethoxy la ted amphetamines (34-5 , 24-5 , 234-) in human subjects and
noted that repositioning of a meta-methoxy group to an ortho-location
in^(methyl mescaline augmented the hallucinogenic effect. Since all
these studies were carried out using human subjects, they present an
opportunity for further validating the animal tests by attempting
to replicate the results. Only eleven of the nineteen possible ring-
methoxylated amphetamines were available. These were 234, 246, 345 and
245 Trimethoxyamphetaminej 23, 35, 25 and 34 Dimethoxyamphetamine
as well as the three mono substituted derivatives. All these compounds
were tested.
Method
Subjects and Apparatus *
Three of the trained Lister hooded rats (R2, R4 and R5) served
as subjects. The standard Grason-Stadler test chamber and programming
equipment was employed.
Procedure:
Due to the wide differences in potency of these compounds,
2 3 4 5 6 Potency Relativeto Mescaline
X X X « M
X X X < M
X X X > M
X X X » M
FIG, 3A: The effect of position and number of ring methoxy
group substitution on the potency of four
methoxylated amphetamines.
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a systematic study was not possible and the drug dosage was altered
throughout the experiment. The final level of each active drug was
examined in at least two animals. All drugs were administered in
0.5 ccs saline after the preinjection period and the animals returned
to the experimental chamber for the two hour test period. Two weeks
elapsed between each administration. The I.R.T.s were collected
and analysed by the standard computer program.
Results and Discussion
The Trimethoxyamphetamines:
Shulgin had observed that 2,4-,5 trimethoxyamphetamine was
seventeen times more active than mescaline. The 3>4->5 he found to
be twice as potent as mescaline and the 2,3,4- was inactive. This
correlation between methoxy group configuration and hallucinogenic
activity is mirrored in the results of the animal experiments (Fig. 34-)
although, as one would expect, there are differences in the
quantitative relationship. All compounds, had some activity at
25.0 mg/kg and gave hallucinogenic profiles on the avoidance schedule
(Appendix B Nos. 53-60). 2,4.,5 trimethoxyamphetamine, not bested
by Shulgin, was less active than mescaline. This finding conflict®
with Shulgin's suggestion than raetamethoxy repositioning to an ortho-
location results in increased potency. In fact, the results of the
methoxylated phenylethylamine and amphetamine series taken together
elude anv simple explanation in terms of molecular structure. Whereas,
the 3,4-»5 substituted compound is the most active in the phenylethylamine
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series, the 2,4,5 is more potent than the 3,4»5 in the amphetamine series.
At least two hypotheses could be put forward to explain these
differences: (l) The ^methyl group on the amphetamine molecule renders
the compounds Immune to amine oxidase and the 'true1 relationship
between methoxy group configuration and hallucinogenic potency is
revealed. In the phenylethylamine series the results are confounded
by the relative protective action of different methoxy group combinations
on the susceptibility of the molecule to amine oxidase. (II) The
methyl group on the amphetamine molecule has stereochemical properties.
Thus, the steric interaction of the methyl group changes the configuration
of the molecule by distorting the electron cloud which encapsulates
the aromatic ring. Any change, however, in the electron distribution
should result in a shift in the U.V. spectrum of the molecule. A
BDmparison of the U.V. spectra of 2,4,5 trimethoxyaiaphetamine and
2,4,5 trimethoxyphenylethylamine is shown in Appendix F. No change
in the wave length of the absorbed energy could be detected, suggesting
that the electron configuration on the ring was very similar for both
molecules.
Some additional information which helps to explain the
differences in the two series was given by the results of the
dimethoxylated and monomethoxyla ted compounds.
The Dimethoxyamphetamines:
Of the four dimethoxy compounds tested (23, 35» 25 and 34 )
only the 34 dimethoxy compound was active at the doses tested
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(Appendix B No.s 61-73)• At only 6.2 mg/kg, this compound gave
a hallucinogenic profile whereas the other three analogues gave a
slight amphetamine-like stimulation at this dose. When the dose was
increased to 12,5 mg/kg, the 23, 35 and 25 dimethoxy derivations
resulted in a marked amphetamine stimulation and the 34- compound
caused a high dose hallucinogenic profile.
The Monomethoxyamphetamines:
These three compounds were the most interesting of all the
drugs studied. Metamethoxyamphetamine gave a very marked amphetamine-
like profile at only, 3.4 mg/kg. At this dosage ortho-methoxy
amphetamine was inactive but an amphetamine-like action was observed
at 6.2 mg/kg. Para-raethoxy amphetamine, on the other hand, proved
to be the most potent 'hallucinogen1 in the series. At 3.1 mg/kg
it produced a typical low dose hallucinogenic profile but at 6.2 mg/kg
it disrupted bar pressing behaviour completely and induced a syndrome
of bizarre behaviour in both the rats tested, at this dose. Although
the rat could walk about normally and appeared to be able to eat
and drink normally, it frequently walked backwards (a typical mescaline
effect), had exaggerated startle repose in the absence of external
stimuli and would frequently engage in bizarre behaviour reminiscent
of shadow boxing, rearing and pawing the air. If placed on a table
it would walk apparently normally towards the edge and fall off. This
could be repeated many times. In both cases the avoidance experiment
was terminated since shock was being delivered every 10 seconds and
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these highly trained animals were very valuable. However, both
animals died. In one case the unusual behaviour pattern peristed
for a week before death, in the other case the animal died after one
day of abnormal behaviour.+
It would appear that the basic requirement for psychoto¬
mimetic potency in the amphetamine series Is the presence of a
4 methoxy group. Substitutions in other positions produced stimulant
drugs similar to amphetamine. The relative stimulant properties
of mono-methoxylated amphetamines has been investigated by Van der Shoot
et al (34.1). They report that metamethoxy substitution leads to a greater
increase in the spontaneous motor activity of mice, than either ortho-
or para- substitution. The para compound is more active than the
ortho. These results are supported by the present experiment if
account is taken of the slight stimulant action of low doses of
hallucinogens. Benington et al (10) have reported that 25.0 mg/kg
of the para-methoxy compound is lethal in cats after producing a
marked rage reaction. The long lasting effects of this drug suggest
that it nay be related to the potent hallucinogen STF. Both molecules
have an amphetamine skeleton but STP has a methyl group in the 4.
position. It it relevant that Knoll (104) has suggested that halogenation
of the para position may result in a psychotomimetic derivative of
+It was decided to investigate this drug at an intermediate dose tut
subsequent deaths made this impossible. These additional deaths
resulted from para-methoxy ohenvlethvlamine in animals pretreated with
MAQI.
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methamphetamine. Further investigation of different substitutions
in the 4 position would appear to be the next step in the present
research program.
It is interesting now to note that every potent hallucinogen
in both the phenylethylamine and amphetamine series is substituted
in the 4 position. The results suggest that 4 methoxy phenylethylamine
and 34 dimethoxyphenylethylamine may be hallucinogenic in subjects
pretreated with an amine oxidase inhibitor.
The superior potency of the mono-inethoxylated derivates of
amphetamine over the dimethoxy analogues may be related to their greater
lipid-solubility (Appendix E).
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EXPERIMENT 10 THE BEHAVIOURAL EFF'CTS OF L METHOXY AND 3L DIMETHOXY
PHENYLETHYIAMINE IN ANIMALS PRETRBATED WITH IPRONIAZID
Method
Subjects and Apparatus?
Two of the trained Lister hooded rats (R1 and R2) served as
subjects, The standard Grason-Stadler programming and recording
equipment was in operation.
Procedure:
Animal R1 received 6.2 rog/kg paramethoxy phenylethylamine three
hours after 50.0 mg/kg Iproniazid (i.p,). Subject R2 was injected
with 6.2 mg/kg 3>4- Dimethoxy and 6,2 mg/kg 2,3 Dimethoxy phenylethylamine
in two separate occasions following a similar dose of Iproniazid three
hours previously."1" Saline injections equivalent to the total fluid
volume of Iproniazid plus drug were given on the pre- and post-drug
days. Three weeks were allowed to elapse between each drug
administration to the same animal.
fipgttUg 3hd Digcrotoq
6,2 mg/kg of 4—methoxy phenylethylamine, which has previously
bedn shown to be inactive at 25.0 mg/kg, had a very toxic effect in
the pretreated animal (Rl)» All bar pressing behaviour stopped and
the rat lay on its side, twitching slightly and unable to move.
This increase in toxicity of 4-methoxy phenylethylamine following MAOI
has also been reported in cats where an intense rage reaction and hypeav
+This dose has been shown to have no behavioural effect at this dose
see Experiment 11.
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thermia were produced (10).
Both 34 and 23 dimethoxy phenylethylamine have been previously
shown to be inactive at 25.0 mg/kg (Experiment 7)« Following the
M&OI, however, 34 dimetboxy gave a typical hallucinogenic profile
whereas the 23 substituted compound had a slight stimulant effect.
The amine oxidase inhibitor appears to bring the behavioural effects of
substituted phenylethylamines into line with the results of the
amphetamine series. It would be interesting to investigate the
order of potency of the trimethoxylated phenylethylamines after amine
oxidase inhibition since the differences found in the two series are
probably due to their relative resistances to amine oxidase*
Ernst (56) has investigated the action of some methoxylated
P-phenylethylamines in cats. These were (a) 4-raethoxypbenylethylamine
(b) 34 Dimethoxyphenylethylamine (c) 345 Trimethoxyphenylethylamine
(d) 35 Dimethoxyphenylethylamine (e) 23 Dimethoxyphenylethylamine
(f) 3 hydroxy-4-me thoxy phenyls thylamine (g) 3 me thoxy-4-hydroxy
phenylethylamine (h) 35 Dimethoxy-4-hydroxy phenyle thylamine and
(k) 3 hydroxy phenylethylamine. He reports that, in the absence of
Iproniazid, only 4 MFE, 34. DMPE and 345 7MPE were capable of producing
a Hypokinetic Rigid Syndrome (HRS) and catatonia. The effects could
be obtained with a lower dose and persisted much longer following
345 TMFE than either 4 MPE or 34 DMPE. The compounds 35 DMPE and
23 DMPE did not produce either catatonia or HRS. Following Iproniazid,
3-hydroxy-4-methoxy PE also produced catatonia and HRS whereas all
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other hydroxylated compounds tested failed to do this. He suggested
that after iproniazid the hydroxylated compounds were methoxylated
by COMT in the liver. Since this methoxylation is specific to the
3 position, then the metabolites of 3-methoxy-4-hydroxy PR and
35-Dimethoxy-^~hydroxy PR were still unable to cross the blood-brain
barrier since a hydroxy group was still present on the ring. He
made the interesting observation that following iproniazid,
3-hydroxy PR had a stimulant effect. This compound could be metabolized
to 3-methoxy-PE which has been shown to have a strong stimulant action
in the present investigations.
Ernst has arrived at a similar conclusion to that of the
present investigator. Methoxylation in the para position appears to
be necessary for the production of HRS and catatonia in cats and the
hallucinogenic profile in rats. However, he found that the duration
of the HRS was positively correlated with the number of places in the
phenol-ring occupied by methoxy groups adjacent to the para position.
The results of the present investigations suggest that this is not the
case and the superior potency of the trimethoxylated derivatives over
the mono and di substituted compounds is probably due to their increased
resistance to amine oxidase. In the presence of an amine oxidase
inhibitor, or in the amphetamine series where there is a high resistance
to amine oxidase, then the mono and di substituted compounds are in
fact more potent than the trimethoxylated derivatives. This increase
in potency with fewer methoxy groups may be related to the increased
lipid solubility of these compounds.
SECTION VII
FHETREATMENT STUDIES'1'
+ Some of these experiments were carried out prior to the investigation
of the methoxylated amphetamines.
IPRONIAZID PRETREATMENT
FIG* Cumulative records showing the effect of Iproniazid
pretreatment on the response to 17.5 mg/kg
Mescaline.
A - 17.5 mg/kg Mescaline.
B - 17.5 mg/kg Mescaline after 50.0 mg/kg Iprdniazid.
C " 17.5 mg/kg Mescaline,
(Subject R4).
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Three of the trained male Lister hooded rats (R4, E5 and R6)
served as subjects. The programming and recording equipment has already-
been described.
Procedure s
Each subject served as his own control and -was injected with
a physiological saline solution (0.5 ccs) on the pre- and post-drug
days. With the exception of pre-treatment days, all drugs were
given after the pre-injection period and the subject was immediately
placed in the Skinner box for the two hour test period. A pilot
study revealed that 100.0 mg/kg iproniazid had some behavioural effects
on the avoidance schedule so the pretreatment dosage was halved to
50.0 mg/kg, At this dose level there was no behavioural effect at
any time after injection. Initially the response of each animal
to 17.5 mg/kg mescaline was determined. Fourteen days later each
animal received 50.0 mg/kg Iproniazid (i.p.) three hours before 17.5 rag/kg
-4ft-
mescaline. As a further control 17.5 mg/kg mescaline was given again
after four weeks.
kpbuUP and
Figure 35 shows the influence of iproniazid pretreatment on
the action of this dose of mescaline. (A deflection of the recorder
17.5 mg/kg Mescaline
50.0 mg/kg Iproniazid






TABLE 1 The effect of iproniazid pretreatment
on the shock frequency following
17.5 mg/kg mescaline.
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pen marks a shock and the baseline event marker shows the occurrence of
burst and premature responses.) An increase in the mescaline response
was verified for all animals (Table l).
This finding does not support the theory of Harley-Mason et al
(32) that mescaline acts through a metabolite and suggests that the
free amine level is the critical factor. An alternative hypothesis
is that increased levels of endogenous monoamines, in some way,
facilitates the hallucinogenic activity of mescaline. A number of
experiments are suggested by the later hypothesis. If endogenous
amine levels are involved then pretreatment with amine depleters,
such as tetrabenazine (TBZ) or reserpine, should decrease hallucinogenic
activity and specific MAQIs (possibly S-octanol) should enhance hallucino¬
genic activity. A reversal of the mescaline effect by pretreatment with
TBZ wpdld avoid any interpretation of the results as due to summated
effects of two independent processes. That is, since both mescaline
and TBZ block the conditioned avoidance response then any reversal of
the mescaline effect would be in the opposite direction from both
manipulations. Furthermore, since pharmacological agents are available
which selectively interfere with the synthesis of particular amines then
it might be possible to further delineate the precise action of mescaline.
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EXPERIMENT 12: THE EFFECTS OF PlffirffiEATMEHT WITH TBZ AND MT
OK THE MESCALINE RESPONSE
Method
Subjects and Apparatus:
Two of the trained male Lister hooded rats (El and F.3) served
as subjects. The standard experimental chambers and programming
equipment were employed.
Procedure:
Each animal's response to 17.5 mg/kg mescaline had been
measured in a previous experiment (Experiment 4)• The effects of
pretreatment with 4»0 mg/kg TBZ and 32.0 mg/kg MT on this response
were determined for each animal. The TBZ was administered in 0.5 mis.
of 0.01 normal HC1 andin 0.5 mis. of a cellulose suspension.
On pretreatment days TBZ was given hours before the animal was
placed in the experimental chamberj theb(MT pretreatment time was
2£ hours. After the normal 'warm up' and 'preinjection' periods
both animals were given 17.5 mg/kg mescaline in 0.5 ccs saline.
During the pre- and post-drug days the drug vehicles were administered
at the pretreatment times and 0.5 ccs saline following the pre-injection
period.
Four weeks were allowed to elapse between each pretreatment
experiment and the effects of 17.5 mg/kg mescaline were redetermined
one month after the last drug administration.
— xo5 —
apd Disppgstop
Wo behavioural effect of the drug vehicles could be detected
on the pre- or post-drug days and no disturbance of lever pressing
was observed during the pre-injection period on pretreatment days.
Biochemical studies, by Weissman (182) have shown that,
followingMMT the rat brain concentration of NA and D are markedly
reduced but 5HT levels are unaffected, TBZ, on the other hand, causes
a reduction in all amine levels. However, neither TBZ nor 6(MT
had a marked effect on the mescaline response. Both drugs, especially
^MT, caused a slight increase in the mescaline effect (Appendix B
K°s. 91-96).
As with iproniazid pretreatment, the results are open to
alternative explanations since TBZ, K MT and mescaline all cause
behavioural suppression and any increase in the mescaline response
following pretreatment may be due to additive effects of the treatment
and pretreatment drugs. The results suggest, however, that a gross
reduction in amine concentration or a selective reduction in HA levels
do not appreciably decrease the mescaline response but may, in fact,
increase the effect. It follows that the iproniazid augmentation
of mescaline described in the previous experiment is probably due
to an increase in the mescaline levels rather than the endogenous
amine levels. Unlike amphetamine, it would appear that mescaline
does not act by a release of free NA,
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EXPERIMENT 13: THE EFFECTS OF PRE TREATMENT WITH 0< MT ON THE




One male Lister hooded rat (R3), who had previously been
trained on the standard avoidance schedule, was the experimental
subject. The apparatus was similar to that described before.
Procedure:
Initially, the behavioural stimulation of 3.1 mg/kg metamethoxy
amphetamine was determined for this animal. Two weeks later a
pretreatment study was carried out in which 32.0 rag/kg ^MT was given
3 hours before 3»1 mg/kg of the methoxyamphetamine. The controls
were similar to those described in the previous experiment. One
month after this pretreatment, the behavioural effects of the amphetamine
analogue were determined once again.
RQgfllt? ?pd Dipcqspj.?^
Appendix B Nos. 34.-86 shows the effects of b^MT on the
behavioural stimulation induced by 3-methoxy amphetamine. This
blockade of stimulation by pretreatment withis similar to the
antiamphetamine effects of tyrosine hydroxylase inhibition described
by Weissman et al (182). The results imply that, like amphetamine,
metamethoxy amphetamine acts by a release of NA rather than a direct
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action on the NA receptor.
Van Rossum (138) has investigated the stimulant action of
^ MmT in mice. The delayed action of the drug, compared with
amphetamine, suggested that it was not DtMmT itself, but a metabolite
that was responsible for the stimulation. He suggested that
3-methoxy amphetamine was the active metabolite but was unable to
block its stimulant action by reserpine. This is not surprising
since reserpine does not interfere with NA synthesis and does not
block the stimulant action of amphetamine (B2). In the present
experiment, where NA synthesis was reduced, 3-methoxy amphetamine
was unable to induce its normal behavioural excitation. It would
appear, then, that the stimulant action of &(MmT is due to decarboxy¬
lation to metahydroxy amphetamine and subsequent 0-methylation to
metamethoxy amphetamine. Since 0-methylation is specific for the
meta position decarboxylated oCMT is not a substrate. Decarboxylation
of O^MeDopa gives 34 dioxyamphetamine which may be converted to
3 methoxy, 4 hydroxy amphetamine. Since methoxylation is predominantly
in the liver this metabolite could not reach the brain. Thus, the
stimulant action of *(MmT, but not^^T nor 0( MeDopa, is probably due
to the formation of 3-methoxy amphetamine which acts by releasing NA.
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EXPERIMENT lAl PRETREATMEHT WITH A CLOSE MESCALINE CONGENER
Method
Subjects and Apparatus:
Two of the trained Lister hooded rats (R1 and R2) served as
subjects. The apparatus was similar to that described before.
Procedure:
Each subject was initially treated with 17.5 mg/kg mescaline.
Fourteen days later these animals were given 25.0 mg/kg 2,4,5 trimethoxy
phenylethylamine in 0.5 ces saline followed after 15 minutes by
17.5 mg/kg 3,4,5 trimethoxyphenylethylamine (mescaline) in 0.5 ccs
saline. The pretreatment compound has already been shown to be inactive
at this dose (Experiment 7). Saline control runs using 1.0 ccs
saline were carried out on the pre- and post-drug days,
fiegultg apd maeuppipq
Saline injection had no effect on behaviour, but the effect of
the pretreatment was to decrease the mescaline response (Appendix B
Nos 87 - 90).
The antagonism between these two closely related compounds
would suggest that the 2,4,5 TMPE is capable of occupying the mescaline
receptor-site, though itself having no central effect. A structive-
activity relationship study of this competative inhibition should throw
some light on the specificity of the mescaline receptor site.
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Two of the trained male lister hooded rats (R2 and R6) served
as subjects. The apparatus has been described previously.
Procedure:
Each subject received 25.0 mg/kg mescaline two weeks before
and one month after the pretreatment study. A single large dose of
imipramine (40.0 rag/kg) in 0.5 ces saline was given six hours before
25.0 mg/kg mescaline (0.5 ccs fluid) during the pretreatment day.
Both animals received a saline injection equivalent to the total fluid
volume (1,0 ccs) on the pre- and post-drug days. All injections
were intraperitoneal.
Result
Saline injections had no effect on behaviour. Imipramine
(40.0 mg/kg) had an initial sedative effect but this was not observed
6 hours after the injection. Following pretreatment with imipramine
the subsequent mescaline injection did not produce Its normal behavioural
disruption (Appendix B Nos. 97-102) but was almost inactive. The
animals appeared normal and a typical saline record was obtained in
both cases. Six hours wereleft between treatment and pretreatment
administrations since it has been suggested that it is a metabolite of
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iraipramine which is responsible for the activity of this drug (23, 37).
Imipramine and desmethylimipraraine are thought to have only
weak &( sympatholytic properties and their main action is probably a
blockade of reuptake on the pre-synaptic membrane. Since this latter
process is now considered to be the main pathway for removing NA from
the synapse (9-4)» then any blockade of reuptake should be the
most effective way of increasing active NA concentrations. Under
these conditions of high NA concentrations, mescaline may be inactive
because (s) it cannot compete with NA for active receptor sites
(b) its action depends on the active uptake process or (c) an unknown
action of imipramine is responsible.
If the first hypothesis is correct, then one would expect
that drugs,which are thought to block the post-synaptic receptor site,
should decrease the mescaline response. CPZ has strong p( sympatholytic
properties and it has been reported to (a) reverse the inhibition
of synaptic conduction in the transcallosal system (115)J (b) protect
mice against lethal dtbses of mescaline (127) and (c) block the effects
of mescaline in 24 out of 25 human subjects (50).
- Ill -
EXPERIMENT 16» MESCALINE AND AMPHETAMINE: TOLERANCE MP CROSS-TOLERANCE
Method
Subjects and Apparatus!
The subject was a male Lister hooded rat (Rl) that had previously
been extensively trained on the avoidance schedule. The standard
Grason-Stadler apparatus was employed.
Procedures
The animal received three doses of 25.0 mg/kg mescaline in
V1XS
0.5 ccs fluid on three separate days. A saline control dayjrun on
the day before and the day after each drug administration and on the
day following the last control day the subject was given 2.0 mg/kg
amphetamine. One month later this procedure was repeated with the
drugs reversed. Saline days alternated with 2.0 mg/kg amphetamine
and the sequence was followed by a dose of 25.0 mg/kg mescaline.
The experimental paradigm can be written:
A B CD
Saline, Drug 1, Saline, Drug 1, Saline, Drug 1, Saline, Drug 2.
where drugs 1 and 2 were either 25.0 mg/kg mescaline or 2.0 rag/kg
amphetamine. The letters above the drug days refer to the data shown
in Figs. 36 and 37. All drug and saline injections consisted of
0.5 ccs of fLuid given intraperitoneally.
FIS. 36? Cumulative records showing the developement of
tolerance to Mescaline and cross-tolerance to
Amphetamine. (Subject Rl)
A, B and C - 25.0 mg/kg Mescaline.




The development of tolerance to mescaline can be seen clearly
on Fig» 36 A, B and C. The rate of responding increased and the
number of shocks (deflections of cumulative recorder pen) decreased
over the three days. Fig. 37 D shows the mescaline response
obtained after three days of amphetamine. A comparison of Fig. 37 D
and Fig. 36 A reveals that the amphetamine treatment markedly decreased
the mescaline response.
Fig. 37 A, B and C are cumulative records showing responding
over the three amphetamine days. The even marker, below each
cumulative record, deflected when a premature or burst response occurred.
As tolerance to amphetamine developed the total response rate and
the number of premature and burst responses all decreased. A similar
reduction in the amphetamine effect was observed following the three
doses of mescaline (cf. Fig. 37 A and Fig. 36 D).
Since no disturbance of behaviour was observed on the control
days it can be concluded that (a) tolerance develops to mescaline
(b) tolerance develops to amphetamine (c) when tolerance has developed
to mescaline there is a marked cross-tolerance to amphetamine and
(d) when tolerance has developed to amphetamine then there is a marked
cross-tolerance to mescaline. These results underline the similarity
between the actions of amphetamine and mescaline outlined in Section V.
Any attempt to explain the findings would be premature 3ince
little is known about the metabolic pathways involved in the
FIG. 37» Cumulative records showing the developement of
tolerance to Amphetamine and cross-tolerance to
Mescaline, (Subject Rl)
A, B and C - 2,0 mg/kg Amphetamine.
D - 25.0 mg/kg Mescaline,
(See text.)
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degredation of either amphetamine or mescaline. Some studies by
Aacelrod, however, suggest that the parahydroxyla tion of amphetamine and
the deamination of mescaline may be the major metabolic pathways
in the rat. If the stimulant action of amphetamine is dependent
upon a release of N& perhaps a common pathway in NA. and mescaline
metabolism is a critical factor.
— 114 ™*
FACTS AND SPECULATIONS
There is some evidence that the effects of high doses of
amphetamine are not due to NA release, Herman (85) has noted that
whereas 0(MT can inhibit the behavioural stimulation caused by low
doses of amphetamine, it has no effect on A.S.B. induced by high
doses of the drug. Furthermore, when NA concentrations are increased
by concomitant treatment with reserpine, nialamide and pyragallol, the
A.S.B. is abolished and only an excitation is observed. This suggests
that amphetamine may have a mixed action (120). Although low
doses release NA, higher doses may compete with the catecholamine
for the active receptor sites. Muscholl (120) has pointed out that
these 'amines with mixed actions represent a gradual transition
from group a to group c rather than a distinct third group. Thus
mescaline could also be a mixed amine with a slight indirect action at
low doses, resulting in behavioural excitation, and the major effect
of the drug may be direct. This direct mode of action of mescaline
is supported by the structural requirements of the drug and the results
of the pretreatment studies. It is relevant that it has recently
been reported that the presence of a meta or para hydroxy group on
the phenol ring appears to be of greater significance (and the presence
of a hydroxy group of less significance) for enhancing the direct
action of an amine, than was previously supposed (120), Hence,
pararaethoxylation of amphetamine or fb-phenylethylamine, may decrease
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the indirect action of these drugs and facilitate a direct mode of
action. This would explain why this small structural change can
convert predominantly stimulant drugs into compounds with
•psychotomimetic properties'.
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num(x,y,s) = num(x,y,s) 4 1
no(y,a) b no(y,s) 4 1
n(«) a n(a) 4 1























if i=0 than caption sequence 4 of 4 throe 4 starts 4 with
if i=i then caption soquonos 4 of 4 three 4 starts 4 with
if i®2 then caption sequence 4 of 4 three 4 starts 4 with









if j=0 then caption second4response4is4a44444burst
if j=l then caption seeond4response4is4a4premature
if j=2 then caption seeond4response4ia4a4offioient












if j«0 then caption second4response4is4a44444burst
if j=l then caption second4response4is4a4premature
4 a 4 burst
4 a 4 premature
4 a 4 efficient
4 a 4 late
if j=2 then caption seeondfcresponseiisiaiefficient












if j=0 then caption seeondiresponseiiaialMMburst
if .1=1 than caption secondtresponseiistaipreinature
if j=2 than caption secondiresponseiistaieffieient






















if i=0 than caption firsttresponseiisftaMtittburst
if 1=1 than caption firsttresponseiisiattpreiBature
if 1=2 then caption firsttresponseiisiaMeffioient













it imO than caption firstireaponaetisiaititi&burst
if i»l than caption firattresponsetlstsMpreiBature
if i«2 than caption firsttresponsetiataMeffioient












if i«*0 than caption flratiraaponaailaiaiiMlibttrat
if i«l than caption firattraaponaa^iataMpraaatura
if i«2 than caption firat ireaponsaftiaiatieffioienf

















if i»0 than caption fraquanoyii tofiitHburat
if i»l than caption frequencyiiiofipreaature
if i*2 than caption frequancyWtofieffieient
if i»3 than caption fraquanoyitfoftiiiitlata
spaoaa<4)
print(n(i),4,3>




if 1=0 then caption probebilitytofHtMburat
lii=l then caption probabilityiof^prematura
17 i=2 then caption probabilitylofiefficiont













































SUBJECT R1 APPENDIX B
TREATMENT 75th AVOIDANCE SESSION NO. 1
FREQUENCY OF BURST 7.0 PROBABILITY OF BURST 0.030
FREQUENCY OF PREMATURE 4.0 PROBABILITY OF PREMATURE 0.017
FREQUENCY OF EFFICIENT 198.0 PROBABILITY OF EFFICIENT 0.850
FREQUENCY OF LATE 24.0 PROBABILITY OF IATE 0.103
DISTRIBUTION WITHIN PREAVERSIVB STIMULUS IN CATEGORIES OF SECOND
1234-56789 10
FREQ. 3 5 13 7 16 26 37 35 30 26
PROB. 0.013 0,021 0.056 0,030 0.069 0,112 0,159 0.150 0.129 0.111
IRT/OP 0.014 0.023 0.061 0.035 0.082 0.14-6 0.243 0.304 0.375 0.52C
TOTAL RESPONSES 233.0 PERCENTAGE REACTION TIME 25.4
SUBJECT R2 APPENDIX B
TREATMENT 75th AVOIDANCE SESSION 2
FREQUENCY OF BURST 6.0 PROBABILITY OF BURST 0.024
FREQUENCY OF PREMATURE 10.0 PROBABILITY OF PREMATURE 0.040
FREQUENCY OF EFFICIENT 225.0 PROBABILITY OF EFFICIENT 0.900
FREQUENCY OF LATE 9.0 PROBABILITY OF LATE 0.036
DISTRIBUTION NITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456789
FREQ. 1 9 14 29 34 34 43 35 19
PROB. 0.004 0.040 0.062 0.129 0.151 0.151 0.191 0.156 0.084
IRT/OP 0.004 0.039 0.063 0.138 0.138 0.231 0.381 0.500 0.543





SUBJECT R3 APPENDIX B
TREATMENT 75th AVOIDANCE SESSION NO. 3
FREQUENCY OF BURST 5.0 PROBABILITY OF BURST 0.020
FREQUENCY OF PREMATURE 10.0 PROBABILITY OF PREMATURE 0.040
FREQUENCE OF EFFICIENT 216.0 PROBABILITY OF EFFICIENT 0,864
FREQUENCY OF LATE 19.0 PROBABILITY OF LATE 0.076
DISTRIBUTION WITHIN PREAVFUSIVE STIMULUS IN CATEGORIES OF SECOND
1234-56789 10
FREQ. 6 9 U 25 24 30 36 36 22 17
PROB. 0.024 0.036 0.044 0.100 0.096 0.120 0.144 0.144 0.088 0.068
IRT/OP 0.026 0.039 0.050 0.120 0.130 0.188 0.277 0.383 0.379 0.472
TOTAL RESPONSES 250.0 PERCENTAGE REACTION TIME 23.9
SUBJECT R4
TREATMENT 75th AVOIDANCE SESSION
APPENDIX B
NO. 4
FREQUENCY OF BURST 6.0 PROBABILITY OF BURST 0.025
FREQUENCY OF PREMATURE 12.0 PROBABILITY OF PREMATURE 0.051
FREQUENCY OF EFFICIENT 193.0 PROBABILITY OF EFFICIENT 0.835
FREQUENCY OF LATE 21.0 PROBABILITY OF LATE 0.089





1210 15 21 24 25 36 31 20
PROB. 0.017 0.042 0.063 0.089 0.101 0.105 0.152 0.131 0.084 0.051
IRT/OP 0.018 0.047 0.073 0.110 0.142 0.172 0.300 0.369 0.377 0.364
TOTAL RESPONSES 237.0 PERCENTAGE REACTION TIME 24.0
SUBJECT R5 APPENDIX B
TREATMENT 75th AVOIDANCE SESSION NO* 5
FREQUENCY OF BURST 2.0 PROBABILITY OF BURST 0.008
FREQUENCY OF PREMATURE 15.0 PROBABILITY OF PREMATURE 0.062
FREQUENCY OF EFFICIENT 207.0 PROBABILITY OF EFFICIENT 0.355
FREQUENCY OF LATE 18.0 PROBABILITY OF LATE 0.074
DISTRIBUTION WITHIN PHEAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FREQ. 3 7 11 19 22 33 4-0 31 26 15
PROB. 0.012 0,029 0.045 0.079 0.091 0.136 0.165 0.128 0.107 0.062
IRT/OP 0.013 0.032 0.051 0.093 0.119 0.202 0.308 0.344 0.441 0.455
TOTAL RESPONSES 242.0 PERCENTAGE REACTION TIME, 24.2
SUBJECT R6 APPENDIX B













DISTRIBUTION WITHIN PKEAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234 56789 10
FREQ. 6 12 10 10 21 30 34 33 27 17
PROB. 0.025 0.050 0.042 0.042 0.083 0.124 0.142 0.138 0.133 0.071
IRT/OP 0.027 0.056 0.050 0.052 0.113 0.186 0.260 0.340 0.422 0.459
TOTAL RESPONSES 240.0 PERCENTAGE REACTION TIME 24.6
SUBJECT R1 APPENDIX B
TREATMENT Approx. 300th AVOIDANCE SESSION NO^ 7
FREQUENCY OF BURST 7.0 PROBABILITY OF BURST 0.029
FREQUENCY OF PREMATURE. 9.0 PROBABILITY OF PREMATURE 0.038
FREQUENCY OF EFFICIENT 201,0 PROBABILITY OF EFFICIENT 0,845
FREQUENCY OF LATE 21.0 PROBABILITY OF LATE 0.038
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234-56789 10
FBEQ. 6 12 10 17 18 26 34 32 26 20
PROB. 0.025 0.050 0.042 0.071 0.076 0.109 0.143 0.134 0.109 0.084
IRT/OP 0.027 0.055 0.049 0.088 0.102 O.I64 0.256 0.323 0.388 0.438
TOTAL RESPONSES 233.0 PERCENTAGE REACTION TIME 24.1
SUBJECT R2 APPENDIX B













DISTRIBUTION WITHIN PHEAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FKEQ. 3 6 16 22 30 36 39 24 24 11
PROB. 0,012 0.024 O.O65 0.090 0.122 0.147 0.159 0.098 0.098 0.045
IRT/OP 0.013 0.027 0.074 0.109 0.163 0.242 0.345 0.324 0.430 0.423
TOTAL RESPONSES 245.0 PERCENTAGE REACTION TIME 21.0
SUBJECT R3 APPENDIX B
TREATMENT approx. 300th AVOIDANCE SESSION Mk 9
FREQUENCY OF BURST 1.0 PROBABILITY OF BURST 0.004
FREQUENCY OF PREMATURE 14.0 PROBABILITY OF PREMATURE 0.057
FREQUENCY OF EFFICIENT 209.0 PROBABILITY OF EFFICIENT 0.857
FREQUENCY OF LATE 20.0 PROBABILITY OF LATE 0.082
DISTRIBUTION WITHIN PHEAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FREQ. 6 9 13 17 22 29 40 32 20 21
PROBL 0.025 0.037 0.053 0.070 0.090 0.119 0.164 0.131 0.032 0,086
IRT/OP 0.026 0.040 0.061 0.085 0.120 0.179 0.301 0.344 0.323 0.512
TOTAL RESPONSES 244.0 PERCENTAGE REACTION TIME 24.3
SUBJECT R4 APPENDIX B
TREATMENT approx. 300th AVOIDANCE SESSION Ik 10
FREQUENCY OF BURST 4.0 PROBABILITY OF BURST 0.017
FREQUENCY OF PREMATURE 4.0 PROBABILITY OF PREMATURE. 0.017
FREQUENCY OF EFFICIENT 209.0 PROBABILITY OF EFFICIENT 0.371
FREQUENCY OF LATE 23.0 PROBABILITY OF LATE 0,096
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FREQ, 4 7 9 19 23 24 38 39 26 20
PROBi 0,017 0,029 0,038 0.079 0.096 0.100 0.153 0.163 0.108 0.083
IRT/OP 0.017 0.031 0.041 0.090 0.199 0,141 0.260 0.361 0.377 0.465
TOTAL RESPONSES 240.0 PERCENTAGE REACTION TIME 24.7
SUBJECT R5 APPENDIX B
TREATMENT approx. 300th AVOIDANCE SESSION jjq^ 11
FREQUENCY OF BURST 6.0 PROBABILITY OF BURST 0.025
FREQUENCY OF PREMATURE 13.0 PROBABILITY OF PREMATURE 0.055
FREQUENCY OF EFFICIENT 201.0 PROBABILITY OF EFFICIENT 0.345
FREQUENCY OF LATE 18.0 PROBABILITY OF LATE 0.076
DISTRIBUTION WITHIN PREAVERSIYE STIMULUS IN CATEGORIES OF SECOND
1234-56739 10
FREQ. 6 6 7 12 17 33 34- 39 26 16
PROB, 0.025 0.027 0.029 0.050 0.071 0.160 0.143 0.164- 0.109 0.067
IRT/OP 0.027 0.028 0.034- 0.060 0.090 0.222 0.256 0.394- 0,4-33 0.471
TOTAL RESPONSES 238.0 PERCENTAGE REACTION TIME 24.9
SUBJECT R6




FREQUENCY OF BURST 4.0 PROBABILITY OF BURST 0.017
FREQUENCY OF PREMATURE 14.0 PROBABILITY OF PREMATURE 0,059
FREQUENCY OF EFFICIENT 195.0 PROBABILITY OF EFFICIENT 0.826
FREQUENCY OF LATE 23.0 PROBABILITY OF LATE 0,097
DISTRIBUTION WITHIN PHEAVF.R3IVE STIMULUS IN CATEGORIES OF SECOND
1234-56739 10
FREQ. o 7 5 17 21 36 38 30 31 10
PRQB. 0.000 0.030 0.021 0.072 0.089 0.153 0.161 0.127 0.131 0.04-2
IRT/OP 0.000 0.032 0.024 0.083 0.111 0,214 0.288 0.319 0.484 0.303
TOTAL RESPONSES 236.0 PERCENTAGE REACTION TIME 23.9
SUBJECT R5 APPENDIX B
TREATMENT o.5 mg/kg Chlorpromazine N0> 13
FREQUENCY OF BURST 19.0 PROBABILITY OF BURST 0.079
FREQUENCY OF PREMATURE 11.0 PROBABILITY OF PREMATURE 0.046
FREQUENCY OF EFFICIENT 144.0 PROBABILITY OF EFFICIENT 0.600
FREQUENCY OF LATE 66.0 PROBABILITY OF LATE 0.275
DISTRIBUTION ,'ITHIN PKEAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234.56739 10
FREQ. 0 3 10 8 13 21 23 25 25 16
PROB. 0.000 0.012 0.042 0.033 0,054 0.087 0,096 0.104 0.104 0.0&7
IRT/OP 0,000 0,014 0.043 0.041 0.069 0.119 0.143 0.189 0.234 0.195
TOTAL RESPONSES 240.0 PERCENTAGE REACTION TIME 28.0
SUBJECT R5 APPENDIX B
TREATMENT 1.0 mg/kg Chlorpromazine 14.
FREQUENCY OF BURST 29.0 PROBABILITY OF BURST 0.131
FREQUENCY OF PREMATURE 12.0 PROBABILITY OF PREMATURE 0.054
FREQUENCY OF EFFICIENT 86.0 PROBABILITY OF EFFICIENT 0,389
FREQUENCY OF LATE 94.0 PROBABILITY OF LATE 0,425
DISTRIBUTION WITHIN PRFAVFRSIVE STIMULUS IN CATEGORIES OF SECOND
1234-56789 10
FREQ. 3 2 4- 8 5 5 13 19 15 12
PROS. 0.014 0,009 0.018 0.036 0.023 0.023 0.059 0.086 0.068 0.054
IRT/OP 0.017 0.011 0.023 0.047 0.031 0.032 0.085 0.136 0.124 0.113
TOTAL RESPONSES 221.0 PERCENTAGE REACTION TIME 38.3
SUBJECT R5
TREATMENT 2.0 rag/kg Chlorpromazine
FREQUENCY OF BURST 19.0
FREQUENCY OF PREMATURE 11.0
FREQUENCY OF EFFICIENT 60.0
FREQUENCY OF LATE 123.0
APPENDIX B
U2a 15
PROBABILITY OF BURST 0.089
PROBABILITY OF PREMATURE 0.052
PROBABILITY OF EFFICIENT 0.282
PROBABILITY OF LATE 0.577
DISTRIBUTION WITHIN PHFAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123-456789 10
FREQ. 115-44-9986 13
PROB. 0.005 0.005 0.023 0.019 0,019 0.042 0.042 0,038 0,023 0.061
IRT/o? 0,005 0.005 0.023 0.023 0,023 0.054 0.057 0.053 0.042 0,096
TOTAL RESPONSES 213.0 PERCENTAGE REACTION TIME 36,9
SUBJECT R6
TREATMENT 0.5 mg/kg Cftlorpromazine
APPENDIX B
NO. 16
FREQUENCY OF BURST 25.0 PROBABILITY OF BURST 0.104
FREQUENCY OF PREMATURE 7.0 PROBABILITY OF PREMATURE 0.029
FREQUENCY OF EFFICIENT 115.0 PROBABILITY OF EFFICIENT 0.479
FREQUENCY OF LATE 93.0 PROBABILITY OF LATE 0.338





FREQ. 0 0 5 7 7 13 17
PROB. 0.000 0.000 0.021 0.029 0.029 0.054 0.071
IRT/OP 0.000 0.000 0.024 0.034 0.036 0.069 0.097
TOTAL RESPONSES 240.0 PERCENTAGE REACTION TIME 29.7
SUBJECT R6
TREATMENT 1*0 mg/kg Ghlororomazine
APPENDIX B
NO. 17
FREQUENCY OF BURST 22.0 PROBABILITY OF BURST 0.094
FREQUENCY OF PREMATURE 3.0 PROBABILITY OF PREMATURE 0,034
FREQUENCY OF EFFICIENT 97.0 PROBABILITY OF EFFICIENT 0.415
FREQUENCY OF LATE 107.0 PROBABILITY OF LATE 0.457
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
FREQ.
123456789 10
3 1 2 4 7 9 10 20 21 20
PROB. 0.013 0,004 0.009 0.017 0.030 0.033 0.043 0.085 0.090 0.085
IRT/OP 0.015 0.005 0,010 0.020 0.036 0.048 0.056 0.119 0.142 0.157
TOTAL RESPONSES 234.0 PERCENTAGE REACTION TIME 29.8
SUBJECT R6 APPENDIX B
TREATMENT 2.0 mg/kg Chlorpromazine NO. ig
FREQUENCY OF BURST 20.0 PROBABILITY OF BURST 0.101
FREQUENCY OF PREMATURE 7.0 PROBABILITY OF PREMATURE 0.035
FREQUENCY OF EFFICIENT 77.0 PROBABILITY OF EFFICIENT 0.387
FREQUENCY OF LATE 95.0 PROBABILITY OF LATE 0.477
DISTRIBUTION WITHIN PREAVERSIVB STIMULUS IN CATEGORIES OF SECOND
1234-56739 10
FREQ. 34- 23 789 10 17 14-
PROBi. 0.015 0.020 0.010 0.015 0.035 0.04-0 0.045 0.050 0.085 0.070
IRT/OP 0.017 0.024 0.012 0.018 0.044 0.052 0.062 0.074 0.135 0.128
TOTAL RESPONSES 199.0 PERCENTAGE REACTION TIME 36.5
SUBJECT ri APPENDIX B
TREATMENT 0.5 mg/kg Amphetamine IOj. 19
FREQUENCY OF BURST 4.0 PROBABILITY OF BURST 0.014
FREQUENCY OF PREMATURE 36.0 PROBABILITY OF PREMATURE 0.128
FREQUENCY OF EFFICIENT 234.0 PROBABILITY OF EFFICIENT 0.830
FREQUENCY OF LATE 8.0 PROBABILITY OF LATE 0.028
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
6 8 9 10
FREQ, 14 72 51 37 20 17 8 9 4 2
PROB. 0.050 0.255 0.181 0.131 0.071 0.060 0.028 0.032 0.014 0.007
IRT/OP 0.058 0.316 0.327 0.352 0.294 0.354 0.258 0.391 0.286 0.200
TOTAL RESPONSES 282.0 PERCENTAGE REACTION TIME 11.7
SUBJECT R1 APPENDIX B
TREATMENT 1.0 rag/kg Amphetamine HO. 20
FREQUENCY OF BURST 6.0 PROBABILITY OF BURST 0.021
FREQUENCY OF PREMATURE 61.0 PROBABILITY OF PREMATURE 0.213
FREQUENCY OF EFFICIENT 213.0 PROBABILITY OF EFFICIENT 0.742
FREQUENCY OF LATE 7.0 PROBABILITY OF LATE 0.024
DISTRIBUTION WITHIN PREAVERS EVE STIMULUS IN CATEGORIES OF SECOND
12345678910
FREQ. 3 26 57 -40 26 25 21 10 2 3
PROS. 0,010 0.091 0.199 0.139 0.091 0.087 0.073 0.035 0,007 0.010
IRT/OP 0.014 0.120 0,298 0.299 0.277 0.368 0.488 0,455 0.167 0,300
TOTAL RESPONSES 287.0 PERCENTAGE REACTION TIME 13.3
SUBJECT R1 APPENDIX B
TREATMENT 2.0 rug/kg Amphetamine NO. 21
FREQUENCY OF BURST 19.0 PROBABILITY OF BURST 0.057
FREQUENCY OF PREMATURE 130.0 PROBABILITY OF PREMATURE 0.393
FREQUENCY OF EFFICIENT H5.0 PROBABILITY OF EFFICIENT 0.438
FREQUENCY OF LATE 37.0 PROBABILITY OF LATE 0.112
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456 '7 39 10
FREQ. 17 39 33 U 16 6 1 5 12 2
PROBl 0.051 0.113 0.100 0.042 0.048 0.013 0.003 0.015 0.036 0.006
IRT/OP 0.093 0.236 0.262 0.151 0.203 0.095 0.013 0.089 0.235 0.051
TOTAL RESPONSES 331.0 PERCENTAGE REACTION TIME 14.3
SUBJECT R1







DISTRIBUTION WITHIN PHEAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456739 10
FREQ. 3 28 27 15 10 7 7 3 5 5
PROB. 0.014 0.133 0.129 0.071 0.043 0.033 0.033 0.014 0.024 0.024
IRT/OP 0.020 0.133 0.223 0.160 0.127 0.101 0.113 0.055 0.096 0.106
FREQUENCY OF BURST 12.0 PROBABILITY OF BURST
FREQUENCY OF PREMATURE 46.0 PROBABILITY OF PREMATURE
FREQUENCY OF EFFICIENT 110.0 PROBABILITY OF EFFICIENT
FREQUENCY OF LATE 42.0 PROBABILITY OF LATE
TOTAL RESPONSES 210.0 PERCENTAGE REACTION TIME 24.0
SUBJECT R4
TREATMENT 4.0 rag/kg Amphetamine
APPENDIX B
NO* 23
FREQUENCY OF BURST 16.0 PROBABILITY OF BURST 0.070
FREQUENCY OF PREMATURE 36.0 PROBABILITY OF PREMATURE 0.157
FREQUENCY OF EFFICIENT 95.0 PROBABILITY OF EFFICIENT 0.415
FREQUENCY OF LATE 82.0 PROBABILITY OF LATE 0.358
DISTRIBUTION WITHIN PBEAVERSIVB STIMULUS IN CATEGORIES OF SECOND
123456739 10
FREQ. 15 19 26 12 6 3 3 5 2 4
PROS. 0.066 0.083 0,114 0.052 0.026 0.013 0.013 0.022 0.009 0.017
IRT/OP 0.035 0.117 0.182 0.103 0.057 0.030 0.031 0.054 0.023 0.047
TOTAL RESPONSES 229.0 PERCENTAGE REACTION TIME 27.9
SUBJECT R4




FREQUENCY OF BURST 11.0 PROBABILITY OF BURST 0.047
FREQUENCY OF PREMATURE 43.0 PROBABILITY OF PREMATURE 0.182
FREQUENCY OF EFFICIENT 113.0 PROBABILITY OF EFFICIENT 0.479
FREQUENCY OF LATE 69.0 PROBABILITY OF LATE 0.292
DISTRIBUTION WITHIN PKEAVERSIVB STIMULUS IN CATEGORIES OF SECOND
123456739 10
FREQ. 17 20 23 21 16 3 0 4 2 2
PROB. 0.072 0.035 0.097 0.039 0,068 0.034 0.000 0.017 0.008 0.003
IRT/OP 0.093 0.121 0.159 0.172 0.158 0.094 0.000 0.052 0.027 0.023
TOTAL RESPONSES 236.0 PERCENTAGE REACTION TIME 26.L
SUBJECT Rl





FREQUENCY OF BURST 3.0 PROBABILITY OF BURST 0.012
FREQUENCY OF PREMATURE 17.0 PROBABILITY OF PREMATURE 0.071
FREQUENCY OF EFFICIENT 197.0 PROBABILITY OF EFFICIENT 0.817
FREQUENCY OF LATE 24..0 PROBABILITY OF LATE 0.100




FREQ. 10 19 23 19 28 31 23 22 17
PROB. 0.021 0.04.1 0.079 0.095 0.079 0,116 0.129 0.095 0.091 0.071
IRT/OP 0.023 0.04-6 0.092 0.123 0.116 0.193 0.265 0.267 0.34-9 0.4-15
TOTAL RESPONSES 24-1.0 PERCENTAGE REACTION TIME 22.8
SUBJECT R1 APPENDIX B
TREATMENT 17.5 mg/kg Mescaline HQ, 26
FREQUENCY OF BURST 9.0 PROBABILITY OF BURST 0.039
FREQUENCY OF PREMATURE 39.0 PROBABILITY OF PREMATURE 0.171
FREQUENCY OF EFFICIENT 109.0 PROBABILITY OF EFFICIENT 0,478
FREQUENCY OF LATE 71.0 PROBABILITY OF LATE 0.311
DISTRIBUTION WITHII? PHEAVF.RSIVE STIMULUS IN CATEGORIES OF SECOND
123456739 10
FREQ. 3 8 12 20 6 13 H 17 7 9
PROB, 0.013 0.035 O.o53 0.083 0.026 0.057 0,061 0.075 0.031 0.039
IRT/OP 0.017 0.045 0.071 0.127 0.044 0.099 0.119 0.163 0.080 0.113
TOTAL RESPONSES 228.0 PERCENTAGE REACTION TIME 31.3
SUBJECT R1 APPENDIX B
TREATMENT 25.0 mg/kg Mescaline NO. 27
FREQUENCY OF BURST 3.0 PROBABILITY OF BURST 0.021
FREQUENCY OF PREMATURE 26.0 PROBABILITY OF PREMATURE 0.183
FREQUENCY OF EFFICIENT 62.0 PROBABILITY OF EFFICIENT 0.437
FREQUENCY OF LATE 51.0 PROBABILITY OF LATE 0.359















PROB. 0.028 0.035 0.070 0.042 0.063 0.042 0.014 0.056 0.049 0.035
IRT/OP 0.035 0.046 0.096 0.064 0.102 0.076 0.027 0.113 0.111 0.089
TOTAL RESPONSES U2.0 PERCENTAGE REACTION TIME 56,3
SUBJECT R2 APPENDIX B
TREATMENT 12.5 mg/kg Mescaline lOi 28
FREQUENCY OF BURST 2,0 PROBABILITY OF BURST 0.008
FREQUENCY OF PREMATURE 3,0 PROBABILITY OF PREMATURE 0.033
FREQUENCY OF EFFICIENT 217.0 PROBABILITY OF EFFICIENT 0.397
FREQUENCY OF LATE 15.0 PROBABILITY OF LATE 0.062
DISTRIBUTION WITHIN FRBAVERBIVE STIMULUS IN CATEGORIES OF SECOND
8 10
5FREQ. 3 10 26 26 25 40 32 32 18
PROB. 0.012 0.041 0.107 0.107 0.103 O.I65 0.132 0,132 0.074 0.021
IRT/O? 0,013 0.044 0.119 0.135 0.150 0.232 0.314 0.457 0.474 0.250
TOTAL RESPONSES 242.0 PERCENTAGE REACTION TIM? 20.7
SUBJECT &g
TREATMENT 17.5 mg/kg Mescaline
APPENDIX B
I&a. 29
FREQUENCY OF BURST 13.0 PROBABILITY OF BURST 0.050
FREQUENCY OF PREMATURE 59.0 PROBABILITY OF PREMATURE 0.228
FREQUENCY OF EFFICIENT 142.0 PROBABILITY OF EFFICIENT 0.548
FREQUENCY OF LATE 45.0 PROBABILITY OF LATE 0.174
DISTRIBUTION WITHIN PHEAVERSJVE STIMULUS IN CATEGORIES OF SECOND
1234-56739 10
FREQ. 5 16 18 16 18 17 17 21 8 6
PRQB. 0.019 0.062 O.O69 0,062 0.069 0.066 0.066 0.031 0.031 0,023
IRT/OP 0.027 0.088 0.108 0.108 0.136 0,149 0,175 0.262 0,136 0.118
TOTAL RESPONSES 259.0 PERCENTAGE REACTION TIME 24. 2
SUBJECT R2 APPENDIX B
TREATMENT 25,0 mg/kg Mescaline NO. 30
FREQUENCY OF BURST 11.0 PROBABILITY OF BURST 0.060
FREQUENCY OF PREMATURE 48.0 PROBABILITY OF PREMATURE 0.261
FREQUENCY OF EFFICIENT 79.0 PROBABILITY OF EFFICIENT 0.429
FREQUENCY OF LATE 46.0 PROBABILITY OF LATE 0.250
DISTRIBUTION WITHIN AVERS IVF. STIMULUS IN CATEGORIES OF SECOND
123456789 10
IBEQ. 0 598141893 85
PROB, 0.000 0.027 0.049 0.043 0.076 0.098 0.049 0,016 0,043 0.027
IRT/O? 0.000 0.040 0.075 0.072 0.136 0.202 0,127 0.048 0,136 0,098
TOTAL RESPONSES 184,0 PERCENTAGE REACTION TIME 48.7
SUBJECT R3
TREATMENT 12,5 Tag/kg Mescaline
FREQUENCY OF BURST 0.0 PROBABILITY OF BURST 0.000
FREQUENCY OF PREMATURE 5.0 PROBABILITY OF PREMATURE 0.021
FREQUENCY OF EFFICIENT 219.0 PROBABILITY OF EFFICIENT 0.916
FREQUENCY OF LATE 15.0 PROBABILITY OF LATE 0.063
APPENDIX B
NO. 31
DISTRIBUTION PITHIN PREATTRSIVE STIMULUS IN CATEGORIES OF SECOND
1234-56789 10
FREQ. 1 6 7 33 52 4-7 29 22 15 7
PROB. 0.004 0.025 0.029 0.138 0.218 0.197 0.121 0.092 0.063 0.029
IRT/OP 0.004 0.026 0.031 0.150 0.278 0,345 0.330 0.373 0.405 0.318
TOTAL RESPONSES 239.0 PERCENTAGE REACTION TIME 20.9
SUBJECT R3 APPENDIX B
TREATMENT 17*5 mg/kg Mescaline
FREQUENCY OF BURST 9.0
FREQUENCY OF PREMATURE 57.0
FREQUENCY OF EFFICIENT 129.0
FREQUENCY OF LATE 49.0
NO. 3?
PROBABILITY OF BURST 0.037
PROBABILITY OF PREMATURE 0.234
PROBABILITY- OF EFFICIENT 0.529
PROBABILITY OF LATE 0.201
DISTRIBUTION WITHIN PREAVTRSIYE STIMULUS IN CATEGORIES OF SECOND
123456739 10
FREQ. 9 9 13 19 15 17 14 12 15 6
PROB. 0.037 0,037 0,053 0.078 0.061 0,070 0.057 0.049 0.061 0.025
IRT/OP 0.051 0,053 0.081 0.129 0.117 0,150 0,146 0.146 0.214 0.109
TOTAL RESPONSES 244.0 PERCENTAGE REACTION TIME 28.6
SUBJECT R3
TREATMENT 25.0 mg/kg Mescaline
APPENDIX B
NO, 33
FREQUENCY OF BURST 9.0 PROBABILITY OF BURST 0,061
FREQUENCY OF PREMATURE 25.0 PROBABILITY OF PREMATURE 0.169
FREQUENCY OF EFFICIENT 73.0 PROBABILITY OF EFFICIENT 0.493
FREQUENCY OF LATE 41.0 PROBABILITY OF LATE 0.277
DISTRIBUTION WITHIN PHEAVERSIVF STIMULUS IN CATEGORIES OF SECOND
FREQ.
234- 5 67 89 10
9 8 13 10 12 7 7 5 1
PROB. 0.007 0.061 0.054 0.088 0.068 0,031 0.047 0.047 0.034 0.007
IRT/OP 0.009 0.060 0.077 0.135 0.120 0.164 0.115 0.130 0.106 0.024
TOTAL RESPONSES 148.0 PERCENTAGE REACTION TBI? 57.5
SUBJECT R4 APPENDIX B
TREATMENT 0.5 mg/kg L.S. D, Wx 34
FREQUENCY OF BURST 15.0 PROBABILITY OF BURST 0.059
FREQUENCY OF PREMATURE 28.0 PROBABILITY OF PREMATURE 0.111
FREQUENCY OF EFFICIENT 192.0 PROBABILITY OF EFFICIENT 0.759
FREQUENCY OF LATE 13.0 PROBABILITY' OF LATE 0.071
DISTRIBUTION WITHIN PRFAVER3IVE STIMULUS IN CATEGORIES OF SECOND
1234-56739 10
FREQ. 1 10 35 21 37 26 39 10 11 2
PROS* 0.004 0.040 0.133 0.083 0.146 0.103 0.1$4 0.040 0,043 0.008
IRT/OP 0.005 0.043 0.176 0.123 0.259 0.245 0.438 0.244 0.355 0.1°0
TOTAL RESPONSES 253.0 PERCENTAGE REACTION TIME 20.3
SUBJECT R4 APPENDIX B
TREATMENT 0.75 rag/kg L.3.D.
FREQUENCY OF BURST 13.0
FREQUENCY OF PREMATURE 77.0
FREQUENCY OF EFFICIENT 124.0
FREQUENCY OF LATE 23.0
NO. 35
PROBABILITY OF BURST 0.073
PROBABILITY OF PREMATURE 0.312
PROBABILITY OF EFFICIENT 0.502
PROBABILITY OF LATE 0.113
DISTRIBUTION WITHIN PREAYERSIVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FREQ. 4 12 16 21 9 14 23 13 9 3
PROB. 0.016 0.149 0.065 0.035 0.036 0.057 0.093 0.053 0.036 0.012
IRT/OP 0.026 0.031 0.113 0.175 0.091 O.I56 0.303 0.254 0.225 0.097
TOTAL RESPONSES 247.0 PERCENTAGE REACTION TIME 28.2
SUBJECT ^ APPENDIX B
treatment ]_#g mg/kg L.s.D• iqa. 36
frequency OF burst 9.0 probability of burst 0.048
frequency of premature 88.0 probability of premature o.466
frequency of efficient 57.0 probability: of efficient 0.302
frequency of late 35.0 probability of late 0.185







prob. 0,005 0,021 0.042 0.032 0.04.2 0.032 0.021 o.O48 0.037
irt/op 0.001 0.044 0.092 0.076 0.110 0.092 0.068 0.164 0.152
TOTAL RESPONSES 189.0 PERCENTAGE REACTION TIME 39.7
SUBJECT R5 APPENDIX B
TREATMENT 25.0 mg/kg Mescaline 12* 37
FREQUENCY OF BURST 2.0 PROBABILITY OF BURST 0.013
FREQUENCY OF PREMATURE 38.0 PROBABILITY OF PREMATURE 0.248
FREQUENCY OF EFFICIENT 51.0 PROBABILITY OF EFFICIENT 0.333
FREQUENCY OF LATE 62.0 PROBABILITY OF LATE O.405
DISTRIBUTION WITHIN PRSAVERSIVE STLMULUS IN CATEGORIES OF SECOND
1234-5678 9 10
FREQ. 33587846 34
PROB. 0.020 0.020 0.033 0.052 0.046 0.052 0,026 0.039 0.020 0.026
IRT/OP 0.027 0.027 0.047 0.078 0.074 0.092 0.051 0,080 0,043 0.061
TOTAL RESPONSES 153.0 PERCENTAGE REACTION TIME 55.4
SUBJECT R5 APPENDIX B
TREATMENT 1.0 mg/kg L.S.D. NO. 38
FREQUENCY OF BU ST 4.0 PROBABILITY OF BURST 0,022
FREQUENCY OF PREMATURE 90.0 PROBABILITY OF PREMATURE 0.506
FREQUENCY OF EFFICIENT 38,0 PROBABILITY OF EFFICIENT 0.213
FREQUENCY OF LATE 46.0 PROBABILITY OF LATE 0.258
DISTRIBUTION WITHIN PREAVERSIYB STIMULUS IN CATEGORIES OF SECOND
123456739 10
FREQ. 3463582241
PROB. 0.017 0.022 0.034 0.017 0.028 0.045 0.011 0.011 0.022 0.006
IRT/OP 0.036 0.049 0.078 0.042 0.074 0.127 0.036 0.038 0.078 0.021
TOTAL RESPONSES 178.0 PERCENTAGE REACTION TIME 43.2
SUBJECT r5 APPENDIX B
TREATMENT 10.0 mg/kg N,N Dimethy1tryotamine I2& 39
FREQUENCY OF BURST 0.0 PROBABILITY OF BURST 0.000
FREQUENCY OF PREMATURE 60.0 PROBABILITY OF PREMATURE 0.411
FREQUENCY OF EFFICIENT 4-3.0 PROBABILITY OF EFFICIENT 0.329
FREQUENCY OF LATE 38.0 PROBABILITY OF LATE 0.260
DISTRIBUTION WITHIN PRFAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234-5678910
FREQ. 164.966824-2
PROBL 0.007 0,04.1 0.027 0.062 0.04-1 0,04-1 0,04-5 0.014- 0.027 0.014
IRT/OP 0.012 0.071 0.051 0.120 0.091 0,010 0.148 0,053 0,091 0.050
TOTAL RESPONSES I46.O PERCENTAGE REACTION TIME 53.3
SUBJECT B2 APPENDIX B
TREATMENT 25,0 mg/kg Mescaline ^0
FREQUENCY OF BURST 9.0 PROBABILITY OF BURST 0.045
FREQUENCY OF PREMATURE 50.0 PROBABILITY OF PREMATURE 0.253
FREQUENCY OF EFFICIENT 86.0 PROBABILITY OF EFFICIENT 0.434
FREQUENCY OF LATE 53.0 PROBABILITY OF LATE 0.268
DISTRIBUTION WITHIN PRSAVERSIVE STIMULUS IN CATE&ORIES OP SECOND
1234567 89 10
FREQ. 1 6 9 14 12 13 13 10 6 2
PROB. 0,005 0.030 0.045 0.071 0.060 0.066 0.066 0.051 0.030 0.010
IRT/OP 0.007 0.043 0.068 0.114 0.110 0.134 0.155 0.141 0.098 0.036
TOTAL RESPONSES 198.0 PERCENTAGE REACTION TIME 47.6
SUBJECT R2
TREATMENT 25.0 mg/kg 2,3>4>5 Tetramethoxy-P.
APPENDIX B
NO. 41
FREQUENCY OF BURST 11.0
FREQUENCY OF PREMATURE 97.0
FREQUENCY OF EFFICIENT 81.0
FREQUENCY OF LATE 67.0
PROBABILITY OF BURST 0.043
PROBABILITY OF PREMATURE 0.379
PROBABILITY OF EFFICIENT 0.316
PROBABILITY 05' LATE 0.262
DISTRIBUTION WITHIN PRFAVERSIVB STIMULUS IN CATEGORIES OF SECOND
123456 7 89 10
FREQ. 4 11 6 15 8 17 16 3 1 0
PROB. 0,016 0.043 0.023 0.059 0.031 0.066 0.063 0.012 0,004 0,000
IRT/OP 0.027 0.076 0.045 0.118 0.071 0.163 0.184 O.O42 0.015 0,000
TOTAL RESPONSES 256.0 PERCENTAGE REACTION TIME 48.2
SUBJECT R2 APPENDIX B
TREATMENT 6.25 mg/kg 2,3,4,5,6 Pentamethoxy-P. NO. 42
FREQUENCY OF BURST 7.0 PROBABILITY OF BURST 0.032
FREQUENCY OF PREMATURE 104.0 PROBABILITY OF PREMATURE 0.471
FREQUENCY OF EFFICIENT 55.0 PROBABILITY OF EFFICIENT 0.249
FREQUENCY OF LATE 55.0 PROBABILITY OF LATE 0.249
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FRF.Q. 1683 3 10 2 11 92
PROS. 0.005 0.027 0.036 0.014 0.014 0.045 0.009 0,050 0,040 0.009
IRT/OP 0.009 0.005 0.078 0.032 0.033 0.112 0.025 0.143 0.136 0.035
TOTAL RESPONSES 221.0 PERCENTAGE REACTION TIME 50.1
SUBJECT R2 APPENDIX B
TREATMENT 25.0 mg/kg Mescaline (after drug NQ^ 43
sequence)
FREQUENCE OF BURST 14..0 PROBABILITY OF BURST 0.059
FREQUENCY OF PREMATURE 61.0 PROBABILITY OF PREMATURE 0.257
FREQUENCY OF EFFICIENT 110.0 PROBABILITY OF EFFICIENT 0.4.64.
FREQUENCY OF LATE 52.0 PROBABILITY 01' LATE 0.219
DISTRIBUTION 'HTHIH PKEAVEKSIVE STIMULUS IN CATEGORIES OF SECOND
12345678910
FREQ, 6 9 17 11 21 13 7 19 4 3
PROB. 0,025 0.038 0.072 O.O46 0,089 0.055 0.030 0.080 0.017 0.013
IRT/Q? 0.037 0,058 0.116 0.085 0.176 0.133 0.082 0.244. 0.067 0.055
TOTAL RESPONSES 237.0 PERCENTAGE REACTION TIME 4.7.1
SUBJECT R1 APPENDIX B
TREATMENT 25.0 mg/kg N-methyl Mescaline NO. 44
FREQUENCY OF BURST 5.0 PROBABILITY OF BURST 0.020
FREQUENCY OF PREMATURE 15.0 PROBABILITY OF PREMATURE 0.060
FREQUENCY OF EFFICIENT 203,0 PROBABILITY OF EFFICIENT 0.812
FREQUENCY OF LATE 27.0 PROBABILITY OF LATE 0.108
DISTRIBUTION WITHIN PREAVEPJ3IVE STIMULUS IN CATEGORIES OF SECOND
123456739 10
FREQ. 2 5 12 20 21 30 33 31 23 16
PROB. 0,003 0.020 0.043 0.030 0.034 0.120 0.152 0.124 0.112 0.064
IRT/O? 0.009 0.022 0.054 0.095 0.110 0.176 0.271 0.304 0.394 0.372
TOTAL RESPONSES 250.0 PERCENTAGE REACTION TIME 24.9
SUBJECT R2 APPENDIX B
TREATMENT 25,0 mg/kg N-Methyl Mescaline NO* 45
FREQUENCY OF BURST 5.0 PROBABILITY OF BURST 0.021
FREQUENCY OF PREMATURE 13.0 PROBABILITY OF PREMATURE 0.054
FREQUENCY OF EFFICIENT 201.0 PROBABILITY OF EFFICIENT 0.831
FREQUENCY OF LATE 23.0 PROBABILITY OF LATE 0.095
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234.567 89 10
FREQ. 4 6 19 19 27 36 32 23 18 12
PROB. 0.017 0.025 0.079 0.079 0.112 O.I49 0.132 0.116 0.074 0.050
IRT/OP 0.018 0.027 0.089 0.097 O.153 0.242 0.233 0.346 0.340 0,343
TOTAL RESPONSES 242.0 PERCENTAGE REACTION TIME 23.6
SUBJECT R3 APPENDIX B
TREATMENT 25.0 Eg/kg N-raethyl Mescaline NO. 46
FREQUENCY OF BURST 3.0 PROBABILITY OF BURST 0.013
FREQUENCY OF PREMATURE 15.0 PROBABILITY OF PREMATURE 0.063
FREQUENCY OF EFFICIENT 199.0 PROBABILITY OF EFFICIENT 0.836
FREQUENCY OF LATE 21.0 PROBABILITY OF LATE 0.088
DISTRIBUTION WITHIN PKEAVERSIVE STIMULUS EI CATEGORIES OF SECOND
1234-56739
FREQ. 12 u 17 23 20 30 30 26 15
PROB. 0.050 0.059 0.071 0.097 0.034 0.126 0.126 0.109 0.063 0
IRT/QP 0*055 0.067 0.083 0.130 0,130 0.224 0.238 0.351 0.313 0
TOTAL RESPONSES 238.0 PERCENTAGE REACTION TIME 24*3
SUBJECT R1
TREATMENT 25.0 rag/kg Trimethoxyphenylethanol
APPENDIX B
47
FREQUENCY OF BURST 6.0 PROBABILITY OF BURST 0.024
FREQUENCY OF PREMATURE 21.0 PROBABILITY OF PREMATURE 0.083
FREQUENCY OF EFFICIENT 204,0 PROBABILITY OF EFFICIENT 0.303
FREQUENCY OF LATE 23.0 PROBABILITY OF LATE 0.091
jurAiJJTio:: urrnp PR^VL^Vl .TI^LUG 14 C,TI:.GJ.JLG 0, SECOND
1234-56739 10
FREQ. 7 10 17 26 26 29 28 27 21 13
PROB, 0.028 0.039 0.067 0.102 0.102 0.114 0.110 0.106 0.083 0.051
IiiT/oP 0.031 0.045 0.081 0.135 0.156 0.206 0.250 0.321 0.368 0.361
TOTAL RESPONSES 254.0 PERCENTAGE REACTION TIT© 24.6
SUBJECT R2 APPENDIX B
TREATMENT 25.0 mg/kg Trimethoxyphenylethanol NO. 4-8
FREQUENCY OF BURST 3.0 PROBABILITY OF BURST 0,013
FREQUENCY OF PREMATURE 14.0 PROBABILITY OF PREMATURE 0,059
FREQUENCY OF EFFICIENT 201.0 PROBABILITY OF EFFICIENT 0.852
FREQUENCY OF LATE 18.0 PROBABILITY OF LATE 0.076
DISTRIBUTION WITHIN PKEAVERSIVF. STIMULUS IN CATEGORIES OF SECOND
1234-56789 10
FREQ. 9 11 11 16 25 3 1 36 29 20 13
PRQB. 0,038 0.04-7 0,04.7 0,068 0.106 0.131 0,152 0.123 0.035 0.055
IRT/OP 0,04.1 0.052 0.055 0.035 0.145 0.211 0.310 0.363 0,392 0.419
TOTAL RESPONSES 236.0 PERCENTAGE REACTION TIME 23.7
SUBJECT R3 APPENDIX B
TREATMENT 25.0 rag/kg Trimethoxyphenylethanol 4-9
FREQUENCY OF BURST 6.0 PROBABILITY OF BURST 0.025
FREQUENCY OF PREMATURE 16.0 ■ROBABILITY OF PREMATURE 0.067
FREQUENCY OF EFFICIENT 193,0 PROBABILITY. OF EFFICIENT 0.325
FREQUENCY OF LATE 20.0 PROBABILITY OF LATE 0.083
DISTRIBUTION WITHIN PHFAVERSIVE STIMULUS IN CATEGORIES Qg SECOND
8 10
3FREQ. 5 10 16 26 28 30 30 26 19
PROB, 0.021 0.04.2 0.067 0.108 0.117 0.125 0.125 0.108 0.079 0.033
IRT/OP 0.023 0.04-7 0.079 0.139 0.174- 0.226 0.291 0.356 0.4.04- 0.286
TOTAL RESPONSES ,24-0.0 PERCENTAGE REACTION Til#: 23.3
SUBJECT R1 APPENDIX B
TREATMENT 25.0 mg/kg TrimethoxyDhenylacetic acid NO* 50
FREQUENCY OF BURST 3.0 PROBABILITY OF BURST 0.013
FREQUENCY OF PREMATURE 16.0 PROBABILITY OF PREMATURE 0.063
FREQUENCY OF EFFICIENT 196.0 PROBABILITY OF EFFICIENT 0.334
FREQUENCY OF LATE 20.0 PROBABILITY OF LATE 0.085
DISTRIBUTION VJITHIH PPEAVTliS IVE STIMULUS EI GATEGOP IBS OF SECOND
1234-56739 10
FKEQ. 3 6 16 13 24 34- 4-1 29 20 10
PROB. 0.013 0.026 0.063 0.055 0.102 0.145 0.174 0.123 0.085 0.043
IRT/OP 0.014 0.023 0.77 0.068 0.135 0.221 0.342 0.367 0.400 0.333
TOTAL RESPONSES 235.0 PERCENTAGE REACTION TIME 24.1
SUBJECT R2 APPENDIX B
TREATMENT 25,0 rag/kg Triinethoxyphenylacetic acid j|cu 51
FREQUENCY OF BURST 2,0 PROBABILITY OF BURST 0.009
FREQUENCY OF PREMATURE 22,0 PROBABILITY OF PREMATURE 0.094
FREQUENCY OF EFFICIENT 199.0 PROBABILITY OF EFFICIENT 0.347
FREQUENCY OF LATE 12.0 PROBABILITY OF LATE 0.051
DISTRIBUTION WITHIN PKEAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234.56709 10
FREQ. 6 9 10 15 24 34 34 30 21 16
PROB, 0,026 0,038 0.043 0,064 0.102 0.145 0.145 0,128 0.039 0.063
IRT/OP 0.023 0.044 0.051 0.081 0.140 0.231 0.301 0.330 0.429 0.571
TOTAL RESPONSES 235.0 PERCENTAGE REACTION TIME 22,0
SUBJECT R3 APPENDIX B
TREATMENT 25.0 rag/kg Trimethoxyphenylacetic acid 52
FREQUENCY OF BURST 9.0 PROBABILITY OF BURST 0.038
FREQUENCY OF PREMATURE 15.0 PROBABILITY OF PREMATURE O.O64
FREQUENCY OF EFFICIENT 195.0 PROBABILITY OF EFFICIENT 0.830
FREQUENCY OF LATE 16.0 PROBABILITY OF LATE 0.068
DISTRIBUTION WITHIN PREAYERSIVE STIMULUS IN CATEGORIES OF SECOND
12345678910
FREQ. 4 3 16 21 24 33 3 1 29 18 11
PROS. 0.017 0.034 0.068 0.039 0.102 0.140 0.132 0.123 0.077 0.047
IRT/OP 0.019 0,039 0.030 0.115 0.148 0.239 0.295 0.392 0.400 0.407
TOTAL RESPONSES 235.0 PERCENTAGE REACTION TIME 23.9
SUBJECT R5 APPENDIX B
TREATISENT 6.2 rag/kg 245 Trimethoxyamphetamine NO 53
FREQUENCY OF BURST 18.0
FREQUENCY OF PREMATURE 87.0
FREQUENCY OF EFFICIENT 111.0
FREQUENCY OF LATE 59.0
PROBABILITY OF BURST O.O65
PROBABILITY OF PREMATURE 0.316
PROBABILITY OF EFFICIENT 0.404
PROBABILITY OF LATE 0.215
DISTRIBUTION WITHIN PREAVERSF/E STIMULUS IK CATEGORIES OF SECOND
12345678910
FREQ. 6 8 14 11 20 7 10 17 10 8
PROB. 0.022 0.029 0.051 0.040 0.073 0.025 0.036 0.062 0.036 0.029
IRT/OP 0,035 0.049 0.090 0.077 0.153 0.063 0.096 0.181 0,130 0.119
TOTAL RESPONSES 275.0 PERCENTAGE REACTION TIME 26.3
SUBJECT R2 APPENDIX B
TREATMENT 6.2 mg/kg 245 Trimethoxyamphetamine Ik 54
FREQUENCY OF BURST 29.0 PROBABILITY OF BURST 0.117
FREQUENCY OF PREMATURE 37.0 PROBABILITY OF PREMATURE 0.150
FREQUENCY OF EFFICIENT 146.0 PROBABILITY OF EFFICIENT 0.591
FREQUENCY OF LATE 35.0 PROBABILITY OF LATE O.L42
DISTRIBUTION WITHIN PKEAVERSIVE STIMULUS IK CATEGORIES OF SECOND
1 23456789 10
FRF.Q. 3 3 21 20 16 21 16 16 14 16
PROB. 0.012 0.012 0.085 0.081 0.065 0.085 0.065 0.065 0.057 0.065
IRT/OP 0.017 0.017 0,120 0.130 0.119 0.178 0.165 0.198 0.215 0.314
TOTAL RESPONSES 247.0 PERCENTAGE REACTION TIME 24.7
appendix bsubject r4
TREATMENT 12.5 mg/kg 34-5 Trimethoxyamphetamine no. 55
FREQUENCY OF BURST 19.0 PROBABILITY OF BURST 0.085
FREQUENCY OF PREMATURE 26.0 PROBABILITY OF PREMATURE 0.117
FREQUENCY OF EFFICIENT 125.0 PROBABILITY OF EFFICIENT 0.561
FREQUENCY OF LATE 53.0 PROBABILITY OF LATE 0.233
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS III CATEGORIES OF SECOND
fheq,
1 2 3 4-5 6 7
5 12 17 17 19 14. 10
8 9 10
3 13 10
prob* 0.022 0.054. 0.076 0.076 0.085 0.063 0.045 0.036 0.058 0.045
IRT/op 0.028 0.069 0.106 0.118 0.150 0.130 0.106 0.095 0.171 0.159
TOTAL RESPONSES 223.0 PERCENTAGE REACTION TIME 15.1
SUBJFCT R5 APPENDIX B
TREATMENT 12.5 mg/kg 34-5 Trimethoxyaraphetamine 56
FREQUENCY OF BURST 6.0 PROBABILITY OF BURST 0.025
FREQUENCY OF PREMATURE, 27.0 PROBABILITY OF PREMATURE 0.112
FREQUENCY OF EFFICIENT 165.0 PROBABILITY OF EFFICIENT 0.685
FREQUENCY OF LATE 43.0 PROBABILITY OF LATE 0.178
DISTRIBUTION WITHIN PREAVER3IVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FREQ. 4 11 16 10 19 17 25 13 21 24
PROB. 0.017 0.046 0.066 0.041 0.070 0.071 0.104 0.075 0.087 0.100
IRT/OP 0.019 0.054 0.083 0.056 0.114 0.115 0.191 0,170 0.239 0.358
TOTAL RESPONSES 241.0 PERCENTAGE REACTION TIME 24*7
SUBJF.CT R2 APPENDIX B
TREATMENT 25.0 mg/kg 246 Trimethoxyamphetamine MO. 57
FREQUENCY OF BURST 8.0 PROBABILITY OF BURST 0.031
FREQUENCY OF PREMATURE 53.0 PROBABILITY OF PREMATURE 0.227
FREQUENCY OF EFFICIENT 145.0 PROBABILITY OF EFFICIENT 0.566
FREQUENCY OF LATE 45.0 PROBABILITY OF LATE 0.176
DISTRIBUTION WITHIN PKEAVERSIVB STIMULUS IN CATEGORIES OF SECOND
123456739 10
FREQ. 3 10 13 24 14 23 15 20 13 10
PROB. 0.012 0.039 0.051 0.094 0.055 0.090 0.059 0.073 0.051 0,039
IRT/OP 0.016 0.053 0.073 0.146 0.100 0.183 0,146 0.227 0,191 0.182
TOTAL RESPONSES 256.0 PERCENTAGE REACTION TIME 25.3
SUBJECT R4 APPENDIX B
TREATMENT 25.0 mg/kg 246 Trlmethoxyamphetaalne no. 53
FREQUENCY OF BURST 11.0 PROBABILITY OF BURST 0.046
FREQUENCY OF PREMATURE 39.0 PROBABILITY OF PREMATURE 0.162
FREQUENCY OF EFFICIENT 159.0 PROBABILITY OF EFFICIENT 0.662
FREQUENCY OF LATE 31.0 PROBABILITY OF LATE 0.129
DISTRIBUTION WITHIN PKEAVF.RSIVF. STIMULUS IN CATEGORIES OF SECOND
12345673910
FREQ. 6 5 18 19 23 15 27 19 10 17
PROB. 0.025 0,021 0.075 0.079 0.096 0.063 0.113 0.079 0,042 0.071
IRT/OP 0.032 0.027 0.101 0.118 0.162 0.126 0.250 0.247 0.172 0.354
TOTAL RESPONSES 240.0 PERCENTAGE REACTION TIME 27.3
SUBJECT R2 APPENDIX B
TREATMENT 25.0 mg/kg 234 Trimethoxyamphetamine HQ* 59
FREQUENCY OF BURST 11.0 PROBABILITY OF BURST 0.046
FREQUENCY OF PREMATURE 36.0 PROBABILITY OF PREMATURE 0.152
FREQUENCY OF EFFICIENT 161.0 PROBABILITY OF EFFICIENT 0.679
FREQUENCY OF LATE 29.0 PROBABILITY OF LATE 0.122
DISTRIBUTION WITHIN EREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FREQ. 6 10 23 19 26 25 25 11 7 9
PROB. 0.025 0.042 0.097 0.080 0.110 0.105 0.105 0.046 0.030 0.038
IRT/OP 0.032 0.054 0.132 0.126 0.197 0.236 0,309 0.196 0.156 0.237
TOTAL RESPONSES 237.0 PERCENTAGE REACTION TIME 21.0
SUBJECT R5 APPENDIX B
TREATMENT 25.0 rag/kg 234 Trlmethoxyamphetamine HO. 60
FREQUENCY OF BURST 3.0 PROBABILITY OF BURST 0.013
FREQUENCY OF PREMATURE 16.0 PROBABILITY OF PREMATURE 0.068
FREQUENCY OF EFFICIENT 185.0 PROBABILITY OF EFFICIENT 0.734
FREQUENCY OF LATE 32.0 PROBABILITY OF LATE 0.136





TOTAL RESPONSES 236.0 PERCENTAGE REACTION TIME 24.3
123456789
FREQ. 0 8 16 19 25 22 25 26 22
PROB. 0.000 0.034 0.068 0.081 0.106 0.093 0.106 0.110 0.093
IRT/OP 0.000 0.037 0.077 0.098 0.144 0.148 0.197 0.255 0.289
SUBJECT R5 APPENDIX B
TREATMENT 6.2 mg/kg 25 Dime thoxyamphetamine NO. 61
FREQUENCY OF BURST 41.0 PROBABILITY OF BURST 0.138
FREQUENCY OF PREMATURE 44.0 PROBABILITY OF PREMATURE, 0,14.8
FREQUENCY OF EFFICIENT 159.0 PROBABILITY OF EFFICIENT 0.535
FREQUENCY OF LATE 53.0 PROBABILITY OF LATE 0.178
DISTRIBUTION WITHIH PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
I 234.56789 10
FREQ. 9 22 35 20 15 18 12 11 9 8
PROB. 0.030 0.074 0.118 0.067 0.051 0.061 0.040 0.037 0.030 0.027
IRT/OP 0.042 0.108 0.193 0.137 0.119 0.162 0.129 0.136 0,129 0.131
TOTAL RESPONSES 297.0 PERCENTAGE REACTION TIME 20.7
SUBJECT R4 APPENDIX B
TREATMENT 6.2 mg/kg 25 Dimethoxyamphetamine NO. 62
FREQUENCY OF BURST 20.0 PROBABILITY OF BURST 0.073
FREQUENCY OF PREMATURE 73.0 PROBABILITY 0hq 1 0.265
FREQUENCY OF EFFICIENT 131.0 PROBABILITY OF EFFICIENT 0.476
FREQUENCY OF LATE 51.0 PROBABILITY OF LATE 0.185
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234-56739 10
FREQ. A 24 13 20 U .10 14- 10 6 11
2RQJB. 0.015 0.087 0.065 0.073 0.051 0.036 0.051 0.036 0.022 0.040
IRT/OP 0.022 0.135 0.117 0.147 0.L21 0.098 0.152 0.123 0.033 0.177
TOTAL RESPONSES 275.0 PERCENTAGE REACTION TIME; 20.6
SUBJECT R2 APPENDIX B
TREATMENT 12,5 mg/kg 25 Dimethoxyamphetamine NO* 63
FREQUENCY OF BURST 34.0 PROBABILITY OF BURST 0.047
FREQUENCY OF PREMATURE 56.0 PROBABILITY OF PREMATURE 0.187
FREQUENCY OF EFFICIENT 226.0 PROBABILITY OF EFFICIENT 0.753
FREQUENCY OF LATE 4.0 PROBABILITY OF LATE 0.013
DISTRIBUTION WITHIN PREAVEISIVE STIMULUS IN CATEGORIES OP SECOND
1 23456789 10
FREQ. 17 29 52 51 37 18 10 6 3 3
PROS, 0.057 0.097 0.173 0.170 0.123 0.060 0.033 0.020 0.010 0.010
IRT/OP 0.074. 0.136 0.263 0.336 0.^57 0.409 0.385 0.375 0.300 0.429
TOTAL RESPONSES 300.0 PERCENTAGE REACTION TIME 12.1
SUBJECT R2
TREATMENT 6,2 mg/kg 34 Dimethoxyamphetamine
APFEKlgX B
NO. 64
FREQUENCY OF BURST 2.0
FREQUENCY OF PREMATURE 19.0
FREQUENCY OF EFFICIENT 201.0
FREQUENCY OF IATI. 23.0
PROBABILITY OF BURST 0.003
PROBABILITY OF PREMATURE 0,©73
PROBABILITY OF EFFICIENT 0.320
PROBABILITY OF LATE 0.094
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIC OF SKCOID
6 8 9 10
FREQ, 21 27 33 30 24 26 20
PROS. 0.003 0.037 0*086 0.110 0.135 0.122 0.098 0.106 0.033 0.037
IRT/OP 0,009 O.O4.I 0.099 0.141 0.200 0.227 0.23 5 0.333 0.335 0.281
TOTAL RESPONSES 245.0 PERCENTAGE REACTION TINE 21.8
SUBJECT R4 APPENDIX B
TREATMENT 6.2 mg/kg 34 Dimethoxyamphetamine NO. 65
FREQUENCY OF BURST 20.0 PROBABILITY OF BURST 0.079
FREQUENCY OF PREMATURE 17.0 PROBABILITY OF PREMATURE 0.067
FREQUENCY OF' EFFICIENT 175.0 PROBABILITY OF EFFICIENT 0.692
FREQUENCY OF LATE 41.0 PROBABILITY OF LATE 0.162
DISTRIBUTION WITHIN P3EAVERSIVE STIMULUS IN CATEGORIES Off SECOND
1234-56789 10
FREQ. 2 6 14- 16 15 26 33 28 20 15
PROB. 0.008 0.024 0.055 0.063 °*°59 0.103 0.130 0.111 0.079 0.059
IRT/OP 0.009 0.028 0.067 0.082 0.084- 0.160 0.241 0.269 0.263 0.268
TOTAL RESPONSES 253.0 PERCENSAGE REACTION TIME 24.2
SUBJECT R5 APPENDIX B
TREATMENT 12.5 mg/kg 34- Dimethojcyaraphetamine NO. 66
FREQUENCY OF BURST 6.0 PROBABILITY OF BURST 0.038
FREQUENCY OF PREMATURE 52.0 PROBABILITY OF PREMATURE 0.325
FREQUENCY OF EFFICIENT 35.0 PROBABILITY OF EFFICIENT 0.219
FREQUENCY OF LATE 67.0 PROBABILITY OF LATE 0.4.19
DISTRIBUTION WITHIN PKEAVERSIVE STIMULUS IN CATEGORIES OF SFCQND
1234-56789 10
FREQ. 4-164.333254-
PROB. 0.025 0.006 0.038 0.025 0.019 0,019 0.019 0.012 0.031 0.025
IRT/OP 0.039 0.010 0.062 0.044- 0.034- 0.036 0.037 0.026 0.066 0.056
TOTAL RESPONSES 160.0 PERCENTAGE REACTION TIME 56.5
SUBJECT R4 APPENDIX B
TREATMENT 12,5 mg/kg 34 Dimethoxysmphetamine 67
FREQUENCY OF BUIiST 14.0 PROBABILITY OF BURST 0.140
FREQUENCY OF PREMATURE 29.0 PROBABILITY OF PREMATURE 0.290
FREQUENCY OF EFFICIENT 34.0 PROBABILITY OF EFFICIENT 0.180
FREQUENCY OF LATE 39.0 PROBABILITY OF LATE 0.390
DISTRIBUTION WITHIN PKEAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FREQ. 2271211200
PROB, 0,020 0,020 0,070 0.010 0.020 0.010 0.010 0.020 0,000 0.000
IRT/OP 0.035 0.036 0.132 0.022 0.044 0.023 0.024 0,049 0.000 0.000
TOTAL RESPONSES 100.0 PERCENTAGE REACTION TIME 75.9
SUBJECT R2 APPENDIX B
TREATMENT 6.2 mg/kg 23 Dimethoxyamphetamine NOj. 68
FREQUENCY OF BURST 8*0 PROBABILITY OF BURST 0.029
FREQUENCY OF PREMATURE 31.0 PROBABILITY OF PREMATURE 0.113
FREQUENCY OF EFFICIENT 221.0 PROBABILITY OF EFFICIENT 0,307
FREQUENCY OF LATE 14.0 PROBABILITY OF LATE 0.051






FREQ. 10 23 46 54 38 20 11 8 8
PROB. 0.036 0.034 0.168 0.197 0.139 0.073 0,040 0.029 0.029
IRT/OP 0.043 0.102 0.228 0.346 0.373 0,312 0.250 0.242 0,320
TOTAL RESPONSES 274.0 PERCENTAGE REACTION TIME 15.2
SUBJECT R4 APPENDIX B
TREATMENT 6.2 mg/kg 23 Dimethoxyamphetamine HOj. 69
FREQUENCY OF BURST 9.0 PROBABILITY OF BURST 0.032
FREQUENCY OF PREMATURE 33.0 PROBABILITY OF PREMATURE 0.136
FREQUENCY OF EFFICIENT 219.0 PROBABILITY OF EFFICIENT 0.785
FREQUENCY OF LATE 13.0 PROBABILITY OF' IATE 0.047






FREQ, 8 26 50 49 37 18 13
PROB. 0.029 0.093 0.179 0.176 0,133 0.065 0.047 0.025 0.022
IRT/OP 0,034 0.116 0.253 0.331 0.374 0.290 0.295 0.226 0.250
TOTAL RESPONSES 279.0 PERCENTAGE REACTION TIME 14,6
SUBJECT R5 APPENDIX B
TREATMENT 12.5 mg/kg 23 Dimethoayamphetamine US*. 7^
FREQUENCY OF BURST 23.0 PROBABILITY OF BURST 0.071
FREQUENCY OF PREMATURE 140.0 PROBABILITY OF PREMATURE 0.433
FREQUENCY OF EFFICIENT 124.0 PROBABILITY OF EFFICIENT 0,384
FREQUENCY OF LATE 36.0 PROBABILITY OF LATE 0,111
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123A567 89 10
FREQ. 4 12 31 30 19 3 8 7 4 1
PROB. 0.012 0.037 0.096 0.093 0.059 0.025 0.025 0,022 0.012 0.001
IRT/OP 0,025 0.077 0.215 0.265 0.229 0.125 0.143 0.14.6 0.098 0.027
TOTAL RESPONSES 323.0 PERCENTAGE REACTION TIME, 20.3
SUBJECT R4 APPENDIX B
TREATMENT 6.2 mg/kg 35 Dime thoxyamphetamine N0» 71
FREQUENCY OF BURST 24.0 PROBABILITY OF BURST 0.090
FREQUENCY OF PREMATURE 14.0 PROBABILITY OF PREMATURE 0.053
FREQUENCY OF EFFICIENT 187.0 PROBABILITY OF EFFICIENT 0.703
FREQUENCY OF LATE 41.0 PROBABILITY OF LATE 0.154
DISTRIBUTION WITHIN PRKAVER5IVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FREQ, 7 17 35 31 22 16 19 16 15 9
BROS. 0.026 0.064 0.132 0.117 0.083 0.060 0.071 0.060 0.056 0.034
IRT/OP 0.03 1 0.077 0.172 0.183 0.159 0*138 0.190 0.198 0.231 0.180
TOTAL RESPONSES 266.0 PERCENTAGE REACTION TIME 21.2
SUBJECT R5 AFFENDIX B
TREATMENT 6.2 mg/kg 35 Dimetho^amphetamine 72
FREQUENCY OF BUIiST 15.0 PROBABILITY OF BURST 0.056
FREQUENCY OF PREMATURE 29.0 PROBABILITY OF PREMATURE 0,108
FREQUENCY OF EFFICIENT 204,0 PROBABILITY OF EFFICIENT 0.761
FREQUENCY OF LATE 20.0 PROBABILITY OF LATE 0.075
DISTRIBUTION WITHIN PHEAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FREQ. 9 29 45 25 16 19 21 18 H 8
PROB. 0.034- 0,108 0.168 0.093 0.060 0.071 0.078 0.067 0.052 0.030
IRT/OP 0.040 0.135 0.242 0.177 0.138 0.190 0.259 0.300 0.333 d.286
TOTAL RESPONSES 268.0 PERCENTAGE REACTION TIME 17.5
SUBJECT R2 APPENDIX B
TREATMENT 12.5 mg/kg 35 Dimethoxyaraphetamine NCR 73
FREQUENCY OF BURST 6.0 PROBABILITY OF BURST 0.019
FREQUENCY OF PREMATURE 137.0 PROBABILITY OF PREMATURE 0,434
FREQUENCY OF EFFICIENT 157.0 PROBABILITY OF EFFICIENT 0.497
FREQUENCY OF LATE 16.0 PROBABILITY OF LATE 0.051





FKEQ. 10 18 35 34 21 12 11 7 2
PROB, 0,032 0.057 0.111 0.108 0.066 0.038 0.035 0.022 0.006
IHT/OP 0.058 0.110 0.241 0.309 0.276 0.218 0.256 0.219 0.080
TOTAL RESPONSES 316.0 PERCENTAGE REACTION TIME 12.9
SUBJECT R2 APPENDIX B
TREATMENT 3.1 rag/kg 3 Methoxyamphetamine HQ. 74
FREQUENCY OF BURST 34.0 PROBABILITY OF BURST 0.092
FREQUENCY OF PREMATURE 179.0 PROBABILITY OF PREMATURE 0.482
FREQUENCY OF EFFICIENT 152.0 PROBABILITY OF EFFICIENT 0.410
FREQUENCY OF LATE 6.0 PROBABILITY OF LATE 0.016
DISTRIBUTION WITHIN PREAVLRSIVE STIMULUS IN CATEGORIES OF SECOND
1 234- 56789 10
FHEQ. 14 25 44. 24 23 11 5 3 3 0
PROB. 0.038 0.067 0.119 0.065 0.062 0.030 0.013 0.008 0.008 0.000
IRT/OP 0.089 0.174 0.370 0.320 0.451 0.393 0.294 0.250 0.333 0.000
TOTAL RESPONSES 371.0 PERCENTAGE REACTION TIME 8.1
SUBJECT R4 APPENDIX B
TREATMENT 3.1 mp/kg 3 Methoxyfmphetamine Ik 75
FREQUENCY OF BURST 61.0 PROBABILITY OF BURST 0.152
FREQUENCY OF PREMATURE 179.0 PROBABILITY OF PREMATURE 0.445
FREQUENCY OF EFFICIENT 146.0 PROBABILITY OF EFFICIENT 0.363
FREQUENCY OF LATE 16.0 PROBABILITY OF LATE 0.040
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234-56789
FREQ, 16 16 26 27 18 u 15 7 5
10
2
PRGB. 0.04-0 0.040 0.065 0.067 0.045 0.035 0.037 0.017 0,012 0.005
IRT/OP 0.099 0.110 0.200 0.260 0,234 0.237 0.333 0.233 0.217 0.111
TOTAL RESPONSES 402.0 PERCENTAGE REACTION TIME 12.1
SUBJECT R4 APPENDIX B
TREATMENT 3.1 mg/kg 2 Methoxyamphetaraine NO. 76
MMt
FREQUENCY OF BURST 6.0 PROBABILITY OF BURST 0.025
FREQUENCY OF PREMATURE 4,0 PROBABILITY OF PREMATURE 0.017
FREQUENCY OF EFFICIENT 206.0 PROBABILITY OF EFFICIENT 0.366
FREQUENCY OF LATE 22.0 PROBABILITY OF LATE 0.092
DISTRIBUTION WITHIN PREAVERSIVF STIMULUS IN CATEGORIES OF SECOND
12 3 4 5 6 7 3 9
FREQ. 4 3 6 17 31 34 29 41 23
10
13
PROB. 0.017 0.034 0.025 0.071 0.130 0.143 0.122 0.172 0.097 0.055
IRT/OP 0.013 0.036 0.023 0.081 0.161 0.210 0.227 0.414 0.397 0.371
TOTAL RESPONSES 236.0 PERCENTAGE REACTION TIME 23.3
SUBJECT R5 APPENDIX B
TREATMENT 3.1 mg/kg 2 Methoxyamphetamine NO. 77
FREQUENCY OF BURST 4.0 PROBABILITY OF BURST 0,017
FREQUENCY OF PREMATURE 2.0 PROBABILITY OF PREMATURE 0.008
FREQUENCY OF EFFICIENT 214.0 PROBABILITY OF EFFICIENT 0.916
FREQUENCY OF LATE 14.0 PROBABILITY OF LATE 0.056






FREQ, 1 10 14 14 26 38 47 33 22
PROS. 0.004 0.042 0.059 0.059 0,109 0.160 0.197 0.139 0.092
IRT/OP 0.004 0,043 0.063 0.068 0.135 0.228 0.364 0.402 0.449
TOTAL RESPONSES 238.0 PERCENTAGE REACTION TIME 22.3
SUBJECT R2 I PPENDIX B
TREATMENT 6.2 mg/kg 2 Methoxyamphetamine HO. 73
FREQUENCY OF BURST 3.0 PROBABILITY OF BURST 0.012
FREQUENCY OF PREMATURE 29.0 PROBABILITY OF PREMATURE 0.112
FREQUENCY OF EFFICIENT 214.0 PROBABILITY OF EFFICIENT 0.826
FREQUENCY OF LATE 13.0 PROBABILITY OF LATE 0.050
DISTxilo LiTIOH WITHIN P:£aVL,SIYE ..TIIIULUS III GATE 001; ITS OF SECOND
1234 56739 10
FREQ. 6 13 33 4-1 34 24 22 14 17 5
PROB. 0.023 0.069 0.127 0.153 0.131 0.093 0.085 0.054 0.066 0.019
IET/OP 0.026 0.031 0.163 0.241 0.264 0.253 0.310 0.296 0.436 0.278
TOTAL RESPONSES 259.0 PERCENTAGE REACTION TIME 17.0
SUBJECT R4 APPENDIX B
TREATMENT 6,2 mg/kg 2 Methoxyamphetamine NO, 79
FREQUENCY OF BURST 6,0 PROBABILITY OF BURST 0.022
FREQUENCY OF PREMATURE 32.0 PROBABILITY OF PREMATURE 0.120
FREQUENCY OF EFFICIENT 219.0 PROBABILITY OF EFFICIENT 0.820
FREQUENCY OF LATE 10.0 PROBABILITY OF LATE 0.037
DISTRIBUTION WITHIN FKEAVEiSIVE STIMULUS IN CATEGORIES UP SECOND
1234-5678910
FREQ. 9 19 34 33 30 25 21 19 16 13
PROB. 0,034 0.071 0,127 0,124 0.112 0.094 0.079 0.071 0.060 0.049
IRT/OP 0.039 0.086 0.169 0.198 0.224 0.240 0.266 0.328 0,410 0.565
TOTAL RESPONSES 267.0 PERCENTAGE REACTION TIME 17.5
SUBJECT R4 APPENDIX B
TREATMENT 3.1 mg/kg 4- Methoxyamphetamine NO. 80
FREQUENCY OF BURST 5.0 PROBABILITY OF BURST 0.020
FREQUENCY OF PREMATURE 17.0 PROBABILITY OF PREMATURE 0.069
FREQUENCY OF EFFICIENT 208.0 PROBABILITY OF EFFICIENT 0.839
FREQUENCY OF LATE 18.0 PROBABILITY OF LATE 0.073
DISTRIBUTION WITHIN PKFAVERSIVE STIMULUS IN CATEGORIES Or' SECOND
123456789 10
FREQ. 6 11 19 16 32 27 39 25 20 13
PROB. 0.024 0.044 0.077 0.065 0.129 0.109 0.157 0.101 0.031 0.052
IRT/OP 0.027 0.050 0.091 0.034 0.184 0.190 0.339 0.329 0.392 0.419
TOTAL RESPONSES 248.0 PERCENTAGE REACTION TIME 20.8
SUBJECT R5 APPENDIX B
TREATMENT 3.1 mg/kg 4 Methoxyamphetamine 12a 81
FREQUENCY OF BURST 3.0 PROBABILITY OF BURST 0.012
FREQUENCY OF PREMATURE 8.0 PROBABILITY OF PREMATURE 0.033
FREQUENCY OF EFFICIENT 216.0 PROBABILITY OF EFFICIENT 0.382
FREQUENCY OF LATE 18.0 PROBABILITY OF LATE 0.073
DISTRIBUTION WITHIN PREAVBRGIVE STIMULUS IN CATEGORIES OF SECOND
1234-567 3910
FREQ. 5 11 19 30 29 39 36 27 10 10
PROS. 0.020 0.04-5 0.078 0.122 0.113 0.159 0.147 0.110 0.041 0.04-1
IRT/OP 0.021 0.048 0.087 0.151 0.172 0.279 0.356 0.415 0.263 0.357
TOTAL RESPONSES 245.0 PERCENTAGE REACTION Til® 20.3
SUBJECT R2 APPENDIX B
TREATMENT 25.0 mg/kg 3 >4 Uimethoxyamphetamine NO. 82
after 50.0 mg/kg Iproniazid
FREQUENCY OF BURST 34*0 PROBABILITY OF 3URST 0.143
FREQUENCY OF PREMATURE 39.0 PROBABILITY OF PREMATURE 0.164
FREQUENCY OF EFFICIENT 99.0 PROBABILITY OF EFFICIENT 0.416
FREQUENCY OF UTS 66,0 PROBABILITY OF LATE 0.277
DISTRIBUTION WITHIN PRFAVERSIVE STIMULUS IK CATEGORIES OF SECOND
123456739 10
FREQ. 1 9 12 10 U 13 9 12 9 10
PROB.. 0.004 0.033 0.050 0.042 0.059 0.055 0.033 0.050 0.033 0,042
IRT/OP 0.006 0.055 0,077 0.070 0,105 0.109 0.085 0.124 0.106 0.132
TOTAL RESPONSES 233.0 PERCENTAGE REACTION TIME 37.2
SUBJECT R2 APPENDIX B
TREATMENT 25.0 mg/kg 2,3 Dimethoxyaraphetamine WO. 83
after 50.0 mg/kg Iproniazid
FREQUENCY OF BURST 12.0 PROBABILITY OF BURST 0.046
FREQUENCY OF PREMATURE 25.0 PROBABILITY OF PREMATURE 0.095
FREQUENCY OF EFFICIEBT 201.0 PROBABILITY OF EFFICIENT 0.764
FREQUENCY OF LATE 25.0 PROBABILITY OF LATE 0.095
DISTRIBUTION WITHIN PKEAVBRSIVE STIMULUS IN CATEGORIES OF SECOND
1234567 89 10
FREQ. 4 19 22 31 32 23 26 23 14 7
PROB. 0.015 0.072 O.O84 0.118 0.122 0.087 0.099 0.087 0.053 0.027
IRT/OP 0.018 0.086 0.108 0.171 0.213 0.195 0.274 0.333 0.304 0.219
TOTAL RESPONSES 263.0 PERCENTAGE REACTION TIME 19.6
SUBJECT R3 APPENDIX B
TREATMENT 3*1 mg/kg 3 Methoxyamphetamine BJ+
FREQUENCY OF BURST 1.0
FREQUENCY OF PREMATURE 23.0
FREQUENCY OF EFFICIENT 242.0
FREQUENCY OF LATE 2.0
PROBABILITY OF BURST 0.004
PROBABILITY OF PREMATURE 0.086
PROBABILITY OF EFFICIENT 0.903
PROBABILITY OF LATE 0.007
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234567 89 10
FHEQ. 4 27 40 57 60 25 18 4 6 1
PROB. 0.015 0.101 0.149 0.213 0.224 0.093 0.067 0.015 0.022 0.004
IRT/OP 0.016 0.113 0.188 0.329 0.517 0.446 0,561 0.308 0.667 0.333
TOTAL RESPONSES 268.0 PERCENTAGE REACTION TIME 14.2
SUBJECT R3 APPENDIX B
TREATMENT 3.1 mg/kg 3 Methoxyamphetamine after NO. 85
32.0 mg/kg c< Methyltyrosine
FREQUENCY OF BURST 3.0 PROBABILITY OF BURST 0.012
FREQUENCY OF PREMATURE 6.0 PROBABILITY OF PREMATURE 0.025
FREQUENCY OF EFFICIENT 223.0 PROBABILITY OF EFFICIENT 0.918
FREQUENCY OF LATE 11.0 PROBABILITY OF LATE 0.045
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234567 89 10
FREQ. 7 7 18 26 59 40 33 28 16 9
PROB. 0.029 0.029 0.074 0.107 0.160 0.165 0.136 0.115 0.066 0*037
IRT/OP 0.030 0.031 0.082 0.129 0.222 0.292 0.340 0.438 0.444 0.450
TOTAI. RESPONSES 243.0 PERCENTAGE REACTION TIME 20.3
SUBJECT R3 APPENDIX g
TREATMENT 3,1 mg/kg 3 Methoxyamphetamine NO, g£,
FREQUENCY OF BURST 6.0 PROBABILITY OF BURST 0,023
FREQUENCY OF PREMATURE 17.0 PROBABILITY OF PREMATURE 0.064
FREQUENCY OF EFFICIENT 236.0 PROBABILITY OF EFFICIENT 0.894
FREQUENCY OF LATE 5.0 PROBABILITY OF LATE 0.019
DISTRIBUTION WITHIN PREAVERSIYB STIMULUS IN CATEGORIES OF SECOND
1234567 89 10
FREQ. 9 26 36 50 36 36 24 11 5 3
PROB. 0.034 0.098 0.136 0.I89 0.136 0.136 0.091 0.042 0.019 0.011
IRT/OP 0.037 0.112 0,175 0.294 0.300 0.429 0.500 0.458 0.385 0.375
TOTAL RESPONSES 264.O PERCENTAGE REACTION TIME 15.5
SUBJECT R1 APPENDIX B
TREATMENT 17.5 mg/kg Mescaline 37
FREQUENCY OF BURST 7.0 PROBABILITY OF BURST 0,031
FREQUENCY OF PREMATURE 36.0 PROBABILITY OF PREMATURE 0.160
FREQUENCY OF EFFICIENT 114-.0 PROBABILITY OF EFFICIENT 0.507
FREQUENCY OF LATE 68.0 PROBABILITY OF LATE 0.302
DISTRIBUTION WITHIN PREAVF.RSIVE STIMULUS IN CATEGORIES OF SECOND
1 2 3 A 5 6 7 8 9
FREQ. 1 7 12 16 23 20 13 U 1
10
1
PROB. 0.004- 0.031 0.053 0.071 0.102 0.089 0.058 0.062 0.031 0.004.
IRT/OP 0.005 0.039 0.069 0.099 0.158 0.163 0.126 O.I56 0.092 0.014
TOTAL RESPONSES 225.0 PERCENTAGE REACTION TIME 30.3
SUBJECT R1 APPENDIX B
TREATMENT 17.5 rag/kg Mescaline after 25 rag/kg NCR SB
of 24.5 Triinethoxypheylethylamine.
FREQUENCY OF BURST 6.0 PROBABILITY OF LURST 0.026
FREQUENCY OF PREMATURE 12.0 PROBABILITY OF PREMATURE 0.052
FREQUENCY OF EFFICIENT 175.0 PROBABILITY OF EFFICIENT 0.761
FREQUENCY 01' LATE 37.0 PROBABILITY OF LATE 0.161
DISTRIBUTION WITHIN P3FAVKRSIVE STIMULUS IN CATEGORIES QF SECOND
1234.56739 10
FREQ. 10 18 17 24 34 23 19 14 10 6
PROB. 0.043 0.078 0.074 0.104 0.148 0.100 0.083 0.061 0.043 0.026
IRT/OP 0.047 0.039 0.092 0.144 0.238 0.211 0,221 0.209 0.189 0*340
TOTAL RESPONSES 230.0 PERCENTAGE REACTION TIME 23.6
SUBJECT R2 APPENDIX B
TREATMENT 17,5 mg/kg Mescaline NO, 89
FREQUENCY OF BURST 8.0 PROBABILITY OF BURST 0.029
FREQUENCY OF PRFMATUitE 56,0 PROBABILITY OF PREMATURE 0.201
FREQUENCY OF EFFICIENT 163.0 PROBABILITY OF EFFICIENT 0.536
FREQUENCY OF LATE 51.0 PROBABILITY OF LATE 0.183
DISTRIBUTION WITHIN PHFAVERSIVE STIMULUS IN CATEGORIES OF SECOND
123456789 10
FREQ. 7 13 16 21 17 30 IS 15 16 10
PROS. 0.025 0.04.7 0.058 0.076 0.061 0.108 O.065 0.054- 0.053 0,036
IRT/OP 0.033 0.063 0.082 0.118 0.108 0.214 O.I64 0.163 0.208 O.I64
TOTAL RESPONSES 273.0 PERCENTAGE REACTION TIME 25.6
SUBJECT R2 APPENDIX B
TREATMENT 17.5 rag/kg Mescaline after 25 nig/kg
of 245 Trimethoxyphenylethylamine.
NO. 90
FREQUENCY OF BURST 6.0
FREQUENCY OF PREMATURE 17.0
FREQUENCY OF EFFICIENT 200.0
FREQUENCY OF LATE 28.0
PROBABILITY OF BURST 0.024
PROBABILITY OF Pr F "ATURE 0,068
PROBABILITY OF EFFICIENT 0.797
PROBABILITY OF LATE 0.112
DISTRIBUTION WITHIN PiiEAVERSIVE STIMULUS IN CATEGORIES OF SECOND
10
FREQ. 13 27 34 31 30 26 18 12
PROB. 0.012 0.052 0.108 0.135 0.124 0.120 0.104 0,072 0.04S 0.024
IRT/OP 0.013 0.058 0.127 0.184 0.205 0.250 0.289 0.281 0.261 0.176
TOTAI. RESPONSES 251.0 PERCENTAGE REACTION TIME 24.7
SUBJECT R1 APPENDIX g
TREATMENT 17.5 mg/kg Mescaline after NO. 91
after 32.0 mg/kg Methyltyrosine
FREQUENCY OF BURST 16.0 PROBABILITY OF BURST 0.079
FREQUENCY OF PREMATURE 21.0 PROBABILITY OF PREMATURE 0.104
FREQUENCY OF EFFICIENT 61.0 PROBABILITY OF EFFICIENT 0.302
FREQUENCY OF LATE 104.0 PROBABILITY OF LATE 0.515
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234-56789 10
FREQ. 4-4-7934-8859
PROB. 0.020 0.020 0.035 0.045 0.015 0.020 0.040 0.040 0.025 0.045
IRT/OP 0.024 0.025 0.045 0.060 0.021 0.029 0.060 0.063 0.042 0.030
TOTAL RESPONSES 202.0 PERCENTAGE REACTION TIME 40.9
SUBJECT R1 APPENDIX B
TREATMENT 17*5 nig/kg Mescaline after 4-.0 mg/kg NO* 92
Tetrabenazine
FREQUENCY OF BURST 29.0 PROBABILITY OF BURST 0.119
FREQUENCY OF PREMATURE 22.0 PROBABILITY OF PREMATURE 0.019
FREQUENCY OF EFFICIENT 107.0 PROBABILITY OF EFFICIENT 0.440
FREQUENCY OF LATE 85.0 PROBABILITY OF LATE 0.350
DISTRIBUTION WITHIN PRFAVERSIVE STIMULUS IN CATF.GORIFS OF SECOND
123456789 10
FREQ. 5 12 14 7 11 13 11 14 10 10
PROBl 0.021 0,049 0.058 0.029 O.O45 0.053 0.045 0.058 0.041 0.041
IRT/OP 0.026 0.064 0.080 0.043 0.071 0.091 0.085 0.118 0.095 0.105
TOTAL RESPONSES 243.0 PERCENTAGE REACTION TIME 31.2
SU3JECT R1 APPENDIX B
TREATMENT 17.5 mg/kg Mescaline
FREQUENCY OF BURST 5.0
FREQUENCY OF PREMATURE 43.0
FREQUENCY OF EFFICIENT 121.0
FREQUENCY OF LATE 80.0
NO. 93
PROBABILITY OF BURST 0.020
PROBABILITY OF PREMATURE 0.173
PROBABILITY OF EFFICIENT 0.4.86
PROBABILITY OF LATE 0.321
?jSTRffqTy)N wyrqiN PREA7ERSIVE STIMULUS IN CATEGORIES OF SECOND
12345678910
FKEQ. 1 2 9 16 14 21 20 19 3 11
PROB. 0.004 0.008 0.036 0.064 0.056 0,084 0.080 0.076 0.032 0.044
IRT/OP 0.005 0.010 0.045 0.035 0.0 81 0,^2 0.345 0.161 0.081 0.121
TOTAL RESPONSES 249.0 PERCENTAGE REACTION TIME 29.7
SUBJECT R3 APPENDIX B
TREATMENT 17#5 mg/kg Mescaline affier
32.0 mg/kg t* Methyltyrosine
NO. 94
FREQUENCY OF BURST 21.0 PROBABILITY OF BURST 0.093
FREQUENCY OF PREMATURE 54.0 PROBABILITY OF PREMATURE 0.238
FREQUENCY OF EFFICIENT 78.0 PROBABILITY OF EFFICIENT 0.344
FREQUENCY OF LATE 74.0 PROBABILITY OF LATE 0.326
DISTRIBUTION WITHIN PREAV5RSIVE STIMULUS IN CATEGORIES OP SECOND
FREQ.
34-56789 10
3 6 16 11 11 8 6 7
PROS. 0.009 0.013 0.035 0.026 0.070 0.048 0.048 0.035 0.026 0.031
IRT/OP 0.013 0.020 0.054 0.043 0.120 0.094 0,104 0.084 0.069 0.086
TOTAL RESPONSES 227.0 PERCENTAGE REACTION TIME 41.2
SUBJECT R3 APPENDIX B
TPJEATMENT 17.5 mg/kg Mescaline after
4.0 mg/kg Tetrabenazine
NO. 95
FREQUENCY OF BURST 31.0 PROBABILITY OF BURST 0.126
FREQUENCY OF PREMATURE 57.0 PROBABILITY OF PREMATURE 0.232
FREQUENCY OF EFFICIENT 84*0 PROBABILITY OF EFFICIENT' 0.341
FREQUENCY OF LATE 74.0 PROBABILITY OF LATE 0.301




PROB. 0.003 0.012 0.037 0.016 0.057 0.057 0,065 0.033 0.023 0.023
IRT/OP 0.013 0.019 0.059 0.023 0.100 0.111 0.143 0.033 0.030 0.086
TOTAL RESPONSES 246.0 PERCENTAGE REACTION TIME 38.5
SUBJECT R3 APPENDIX B
TREATMENT 17.5 mg/kg Mescaline NO. 96
FREQUENCY OF BURST 7.0 PROBABILITY BF BURST 0.028
FREQUENCY OF PREMATURE 61.0 PROBABILITY OF PREMATURE 0.243
FREQUENCY OF EFFICIENT 136.0 PROBABILITY OF EFFICIENT 0.542
FREQUENCY OF LATE 47.0 PROBABILITY OF IATE 0.137
DISTRIBUTION WITHIN PREAVERS IVE STIMULUS IN CATEGORIES OF SECOND
FKEQ.
1234-56739 10
4- 10 13 15": 21 16 20 21 9 7
PROS. 0.016 0.040 0.052 0.060 0.034 0.064 0.030 0.^84 0.036 0.028
IRT/OP 0.022 0.056 0.077 0.096 0.149 0.133 0,192 0.250 0.143 0.130
TOTAL RESPONSES 251.0 PERCENTAGE REACTION TIME 30.0
















DISTRIBUTION WITHIN PREAVERSIVB STIMULUS IN CATEGORIES OF SECOND
1234- 56739 10
FREQ. 1 4 12 12 16 17 12 7 2 0
PROB. 0.005 0.021 0.063 0.063 0.083 0.089 0.063 0.036 0.010 0.000
IRT/OP 0.008 0.031 0.094 0.104 0.155 0.195 0.171 0.121 0.039 0.000
TOTAL RESPONSES 192.0 PERCENTAGE REACTION TIME 48.6
SUBJECT R2 APPENDIX B
TREATMENT 25.0 rag/kg Mescaline after 4-0.0 mg/kg IELi. . 93
Imipraraine
FREQUENCY OF BURST 2.0 PROBABILITY OF BURST 0,008
FREQUENCY OF PREMATURE 6.0 PROBABILITY OF PREMATURE 0.025
FREQUENCY OF EFFICIENT 2I4.O PROBABILITY OF EFFICIENT 0.895
FREQUENCY OF LATE 17.0 PROBABILITY OF LATE 0.071
DISTRIBUTION WITHIN PItEAVERSIVE STIMULUS IN CATEGORIES OP SECOND
I 234-56789 10
FREQ. o 10 13 27 35 36 37 32 17 7
PR0B. 0,000 0.04-2 0.054 0.113 O.I46 0.151 0.155 0.134 0.071 0.029
IRT/OP 0.000 0.043 0.059 0.130 0.193 0.247 0.336 0.433 0.415 0.292
TOTAL RESPONSES 239.0 PERCENTAGE REACTION TIME 21.8
SUBJECT R2 APPENDIX B
TREATMENT 25.0 mg/kg Mescaline ^ 99
FREQUENCY OF BURST 7.0 PROBABILITY OF BURST 0.033
FREQUENCY OF PREMATURE 61.0 PROBABILITY OF PREMATURE 0.288
FREQUENCY OF EFFICIENT 96.0 PROBABILITY OF EFFICIENT 0.453
FREQUENCY OF LATE 48.0 PROBABILITY OF LATE 0.226
DISTRIBUTION WITHIN PKEAVER3IVE STIMULUS IN CATEGORIES OF SECOND
123456739 10
FREQ. 2 5 3 19 1424 17 6 1 0
PROB. 0.009 0.024 0.038 0.090 0.066 0.113 0.030 0.028 0.005 0,000
IRT/OP 0.014 0.035 0.058 0.147 0.127 0.250 0.236 0.109 0.020 0.000
TOTAL RESPONSES 212.0 PERCENTAGE REACTION TIME 51.1
SUBJECT R6 APPENDIX B
TREATMENT 25,0 mg/kg Mescaline NO. 100
FREQUENCY OF BURST 7.0 PROBABILITY OF BURST 0.04-5
FREQUENCY OF PREMATURE 38.0 PROBABILITY OF PREMATURE 0.245
FREQUENCY OF EFFICIENT 73.0 PROBABILITY OF EFFICIENT 0.471
FREQUENCY OF LATE 37.0 PROBABILITY OF LATE 0.239
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1234- 56789 10
FREQ. 1 5 13 10 18 11 10 i 0 1
PROB. 0.006 0.032 0.084. 0.065 0.116 0.071 0.065 0.026 0.000 0.006
IRT/OP 0.009 0.04-6 0.125 0.110 0.222 0.175 0.192 0.095 0.000 0.026
TOTAL RESPONSES 155.0 PERCENTAGE REACTION TIME 46.3
SUBJECT R6 APPENDIX B
TREATMENT 25.0 mg/kg Mescaline after 40.0 mg/kg Iraipramine IJO. 101
FREQUENCY OF BUIiST 9.0 PROBABILITY OF BURST 0.036
FREQUENCY OF PREMATURE 17.0 PROBABILITY OF PREMATURE 0.068
FREQUENCY OF EFFICIENT 198.0 PROBABILITY OF EFFICIENT 0.789
FREQUENCY OF LATE, 27.0 PRC©ABILITY OF LATE- 0.108
DISTRIBUTION WITHIN PREAVERSIVE STIMULUS IN CATEGORIES OF SECOND
1 2 3 4-5
FKBQ. 7 8 10 19 27
PROD. 0.028 0.032 0.04-0 0.076 0.108
IRT/OP 0.031 0.037 0.043 0.095 0.149
10
34 36 24 21 12
0.135 0.143 0.096 0.084 0.048
0.221 0.300 0.236 0.350 0.308
TOTAL RESPONSES 251.0 PERCENTAGE REACTION TIME 24.9
SUBJECT R6 APPENDIX B
TREATMENT 25.0 mg/kg Mescaline NO. 102
FREQUENCY OF BURST 9.0 PROBABILITY OF BURST 0.053
FREQUENCY OF PREMATURE 40.0 PROBABILITY OF PREMATURE 0.234
FREQUENCY OF EFFICIENT 79.0 PROBABILITY OF EFFICIENT 0.462
FREQUENCY OF LATE . 43.0 PROBABILITY OF LATE 0.251
DISTRIBUTION WITHIN PKEAVEItSIVE STIMULUS IN CATEGORIES OF SECOND
FREQ.
1234-56789 10
2 6 7 12 12 12 14- 8 4- 2
PROB. 0.012 0.035 0.041 0.070 0.070 0.070 0.082 0.047 0.023 0.012
IRT/OP 0.016 0.050 0.061 0.112 0.126 0.145 0.197 0.140 0.082 0.044




SUBJECT R5 APPENDIX c
TREATMENT 0.5 mg/kg Chlorpromazine NO






is a .... BURST 3.000 2.000 7.000
is a PREMATURE 0.000 0.000 4,000
is a EFFICIENT 1.000 2.000 107.000



















First Response is a
First Response is a
First Response is a





















SUBJECT R5 APPENDIX C
TREATMENT 1.0 ra^kg Chlorpromazine NO.
SECOND RESPONSE IS A .. BURST PREMATURE EFFICIENT LATE
FREQUENCIES
is a .... BURST 2,000 1.000 7.000
is a PREMATURE 0.000 1.000 3.000
is a EFFICIENT 0.00c 4.000 48,000






First Response is a .... BURST 0.009 0.005 0,032 0.086
First Response is a PREMATURE 0.000 0.005 0.014 0.036
First Response is a EFFICIENT 0.000 0.018 0.217 0.154
First Response is a LATE 0.122 0,027 0.127 0.145
CONDITIONAL PROBABILITIES
First Response is a
First Response is a
First Response is a





















SUBJECT R5 APPENDIX c
TREATMENT 2.0 rag/kg Chlorpromazine NO,
SECOND RESPONSE IS A .. BURST PREMATURE EFFICIENT LATE
FREQUENCIES
First Response is a .... BURST 1.000 1.000 5.000
First Response is a PREMATURE 0.000 2.000 4.000
First Response is a EFFICIENT 0.000 4.000 24.000










is a .... BURST
is a PREMATURE
is a EFFICIENT










First Response is a ...» BURST 0.053 0.053 0.263 0.632
First Response is a PREMATURE 0.000 0.182 0.364 0.455
First Response is a EFFICIENT 0.000 0.067 0.400 0.533
First Response is a ..... LATE O.I46 0.033 0.211 0.602
SUBJECT R6 APPENDIX
TREATMENT mg/kg Chlorpronazine 22j
SECOND RESPONSE IS A .. BURST PREMATURE EFFICIENT LATE
FREQUENCIES
First Response is a .... BURST 2,000 0,000 20,000 3.000
First Response is a PREMATURE 0.000 0.000 2.000 5.000
First Response is a EFFICIENT 0.000 4.000 42.000 68.000



















First Response is a .... BURST 0.080 0.000 0.800 0.120
First Response is a PREMATURE 0.000 0.000 0,286 0.714
First Response is a EFFICIENT 0.000 0.035 0.365 0.591
First Response is a ..... LATE 0.247 0.032 0.548 0.172
SUBJECT R6 APPEHDIX c
TREATMENT x.O mg/kg Chlorpromazine HQs.
SECOND RESPONSE IS A ., BURST PREMATURE EFFICIENT LATE
FREQUENCIES
First Response is a .... BURST 2.000 4-.000 13.000 3.000
First Response is a PREMATURE 0.000 0.000 3.000 5.000
First Response is a EFFICIENT 0.000 2.000 29.000 66.000






is a .... BURST
is a PREMATURE
is a EFFICIENT










First Response Is a
First Response is a
First Response is a






























































First Response is a .... BURST 0.000 0.000 1.000 0.000
First Response is a PREMATURE 0.000 0.306 0.667 0.028
First Response is a EFFICIENT 0.013 0.098 0.859 0.026
First Response is a LATE 0.125 0.250 0.625 0.000
SUBJECT R1 APPENDIX 0
TREATMENT ms/^S Amphetamine ^0, ^
SECOND RESPONSE IS A .. BURST PNEM1ATURE EFFICIENT LATF,
FREQUENCIES
First Response is a .... BURST 0.000 0.000 5.000 1.000
First Response is a PREMATURE 1.000 22.000 38.000 0.000
First Response is a EFFICIENT 4.000 36.000 168.000 4.000






is a .... BURST
is a PREMATURE
is a EFFICIENT










First Response is a
First Response is a
First Response is a





















SUBJECT R1 APPENDIX C
TREATMENT 2.0 mg/kg Ampetamine N0« 9
SECOND RESPONSE IS A .. BURST PREMATURE EFFICIENT LATE
FREQUENCIES
First Response is a .... BURST 2.000 9.000 6.000 2.000
First Response is a PREMATURE 14.000 65.000 42.000 9.000
First Response is a EFFICIENT 1.000 41.000 84.000 18.000



















First Response is a .... BURST 0.105 0.474 0.316 0.105
First Resnonse is a PREMATURE 0.108 0.500 0.323 0.069
First Resnonse is a EFFICIENT 0.007 0,233 0.579 0.124
First Response is a ..... LATE O.054 0.405 0,351 0.189
SUBJECT R1 APPENDIX C
TREATMENT 12,5 mg/kg Mescaline nq. 10
SECOND RESPONSE IS A ,. BURST PREMATURE EFFICIENT LATE
FKEUUEHCIES
First Response is a .... BURST 0.000 0,000 2.000 1.000
First Response is a PREMATURE 1.000 4»000 11,000 1.000
First Response is a EFFICIENT 0.000 10.000 168.000 18.000






is a .... BURST
is a PREMATURE
is a EFFICIENT










First Response is a .... BURST 0.000 0.000 0.667 0.333
First Response is a PREMATURE 0.059 0.235 0.647 0.055
First Response is a EFFICIENT 0.000 0.051 0.853 0.091
First Response is a ..... LATE 0.033 0.125 0.625 0.167
SUBJECT R1
TRFATMBNT 17.5 mg/kg Mescaline
appendix c
NOs. 11



















First Response is a .... BURST 0.000 0.013 0.018 0.009
First Response is a PREMATURE 0.004 0.044 0,083 0.039
First Response is a EFFICIENT 0.004 0.066 0.254 0.149
First Response is a ..... LATE 0.031 0.048 0.118 0.114
CONDITIONAL PROBABILITIES
First Response is a .... BURST 0.000 0.333 0.444 0.222
First Response is a PREMATURE 0.026 0.256 0.437 0.231
First Response is a EFFICIENT 0.009 0.138 0.532 0.312
First Response is a ..... LATE 0.099 0.155 0.380 0.366
SUBJECT R1 APPENDIX C
TREATMENT 25.0 mg/kg Mescaline x2
SECOND RESPONSE IS A BURST PREMATURE EFFICIENT LATE
FREQUENCIES
First Response is a .... BURST 0.000 1.000 1.000 1.000
First Response is a PREMATURE 1.000 3.000 12.000 8.000
First Response is a EFFICIENT 2.000 11.000 . 30,000 18.000






is a ... BURST
is a PREMATURE
is a EFFICIENT










First Response is a .... BURST 0.000 0.333 0.333 0,333
First Response is a PREMATURE 0.038 0.192 0.462 0.308
First Response is a EFFICIENT 0.032 0.177 0.484 0.290
First Response is a ..... LATE 0.000 0.176 0.353 0.471
SUBJECT R2 APPENDIX C
TREATMENT 12.5 rag/kg Mescaline NO. 13
SECOND RESPONSE IS A BURST PREMATURE EFFICIENT LATE
FREQUENCIES
is a .... BURST 0.000 0.000 2.000
Is a PREMATURE 0.000 0.000 7.000
is a EFFICIENT 0.000 8.000 195.000










is a .... BURST
is a PREMATURE
is a EFFICIENT










First Response is a .... BURST 0.000 0.000 1,000 0.000
First Response is a PREMATURE 0.000 0,000 0.875 0.000
First Response is a EFFICIENT 0.000 0.037 0.899 0.065
First Response is a ..... LATE 0,133 0.000 0.800 0.067
SUBJECT R2 APPENDIX c
TREATMENT 17• 5 mg/kg Mescaline NO. 14
SECOND RESPONSE IS A .. BURST PREMATURE EFFICIENT LATE
FREQUENCIES
First Response is a .... BURST 3.000 1.000 6.000 3.000
First Response is a PREMATURE 0.000 12.000 38.000 9.000
First Response is a EFFICIENT 0.000 36.000 84.000 22.000



















First Response is a .... BURST 0.231 0.077 0.462 0.231
First Response is a PREMATURE 0.000 0.203 0.644 0.153
First Response is a EFFICIENT 0.000 0.254 0.592 0.155
First Response is a ..... LATE 0,222 0.200 0.311 0.244
SUBJECT R2 APPENDIX C
TREATMENT 25.0 mg/kg Mescaline NO. 15
SECOND RESPONSE IS A BURST PREMATURE EFFICIENT LATE
FREQUENCIES
is a .... BURST 1.000 1.000 6.000 3.000
is a PREMATURE 3.000 17.000 16.000 11.000
is a EFFICIENT 1.000 16.000 46.000 16.000
is a ..... LATE 6.000 13.000 11.000 16.000
PROBABILITIES
First Response is a .... BURST 0.005 0.005 0.033 0.016
First Response is a PREMATURE 0.016 0.092 0.087 0.060
First Response is a EFFICIENT 0.005 0.087 0.250 0.087
First Response is a ..... LATE 0.033 0.071 0.060 0.087
CONDITIONAL PROBABILITIES
First Response is a
First Response is a
First Response is a





















SUBJECT R3 APPENDIX c
TREATMENT 12.5 rag/kg Mescaline NOj. 16
SECOND RESPONSE IS A .. BURST PREMATURE EFFICIENT LATE
FREQUENCIES
.... BURST 0.000 0.000 0.000 0.000
PREMATURE 0.000 0.000 5.000 0.000
EFFICIENT 0.000 5.000 198.000 15.000























First Response is a
First Response is a
First Response is a





















SUBJECT R3 APPENDIX C
TREATMENT 17»5 mg/kg Mescaline ho. 17























is a .... BURST
is a PREMATURE
is a EFFICIENT










First Response is a .... BURST 0.333 0.222 0.333 0.111
First Response is a PREMATURE 0.000 0.211 0.684 0.105
First Response is a EFFICIENT 0,000 0.256 0.589 0.147
First Response ia a ..... LATE 0.122 0,204 0.204 O.469
SUBJECT R3 APPENDIX C
TREATMENT 25#0 mg/kg Mescaline ^ 18




































First Response is a
First Response is a
First Response is a






















CONDITIONED INFLATION AND DISCRIMINATION DATA
SUBJECT R7 APPENDIX D
TREATMENT Saline NO,
, Periods S1 *2 dE CE
o-R
2 T.R. Ei
1 8 1 1 1 0 9 0
2 1 9 1 0 0 10 0
3 9 0 0 0 0 9 0
4 0 7 0 0 0 7 0
5 8 0 0 0 0 8 0
6 0 7 0 0 0 7 0
7 8 0 0 0 0 8 0
8 0 8 0 0 0 8 0
9 7 0 0 0 0 7 0
10 0 9 0 0 0 9 0
11 7 0 0 0 0 7 0
12 0 8 0 0 0 8 0
13 7 0 0 0 0 7 0
14 0 8 0 0 0 8 0
15 8 0 0 0 0 8 0
16 0 7 0 0 0 7 0
17 7 0 0 0 1 7 0
18 0 8 0 0 0 8 0
19 8 0 0 0 0 8 0
20 0 8 0 0 0 8 0
>tal 78 80 2 1 1 158 0
- Responses on first lever
R2 - Responses on second lever
D„ • Discrimination errors




Eg - Escape failures
Periods 7-15 are shown in fig. 22
SUBJECT R7 APPENDIX D
TREATMENT 1.0 mg/kg Amphetamine no. 2
min. Periods R1 R2 CE s-R2 T.R.
1 0 9 0 0 0 9 0
2 8 0 0 0 0 8 0
3 0 9 0 0 0 9 0
4 12 1 1 0 1 13 0
5 0 14 0 0 0 14 0
6 12 0 0 0 0 12 0
7 0 9 0 0 0 9 0
8 13 0 0 0 0 13 0
9 0 16 0 0 0 16 0
10 15 2 2 0 0 17 0
11 0 21 0 0 0 21 0
12 13 0 0 0 0 13 0
13 0 15 0 0 0 15 0
14 14 1 1 0 0 15 0
15 0 10 0 0 0 10 0
16 15 0 0 0 0 15 0
17 0 13 0 0 0 13 0
18 13 0 0 0 0 13 0
19 0 13 0 0 0 13 0
20 ? 0 0 0 0 9 0
Total 124 133 4 0 1 257 0




R2 - Responses on second lever T.R. - Total responses
de - Discrimination errors EP - Escape failures
ce - Change-over errors
Periods 7-15 ere shown in Pig. 23
SUBJECT R7 APPENDIX D
TREATMENT 17.5 mg/kg Mescaline NO.
3 min. Periods R, E E
,-R
T.R, F
1 7 0 0 0 1 7 0
2 0 9 0 0 1 9 0
3 8 1 1 0 1 9 0
4 0 9 0 0 2 9 0
5 8 0 0 0 1 8 0
6 0 8 0 0 3 8 1
7 9 0 0 0 1 9 0
8 1 11 1 0 1 12 0
9 8 0 0 0 4 8 0
10 0 12 0 0 6 12 2
11 10 3 3 1 4 13 1
12 1 7 1 0 6 8 0
13 7 0 0 0 3 7 1
14 0 9 0 0 4 9 1
15 12 0 0 0 5 12 1
16 0 11 0 0 4 11 0
17 12 0 0 0 0 12 0
18 0 10 0 0 2 10 0
19 11 0 0 0 4 11 0
20 0 11 0 0 } 11 0
Total 94 101 6 1 56 195 7
- Responsej on first lever S2H - Shock
R2 • Responses on second lever
Dt, - Discrimination errorsE
T.R.- Total responses
Ep - Escape failures
Cg - Change-over errors
SUBJECT R7 APPENDIX D
TREATMENT 2,0 m&/kg C.P.Z, NO.
Ln. Periods R1 R2 dE CE S~R2 T.R. ®P
1 0 7 0 0 1 7 0
2 6 1 1 1 1 7 0
3 1 5 1 1 4 6 1
4 6 0 0 0 3 6 0
5 1 6 1 1 5 7 1
6 5 1 1 1 4 6 1
7 0 6 0 0 5 6 1
8 5 1 1 1 6 6 2
9 1 6 1 0 6 7 1
16 5 0 0 0 3 5 0
11 0 6-;i- 0 0 4 6 0
12 4 , 1 1 1 6 5 1
13 0 5 0 0 4 5 1
14 5 1 1 1 6 6 1
15 1 5 1 0 6 6 1
16 6 0 0 0 4 6 1
17 1 5 1 1 6 6 2
18 6 1 1 1 4 7 1
19 1 5 1 1 4 6 2
20 6 0 0 0 4 6 1
Total 60 62 12 10 86 122 18
R^ • Responses on first lever
R2 - Responses on second lever
Dg - Discrimination errors
* Shook
T.R.- Total responses
Ep - Escape failures
Cg - Change-over errors
Periods 7 • 15 are shown in Pig. 24
subject r7 appendix d
TREAGENT 25.0 mg/kg Mescaline no.
Ln. Periods H1 r2 °E CE T.r. £P
1 9 0 0 0 1 9 0
2 1 9 1 0 1 10 0
3 9 1 1 1 0 10 0
4 2 11 2 1 1 13 0
5 6 1 1 0 2 7 1
6 3 4 3 0 8 7 3
7 7 0 0 0 3 7 1
8 5 4 5 1 9 9 2
9 8 10 10 0 6 18 1
10 7 4 7 1 7 11 2
11 6 5 5 0 9 11 2
12 2 9 2 0 1 11 0
13 7 6 6 1 0 13 0
14 0 10 0 0 0 10 0
15 6 3 3 1 0 9 0
16 6 5 6 0 0 11 0
17 2 6 6 0 0 8 0
18 4 3 4 1 1 7 1
19 3 4 4 0 1 7 0
20 2 7 2 1 0 9 0
Total 95 102 68 8 50 197 13
- Responses on first lever
R2 - Responses on seoond lever
Dg - Discrimination errors
Cg - Change-over errors
Sg - Shock
T.R.- Total responses
Eg - Escape failures
Periods 7-15 are shown in Pig, 25
SUBJECT R7 APPENDIX D
TREATMENT 1.0 rag/kg C.P.Z. NO,




1 0 8 0 0 0 8 0
2 7 0 0 0 0 7 0
3 0 6 0 0 0 6 0
4 7 0 0 0 1 7 0
5 1 4 1 1 0 5 0
6 6 0 0 0 1 6 0
7 0 4 0 0 3 4 0
8 4 0 0 0 4 4 0
9 0 5 0 0 2 5 0
10 8 0 0 0 6 8 1
11 1 6 1 1 2 7 0
12 3 0 0 0 4 3 0
13 0 4 0 0 1 4 0
14 5 0 0 0 3 5 0
15 0 8 0 0 1 8 0
16 6 1 1 1 2 7 0
17 1 7 1 1 2 8 0
18 4 0 0 0 3 4 0
19 0 4 0 0 4 4 0
20 8 0 0 0 1 8 0
Total 61 57 4 4 40 118 1
R^ - Responses on first lever
R2 - Responses on second lever
D„ - Discrimination errors
S~H - Shock
T.R.- Total responses
E_ - Escape failures
C„ - Change-over errors
SUBJECT R7 APPENDIX D
TREATMENT 4.0 rag/kg Amphetamine
3 min. Periods R1 R2 de CE S-R2 T.R.
1 8 0 0 0 0 8 0
2 0 9 0 0 0 9 0
3 11 1 1 0 1 12 0
4 0 14 0 0 0 14 0
5 15 0 0 0 3 15 0
6 2 13 2 1 6 15 3
7 9 4 4 0 3 13 1
8 1 13 2 1 3 14 1
9 10 1 1 1 3 11 0
10 1 9 1 0 2 10 0
11 12 3 3 1 10 15 4
12 4 10 4 1 6 14 3
13 13 3 3 0 5 16 2
14 3 15 3 0 7 18 2
15 14 3 3 1 1 17 0
16 2 12 2 1 2 14 1
17 10 1 1 1 1 11 0
18 2 9 2 1 3 11 1
19 10 1 1 0 6 11 2
20 1 9 1 0 1 10 0
Total 128 130 34 9 65 258 20
R^ - Responses on first lever
-R
V - Shook
R2 - Responses on second lever
Dg - Discrimination errors
C„ - Change-over errors
J&
T.R. - Total responses
Ep - Escape failures
SUBJECT RtO APPENDIX 0
CONDITIONED INFLATION EXPERIMENT NO. 8
C.S. PRESENTATIONS 123456
3 win. pre C.S. 14 17 15 IS 16 15
SALINE (AV. DATA) 3 rain. C.S. 19 34 33 31 31 34
Inflation Ratio l.4(+S) 2.01+3) 2.2(j3) 2.1(«3) l.9(*3) 2.3(«3!
3 rain, pre C.S. 13 10 10 9 8 8
JJwfal 3 rain. C.S. 19 14 16 12 8 8
Inflation Ratio 1.5 1.4 1.6 1.3 1.0 1.0
3 rain, pre C.S. IS 12 12 6 9 9
3 rain. C.S. 22 16 18 6 II 20*
Inflation Ratio 1.5 1.3 1.5 1.0 1.2 2.2
3 rain, pre C.S. 17 21 24 22 20 20
AMPHET. (Imq/ka) 3 rain. C.S. 34 60 54 59 39 43
Inflation Ratio 2.0 2.9 2.3 2.7 2.0 2.1
3 rain, pre C.S. 19 13 13 10 13 24
AMPH$Tf Umq/k*) 3 rain. C.S. 36 14 14 IS 19 38
Inflation Ratio 1.9 I.I I.I 1.5 1.5 1.6
3 rain, pre C.S. 15 13 14 16 18 16
MESC. (12-Wkfl) 3 rain. C.S. 30 34 34 40 36 30
Inflation Ratio 2.0 2.6 2.4 2.5 1.9
3 rain, pre C.S. 13 6 13 12 13 19
MESC. (l7.Wka) 3 rain. C.S. 20 9 25 26 30 33
Inflation Ratio 1.5 1.5 1.9 2.2 2.0 1.7
3 rain, pre C.S. 12 8 0 0 3 10
MESC. (25.0ma/ka) 3 rain. C.S. 14 10 0 0 4 10
Inflation Ratio 1.2 1.3 1.3 1.0
* Unusually high due to six burst responses following a shook.
SUBJECT Rq APPENDIX D
CONDITIONED INFLATION EXPERIMENT
C.S. PRESENTATIONS 1 2 3 4 5 6
3 «l«l. pro C.S. 14 13 12 13 15 15
SALINE (AV. DATA) 3 mln. C.S. 16 27 27 25 30 32
Inflation Ratio f.l<£&> 2.l(j3) 2.3(t3) l.9(*3) 2.«i3) 2.Hi3)
C.P.Z. (Imct/ka)
3 mln. pro C.S. 17 16 12 13 13 12
3 mln. C.S. 28 32 14 17 19 12
Inflation Ratio 1.6 2.0 I.I 1.3 1.5 1.0
3 mln. pro C.S. 17 II 13 It 9 it
C.P.Z. (2m<j/kq) 3 mln. C.S. 28 14 20 10 13 10
Inflation Ratio 1.6 1.3 1.5 0.9 1.4 0.9
3 rain, pre C.S. 20 20 25 26 IS 18
AMPHET. (Ina/ka) 3 rain. C.S. 41 49 63 51 39 33
Inflation Ratio 2.1 2.5 2.5 2.0 2.2 1.8
3 mln. pro C.S. 21 10 9 10 II 18
AMPHET. (4»a/ka) 3 mln. C.S. 41 16 6 10 12 30
Inflation Ratio 2.0 1.6 0.7 1.0 I.I 1.7
3 nin. pro C.S. 17 16 16 17 17 17
MESC. (!2.Wkq) 3 mln. C.S. 33 34 41 26 39 29
Inflation Ratio 1.9 2.1 2.6 1.5 2.3 1.7
3 mtn. pro C.S. 18 14 IS 16 13 16
MESC. {|7.5mq/ka) 3 mtn. C.S. 35 27 31 28 24 32
Inflation Ratio 1.9 1.9 2.1 1.8 1.8 2.0
3 mln. pro C.S. 6 3 3 0 II 15
MESC. <23.0nfl/ko) 3 mln. C.S. 1 0 5 1 13 23
Inflation Ratio 0.2 0.0 1.7 1.2 1.5
APPENDIX E
PARTITION COEFFICIENTS
Method for determining partition coefficients
Reagentsi- (1) Chloroform (Analar grade B.D.H.)
(2) 0.1 Molar phosphate buffer pH 7.5 (NaH^PO^)
Method:- (l) Each compound was dissolved in 10 ccs of the
phosphate buffer and the spectrum recorded
against a buffer blank. The peak height
(in the 250-300 millimicron range) was noted (A)
(2) 10.0 ccs of chloroform were then added to each
sample (including the blank) and the tubes
shaken for 10 minutes.
(3) The samples were centrifuged at 3,500 r.p.m.
for 5 minutes.
(4.) The spectra were re-recorded against the
•exhausted' buffer blank. The peak height
(in the 250-300 millimicron range) was again
noted (B).
(5) The partition coefficients were calculated
from the equation:-
A - BPartition Coefficient
B
PARTITION COEFFICIENTS RELATIVE
TO MESCALINE
METHOXI GROUP
POSITION
345
246
235
245
236
2346
2345
23456
RELATIVE PARTITION
COEFFICIENT
1.0
1.3
1.6
0.8
1.0
1.6
2.5
4.1
AMPHET. 0.9
2 1.6
3 2.1
4 3.3
34 2.1
25 2.7
35 4.5
23 2.4
245 2.5
345 1.5
234 1.0
246 2.1
APPENDIX F
U.V. SPECTRA
 
